Identification of new molecular targets and antibiotics as novel strategies against filarial infections: Characterization of lipid II biosynthesis in *Wolbachia* endobacteria
Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn

1. Gutachter: Prof. Dr. Achim Hörauf
2. Gutachter: Prof. Dr. Albert Haas
Tag der Promotion: 06.05.2019
Erscheinungsjahr: 2019
Table of Contents

Summary .................................................................................................................................... 1

1 Introduction ............................................................................................................................ 5
  1.1 Neglected tropical diseases and filariasis ................................................................. 5
  1.2 Treatment of filarial diseases ................................................................................... 8
  1.3 Wolbachia endosymbionts as targets for anti-filarial treatment ............................... 9
  1.4 Wolbachia as an intracellular model organism: the benefit of basic research to identify new targets against filariasis ......................................................... 12
  1.5 Bacterial cell wall .............................................................. 13
    1.5.1 Cell wall synthesis and breakdown in bacteria ................................................ 14
    1.5.2 Penicillin-binding proteins (PBP) .................................................................... 17
    1.5.3 Interaction between peptidoglycan and outer membrane proteins ............. 19
    1.5.4 Host response to cell wall fragments .............................................................. 20
    1.5.5 Cell wall biosynthesis as a target for antibiotics .......................................... 20
  1.6 Lipid II metabolism in Wolbachia ........................................................................... 21
    1.6.1 Retained lipid II processing enzymes in Wolbachia ........................................ 22
      1.6.1.1 Penicillin-binding protein PBP2 .................................................................... 23
      1.6.1.2 Penicillin-binding protein PBP3 .................................................................... 23
      1.6.1.3 Penicillin-binding protein PBP6a ................................................................. 24
      1.6.1.4 N-acetylmuramoyl-L-alanine-amidase AmiD ............................................. 25
    1.6.2 Interaction of Wolbachia lipid II and outer membrane proteins .................. 25
    1.6.3 Host response to Wolbachia cell wall fragments ............................................ 26
  1.7 Objectives ....................................................................................................................... 27

2 Materials and methods ........................................................................................................ 28
  2.1 Equipment and consumables .................................................................................... 28
    2.1.1 Chemicals and solvents .................................................................................... 28
    2.1.2 Enzymes .......................................................................................................... 29
    2.1.3 Kits .................................................................................................................... 29
    2.1.4 Technical equipment ........................................................................................ 30
    2.1.5 Culture media and supplements ..................................................................... 31
    2.1.6 Antibiotics ........................................................................................................ 32
    2.1.7 Antibodies and fluorophores .......................................................................... 32
  2.2 Strains, expression vectors and primers ..................................................................... 33
    2.2.1 Cell lines, yeast and bacterial strains ................................................................ 33
    2.2.2 Expression vectors ........................................................................................... 34
    2.2.3 Primers ............................................................................................................. 36
  2.3 Microbiological methods ............................................................................................... 37
    2.3.1 General cultivation of bacterial strains ............................................................ 37
    2.3.2 Preparation of competent E. coli cells ............................................................... 38
      2.3.2.1 Chemically competent E. coli cells ............................................................... 38
      2.3.2.2 Electro-competent E. coli cells ................................................................. 38
    2.3.3 Transformation of chemically competent E. coli cells ...................................... 38
    2.3.4 Transformation of electro-competent E. coli cells ............................................ 39
    2.3.5 Preparation of glycerol stocks .......................................................................... 39
    2.3.6 In vivo activity assays ....................................................................................... 39
      2.3.6.1 In vivo complementation assay of E. coli MCI23 with AmiD<sup>Wm</sup>, PBP2<sup>Wm</sup>, PBP3<sup>Wm</sup> and PBP6a<sup>Wm</sup> ................................................................. 39

IV
2.11 Cell biological methods ................................................................. 60

2.10 Fluorometric methods ........................................................................... 58

2.9 Chromatographic methods ........................................................................ 55

2.8 Instrumental methods .............................................................................. 53

2.7 Biochemical methods .............................................................................. 51

2.6 Electrophoretic methods ............................................................................ 49

2.5 Biotechnological methods .......................................................................... 47

2.4 Molecular Biological Methods ................................................................. 42

2.3 In vitro antibiotic susceptibility assays ...................................................... 40

2.2 Cell-free DD-carboxy- and DD-transpeptidase activity assays using lipid II
as a substrate ...................................................................................................... 51

2.11.1 C6/36 insect cell culture ......................................................................... 60

2.10.1 QuantaBlu assay ..................................................................................... 58

2.9.1 Lipid II Synthesis ...................................................................................... 55

2.8.1 Matrix assisted laser desorption/ionization (MALDI) ................................ 53

2.7.1 Protein determination via Bradford assay ................................................ 51

2.6.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis ..................... 49

2.5.1 Overproduction using Strep-tagged proteins .............................................. 47

2.4.6 Site-directed mutagenesis .......................................................................... 46

2.4.5 Cloning ....................................................................................................... 44

2.4.4 Quantitative real-time PCR ........................................................................ 43

2.4.3 Agarose gel electrophoresis ....................................................................... 43

2.4.2 Polymerase chain reaction (PCR) .............................................................. 42

2.4.1 Isolation of genomic and plasmid DNA ..................................................... 42

2.3.6.4 In vivo complementation assay with PBP2<sup>Δbm</sup> and PBP3<sup>ΔMel</sup> in the presence of
antibiotics ............................................................................................................. 40

2.3.7 Preparation of Remazol Brilliant Blue (RBB)-peptidoglycan sacculi .......... 40

2.3.6.2 In vivo complementation assay of E. coli ADE24 ΔamiABC with AmiD<sup>ΔMel</sup> ... 40

2.3.6.3 Growth kinetics ......................................................................................... 40

2.3.5 Thin layer chromatography (TLC) ............................................................. 48

2.3.4 Cleavage of anhydromuropeptides by AmiD .............................................. 45

2.3.3 Protein determination via Bradford assay ................................................... 44

2.3.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis ..................... 44

2.3.1 Isolation of genomic and plasmid DNA ..................................................... 42

2.2.1 Determination of phosphate concentration ................................................. 58

2.2.1.1 Isolation of UDP-MurNAc-pentapeptide substrate ..................................... 55

2.2.1.2 Membrane preparation .............................................................................. 56

2.2.1.3 In vitro lipid II synthesis .......................................................................... 57

2.2.1.4 Purification of lipid II via high performance liquid chromatography (HPLC) .... 57

2.2.1.5 Determination of phosphate concentration ................................................. 58

2.2.1.6 In vitro β-lactamase activity assay ............................................................. 59

2.2.1.7 Penicillin-binding assay ............................................................................ 59

2.2.1.8 C6/36 insect cell culture ........................................................................... 60

2.11.2 Isolation of wAlbB from C6/36 insect cells ............................................... 60

2.11.3 Cell-free wAlbB culture ........................................................................... 60
3 Results ................................................................................................................................... 66

3.1 Functional analysis of PBP6α

3.1.1 Primary structure analysis of PBP6α

3.1.2 Secondary structure analysis of PBP6α

3.1.3 Characterization of PBP6α in vivo

3.1.4 Active site analysis of PBP6α in vivo

3.1.5 Periplasmic expression and purification of recombinant PBP6α

3.1.6 Activity of PBP6α in vitro using lipid II as a substrate

3.1.7 Active site analysis of PBP6α in vitro

3.1.8 Resistance of PBP6α to β-lactam antibiotics in vitro

3.1.9 In vivo β-lactamase activity assay of PBP6α

3.1.10 In silico binding of PBP6α to cefoxitin

3.2 Functional analysis of PBP2

3.2.1 Primary structure analysis of PBP2

3.2.2 Secondary structure analysis of PBP2

3.2.3 Characterization of PBP2 in vivo

3.2.4 Active site analysis of PBP2 in vivo

3.2.5 Mecillinam treatment of PBP2 in vivo

3.2.6 Periplasmic expression and purification of recombinant PBP2

3.2.7 Characterization of PBP2 in vitro

3.2.8 In vivo β-lactamase activity assay of PBP2

3.2.9 In silico modeling of PBP2

3.3 Functional analysis of Pal

3.3.1 Primary structure analysis of Pal

3.3.2 Pal interaction with PBP2

3.3.3 Pal interaction with lipid II

3.4 Functional analysis of AmiD

3.4.1 Primary structure analysis of AmiD

3.4.2 Secondary structure analysis of AmiD

3.4.3 Characterization of AmiD in vivo

3.4.4 Overexpression and purification of AmiD

3.4.5 Peptidoglycan as a substrate for AmiD

3.4.6 Lipid II as a substrate for AmiD

3.4.7 Inhibition of AmiD activity in vitro
3.4.4.5 Cleavage of anhydromuropeptides ................................................................. 99
3.4.5 Characterization of a putative DD-carboxypeptidase activity of AmiD<sup>W<sub>Mel</sub></sup> .... 100
  3.4.5.1 DD-carboxypeptidase activity of AmiD<sup>W<sub>Mel</sub></sup> in vivo ................................ 101
  3.4.5.2 Active site analysis of DD-carboxypeptidase activity of AmiD<sup>W<sub>Mel</sub></sup> in vivo .... 102
  3.4.5.3 DD-carboxypeptidase activity of AmiD<sup>W<sub>Mel</sub></sup> in vitro .......................... 102
  3.4.5.4 Penicillin-binding assay of AmiD<sup>W<sub>Mel</sub></sup> ........................................... 103
  3.4.5.5 In vivo β-lactamase activity assay of AmiD<sup>W<sub>Mel</sub></sup> .............................. 104
3.5 Functional analysis of PBP3<sup>W<sub>Mel</sub></sup> ................................................................ 104
  3.5.1 Primary structure analysis of PBP3<sup>W<sub>Mel</sub></sup> ............................................. 104
  3.5.2 Secondary structure analysis of PBP3<sup>W<sub>Mel</sub></sup> ....................................... 105
  3.5.3 Characterization of PBP3<sup>W<sub>Mel</sub></sup> and active site analysis in vivo ............... 106
  3.5.4 Aztreonam treatment of PBP3<sup>W<sub>Mel</sub></sup> in vivo ........................................ 108
  3.5.5 In vivo β-lactamase activity assay of PBP3<sup>W<sub>Mel</sub></sup> .................................. 109
  3.5.6 In silico modeling of PBP3<sup>W<sub>Mel</sub></sup> ......................................................... 110
3.6 Fluorescent labeling of D-Ala-D-Ala dipeptides .................................................. 111
  3.6.1 Dipeptide labeling of B. subtilis 168 and E. coli W3110 ............................ 111
  3.6.2 Dipeptide labeling of wAlbB .............................................................. 113
  3.6.3 Dipeptide labeling of fosfomycin-treated wAlbB ..................................... 115
  3.6.4 Cell-free wAlbB viability in different media ............................................ 115
3.7 Cell-free wAlbB culture ................................................................................... 116
  3.7.1 Cell-free wAlbB with modified growth conditions ..................................... 117
    3.7.1.1 Incubation on actin-coated streptavidin plates ...................................... 117
    3.7.1.2 Cell-free growth in a lowered oxygen environment ............................ 117
    3.7.1.3 Supplementation of cell-free wAlbB standard culture medium .......... 117
  3.7.2 Growth of cell-free wAlbB in the presence of antibiotics ......................... 118
    3.7.2.1 Cell-free growth in the presence and absence of penicillin/streptomycin ... 118
    3.7.2.2 Cell-free growth in the presence of antibiotics effective against Wolbachia ... 119
  3.7.3 Morphology of cell-free wAlbB in the presence of antibiotics ................. 121
4 Discussion ........................................................................................................ 123
  4.1 Functional characterization of PBP6<sup>W<sub>Bm</sub></sup> .................................................. 123
  4.2 Functional characterization of PBP2<sup>W<sub>Bm</sub></sup> .................................................. 126
  4.3 Functional characterization of PBP3<sup>W<sub>Mel</sub></sup> .................................................. 129
  4.4 Interaction of Pal<sup>W<sub>Bm</sub></sup> with lipid II and PBP2ΔTM<sup>W<sub>Bm</sub></sup> ..................... 131
  4.5 Functional characterization of AmiD<sup>W<sub>Mel</sub></sup> ............................................. 132
  4.6 Growth requirements of Wolbachia wAlbB in a cell-free culture ..................... 134
  4.7 Antibiotic treatment of Wolbachia wAlbB in a cell-free culture ..................... 138
  4.8 Lipid II labeling of wAlbB ........................................................................ 141
  4.9 Lipid II metabolism and its role in Wolbachia biology .................................... 142
Supplement .......................................................................................................... 146
Literature ............................................................................................................ 163
List of abbreviations .......................................................................................... 176
Summary

Filarial nematodes are prevalent in tropical regions worldwide with some species pathogenic to humans. Filarial diseases include lymphatic filariasis (68 million infected people) and onchocerciasis (37 million infected people) that can result in severe symptoms and are a health problem in affected communities. Anthelmintic drugs must be applied for years as the substances do not act against the adult worms. Moreover, reported side effects and suspected reduced efficacy of the currently used anthelmintics are worrisome. The development of novel substances effective against all life stages of the filariae and suitable for mass drug administration programs is substantial to successfully eliminate filarial diseases. *Wolbachia* are obligate intracellular Gram-negative bacteria that are widespread in arthropods and found in several filarial nematode species. In filarial worms, *Wolbachia* are obligate mutualistic endosymbionts required for survival of their hosts and for embryogenesis in the female worms. Thus, filariasis can be effectively treated with antibiotics targeting *Wolbachia*. However, the currently used antibiotics are not suitable for mass drug administration programs and new substances, which are well-tolerated by patients, are required. A better understanding of *Wolbachia* biology is crucial to identify novel potential antibiotic targets. The genome of *Wolbachia* is highly reduced due to adaption to their hosts and in contrast to free-living bacteria, they do not need a protective cell wall composed of the macromolecule peptidoglycan. However, the peptidoglycan precursor lipid II has already been shown to be synthesized and required for cell division in *Wolbachia*. Until now, it is unclear if and how lipid II is modified and peptidoglycan has never been detected in these endobacteria.

To provide insight into wolbachial lipid II processing, the putative penicillin-binding proteins (PBPs) PBP2 and PBP6a from *Wolbachia* endosymbionts of the filarial nematode *Brugia malayi* (*wBm*) were analyzed in this study. Also, the activity of AmiD and PBP3 from *Wolbachia* endosymbionts of *Drosophila melanogaster* (*wMel*) were characterized, two lipid II processing enzymes additionally present in genomes of *Wolbachia* residing in arthropods. Binding studies were performed to measure a potential interaction between the peptidoglycan-associated outer membrane lipoprotein (Pal) from *wBm* and lipid II as well as PBP2. To detect a putative peptidoglycan-like structure in *Wolbachia*, lipid II was labeled in *Wolbachia* from *Aedes albopictus* using dipeptide analogues. Moreover, an established cell-free *Wolbachia* culture was further studied regarding potential growth facilitating factors and impact of antibiotics.
The results of the present study demonstrate PBP activity in dependence on functional serines of the active site motifs SXXK. PBPs are typically blocked by β-lactam antibiotics that bind to the serine of the highly conserved SXXK motif. Nevertheless, the PBPs were resistant to β-lactams. Contrary to their *E. coli* orthologs, all examined wolbachial PBPs encode additional SXXK motifs which might contribute to enzyme functionality and might explain β-lactam resistance. *In silico* analyses predicted that due to protein folding, β-lactams might not have access to all active site motifs. Therefore, in contrast to canonical systems like *E. coli*, these enzymes are not appropriate targets to deplete *Wolbachia*. AmiD showed zinc-dependent amidase activity and cleaved intact peptidoglycan, monomeric lipid II and additionally anhydromuropeptides, substrates that are generated by cleaved glycosidic bonds of glycan strands. The conservation of the capability of AmiD to cleave anhydromuropeptides gives a hint that at least insect *Wolbachia* may contain a peptidoglycan-like structure with connected glycan strands. Lipid II and PBP2 both interacted with the outer membrane protein Pal from *wBm* suggesting that lipid II and PBP2 are present in the *Wolbachia* periplasmic space. These results together with the active PBPs from *wBm* indicate that lipid II might be processed to a peptidoglycan-like structure also in *Wolbachia* residing in filarial nematodes. The dipeptide labeling provided visual evidence of a lipid II-containing structure in *Wolbachia* for the first time, which was absent in fosfomycin-treated cells with impaired lipid II synthesis. Moreover, fosfomycin led to an aberrant phenotype of cell-free *Wolbachia* resulting in enlarged cells. None of the other applied antibiotics including β-lactams showed an effect on morphology providing further evidence that *Wolbachia* are resistant to this class of antibiotics.

In conclusion, the results of this study together with latest research findings regarding peptidoglycan in intracellular bacteria indicate that *Wolbachia* are not cell wall-less bacteria, but rather have a physical structure composed of lipid II that can interact with outer membrane proteins and that is necessary for coordinated cell division.
Zusammenfassung


Um einen Einblick in die mögliche Prozessierung von Lipid II zu bekommen, wurden in der vorliegenden Doktorarbeit die Penicillin-bindenden Proteine (PBPs) PBP2 und PBP6a aus *Wolbachien* des Fadenwurms *Brugia malayi* (wBm) untersucht. Des Weiteren wurden AmiD und PBP3 aus *Wolbachien* der Fruchtfliege *Drosophila melanogaster* (wMel) charakterisiert. Diese beiden Lipid II-prozessierenden Enzyme sind zusätzlich in *Wolbachien* aus Arthropodenspezies annotiert. Außerdem wurden Bindungsstudien durchgeführt, um mögliche Interaktionen zwischen dem Peptidoglykan-assoziierten äußeren Membran Lipoprotein Pal aus wBm und Lipid II bzw. PBP2 zu detektieren. Um eine potentielle


Die Ergebnisse dieser Arbeit, unterstützt durch neuere Forschungsergebnisse bezüglich nachgewiesener peptidoglykanartiger Strukturen in anderen intrazellulären Bakterien, deuten darauf hin, dass Wolbachien keineswegs zellwandlos sind. Sie haben vermutlich eine aus Lipid II bestehende physikalische Struktur, die mit der äußeren Membran interagiert und notwendig für eine koordinierte Zellteilung ist.
1 Introduction

1.1 Neglected tropical diseases and filariasis

Around one billion people in 149 countries are affected by so-called neglected tropical diseases caused by a variety of pathogens including bacteria, helminths, protozoa and viruses (Mackey et al., 2014). Neglected tropical diseases are mainly prevalent in the tropical regions of Africa, Asia and Latin America and play a minor role in research in high-income western countries. Diagnostics, medication and vaccines either do not exist or are outdated and unsuitable for use in areas with poor infrastructure (Mueller-Langer, 2013). Infected people suffer from severe illness, disability, social exclusion and mortality, the economic impact includes low productivity and high health care costs. As neglected tropical diseases are a constraint to economic growth and lower the already low standard of living in affected areas, the gap in equality between developed and developing countries widens further (Gallup and Sachs, 2000). In the past few years, the World Health Organization (WHO) has raised awareness of this topic, for example by publishing a roadmap to accelerate work on neglected tropical diseases (WHO, 2012). Subsequently, private and public partners signed up to the London Declaration on neglected tropical diseases in 2012 which commits them to work on the WHO targets, in particular by funding or supply of drugs. Additionally, the Sustainable Developmental Goals by the United Nations also include neglected tropical diseases as a target to “end the epidemics […] by 2030” (UN, 2015). New and ongoing efforts to control, eliminate and eradicate neglected tropical diseases represent key elements for achieving these goals (Hotez et al., 2016).

Neglected tropical diseases include lymphatic filariasis and onchocerciasis caused by filarial nematodes of the order Spirurida, which are endemic in tropical regions worldwide with around one billion people living in risk areas mainly in Africa and Southeast Asia (WHO, 2016a). Currently, around 68 million people have lymphatic filariasis provoked by Wuchereria bancrofti, Brugia malayi and Brugia timori (Ramaiah and Ottesen, 2014). Infectious third-stage (L3) larvae are transmitted from the intermediate host, mosquitoes of the genera Aedes, Anopheles, Culex and Mansonia during a blood meal onto the skin of the mammalian host (Figure 1). The larvae migrate to and penetrate through the bite wound into their definitive host, where they enter the lymphatic system and molt two more times as they develop into adult worms (Wenk and Renz, 2003). The adult worms reside in lymphatic vessels, mostly of the extremities and male genitalia where they can breed and, in case of Wuchereria bancrofti, survive up to ten years in humans (Wenk and Renz, 2003). After mating, the female worms
release microfilariae which migrate through the lymph into the blood stream, where they are ingested by a mosquito vector taking a blood meal. Inside the mosquito, the microfilariae lose their sheaths and migrate from the midgut into the thoracic musculature where they pass through first-stage (L1) and second-stage (L2) larval stages before becoming infective L3 larvae which migrate into the proboscis (Wenk and Renz, 2003).

Due to the death of the adult worms severe pathologies like hydrocele and lymphedema (elephantiasis) can occur in infected individuals (Figure 2A) (Hoerauf et al., 2001; Taylor et al., 2010). Around 36 million cases of hydrocele and lymphedema are reported and affected people are predisposed to secondary bacterial infections, which can be life-threatening when untreated (Dreyer et al., 2000; Ramaiah and Ottesen, 2014). Lymphatic filariasis-caused
lymphedema is the second leading cause of global disability and moreover, the disfigurement of body parts leads to social stigmatization and marginalization (Ramaiah and Ottesen, 2014).

Onchocerciasis in humans is caused by the filarial worm *Onchocerca volvulus* and is transmitted through the bites of infected blackflies of the genus *Simulium*. Around 37 million people are infected with more than 99% of cases located in Sub-Saharan African countries (Noma et al., 2013; WHO, 2016b). When a blackfly is taking a blood meal on an infected human, microfilariae are ingested and penetrate the blackfly’s midgut and migrate to the thoracic musculature where they pass through L1 and L2 larval stages before they develop into infective L3 larvae which migrate to the head and blackfly’s proboscis (Wenk and Renz, 2003). During another blood meal, the infected blackfly introduces L3 filarial larvae onto the skin of the human host, where they penetrate through the bite wound. In subcutaneous tissues the larvae develop into adult worms, which commonly reside in nodules. Notably, adult filariae causing onchocerciasis can breed and survive up to 15 years in humans (Ômura and Crump, 2004). The ovoviviparous female adult worms release up to 1000 microfilariae per day, which migrate through skin tissues and the eyes. The death of microfilaria induces immune responses that can cause a variety of pathologies in the human body including blindness (river blindness), skin rashes, lesions, intense itching and skin depigmentation (Sowda) (Figure 2B) (Taylor et al., 2010). River blindness is the second leading cause of vision loss induced by infections (Boatin and Richards, 2006). Moreover, recent studies reveal an association between the nodding syndrome and the infection with *O. volvulus* (Foltz et al., 2013; Idro et al., 2016). This seizure disorder, mostly affecting children in Eastern Africa, may be an autoimmune epilepsy induced by *Onchocerca* worms (Johnson et al., 2017).

Although not lethal per se, lymphatic filariasis and onchocerciasis cause 3.9 million disability-adjusted life years (DALYs) annually (WHO, 2016a, 2016b). DALYs regard the
immense limitations of life quality of infected people and measure the impact of the disease on
the affected community. Thus, filarial diseases play a major social as well as economic role in
dermic countries and infections have an enormous impact on the life of millions of people
(Ottesen, 2000; Ramaiah and Ottesen, 2014).

1.2 Treatment of filarial diseases

Currently, there are no approved vaccinations available against filarial diseases (Khatri
et al., 2018). Thus, alternative approaches are needed to interrupt the life cycle of the worms
and to stop transmission. One possibility is the protection against infectious mosquito bites by
repellents or bed nets, but the feasibility for residents of endemic areas is mixed (Sangoro et al.,
2014). Another possibility is vector control, but this requires the use of chemicals like
dichlorodiphenyltrichloroethane (DDT), which persists in the environment, accumulates in
fatty tissues and can cause adverse health effects in humans (Turusov et al., 2002). For people
already infected with filariasis, mainly the anthelmintic drugs albendazole (ALB),
diethylcarbamazine (DEC) and ivermectin (IVM) are applied (Fischer et al., 2017). William C.
Campbell and Satoshi Ōmura were awarded the Nobel Prize in Physiology or Medicine in 2015
for discovering the compound avermectin produced by *Streptomyces avermitilis*, which was
chemically modified to the more effective drug IVM (reviewed by Campbell, 2012). IVM has
radically lowered the incidence of onchocerciasis as well as lymphatic filariasis and, moreover,
has shown efficacy against various other parasitic diseases like strongyloidiasis and also
ectoparasitic infections like scabies (Crump and Ōmura, 2011; Tambo et al., 2015).

The WHO has launched programs to eliminate lymphatic filariasis and onchocerciasis
by 2020 and 2025, respectively (Ramaiah and Ottesen, 2014). The current mass drug
administration (MDA) strategy to treat lymphatic filariasis is to provide repeated, annual doses
of ALB with either DEC or IVM for the lifespan of adult worms (Tisch et al., 2005; Fischer et
al., 2017). Remarkably, it is estimated that about 97 million cases of lymphatic filariasis were
prevented or cured since the beginning of MDA treatments in 2000 leading to a 59 % reduction
of initial infection levels (Ramaiah and Ottesen, 2014). A pilot study reveals that a DEC, IVM
and ALB single-dose triple-drug regimen is safe and more effective than the standard DEC plus
ALB combination (Thomsen et al., 2015). These findings will potentially accelerate efforts to
eradicate lymphatic filariasis (Fischer et al., 2017). DEC has been phased out as the drug of
choice in treating of onchocerciasis as the sudden death of enormous numbers of microfilariae
in the skin can cause serious side effects in patients (Bird et al., 1980; Francis et al., 1985;
Awadzi and Gilles, 1992). Onchocerciasis is treated with IVM in MDA programs (Komlan et
al., 2018). In Latin America, MDA programs were successful achieving that four countries are verified free of onchocerciasis transmission (WHO, 2016b).

Unfortunately, apart from possible side effects and suspected resistance development, one major disadvantage of the presently used anthelmintic drugs is that all of them mainly have microfilaricidal effects and do not act against the adult worms (Osei-Atweneboana et al., 2011). Since these can survive and breed several years in humans, it is necessary to assure the administration of drugs for years, but for example 22 African countries are still challenged with the start, scale-up and continuation of MDA (WHO, 2016a). Moreover, in regions endemic for onchocerciasis with high prevalence it has been shown that transmission is likely to reappear when administration is stopped even after 17 years of annual treatment (Katabarwa et al., 2011).

Additionally, IVM or DEC treatment in regions that are co-endemic for the filarial nematode species *Loa loa* can result in progressive neurologic decline and encephalopathy, thus excluding MDA in these areas (Gardon et al., 1997; Kamgno et al., 2009; Bockarie and Deb, 2010). Despite much progress, a major effort is needed to achieve the WHO goals. For the successful elimination of filarial infections novel drugs with macrofilaricidal or sterilization effects are required, which can be applied in short-term MDA programs and in areas with emerging IVM resistance or *L. loa* co-endemicity (Klarmann-Schulz et al., 2017).

### 1.3 Wolbachia endosymbionts as targets for anti-filarial treatment

Obligate α-proteobacterial endosymbionts of the genus *Wolbachia*, present in many filarial nematodes, have been investigated as a novel approach for chemotherapy to treat filarial diseases (Taylor and Hoerauf, 1999; Bandi et al., 2001; Hoerauf et al., 2003; Walker et al., 2015). These bacteria were first described as “*Rickettsia*-like organisms in insects” in 1924 by the scientists Marshall Hertig and Samuel Wolbach, and later named *Wolbachia* (Hertig and Wolbach, 1924; Hertig, 1936). *Wolbachia* are pleomorphic and cell size usually varies between 0.5 and 1.3 μm (Hertig, 1936). Subsequently, it has been shown that *Wolbachia* indeed belong to the order Rickettsiales and are widespread in arthropods, infecting at least 40 % of species (Zug and Hammerstein, 2012). Unlike members of the related genera *Anaplasma, Ehrlichia* and *Rickettsia*, *Wolbachia* do not routinely infect vertebrates (Werren et al., 2008). *Wolbachia* have attracted considerable interest in the last two decades, primarily because of their effects on their hosts, which range from reproductive manipulation to mutualism, and potential applications in pest and disease vector control (Werren et al., 2008).

*Wolbachia* intracellularly reside in host-derived Golgi-related vacuoles in the cytoplasm of some somatic tissues as well as in cells of the host germline (Tram et al., 2003; Cho et al.,
A general characteristic feature of intracellular bacteria is a highly reduced genome due to the adaption to their host (Stepkowski and Legocki, 2001). Sequenced genomes of different *Wolbachia* strains range from 0.9–1.5 Mb and they have lost many genes compared to free-living bacteria, particularly those involved in biosynthetic pathways (Wu et al., 2004; Foster et al., 2005; Lindsey et al., 2016).

In arthropods, *Wolbachia* are facultative endosymbionts and as survival of the host is not necessarily dependent on the bacteria, manipulating the host by inducing cytoplasmic incompatibility, parthenogenesis, feminization and male killing are strategies of the *Wolbachia* to ensure vertical transmission and survival (Clark, 2007). However, there are exceptions and in some cases the arthropod host requires *Wolbachia* for oogenesis and positive benefits to fitness have also been demonstrated in terms of resistance to different pathogens and in nutrient provisioning (Zug and Hammerstein, 2015). Interestingly, several filarial nematode species also harbor *Wolbachia* (Sironi et al., 1995). Here, the *Wolbachia* are obligate mutualistic endosymbionts required for survival of their hosts and embryogenesis of microfilariae (Bandi et al., 1998; Bandi et al., 1999; Hoerauf et al., 2000).

The current hypothesis is that *Wolbachia* provide their host with essential metabolites and vice versa. For instance, the nematode host is not able to generate flavin adenine dinucleotide, purine, pyrimidine, riboflavin and heme and therefore needs to obtain these compounds by external sources or from its endosymbiont that is able to synthesize them (Foster et al., 2005; Slatko et al., 2010). In turn, *Wolbachia* strains residing in filarial nematodes have a smaller genome than strains living in arthropods and thus need essential compounds provided by their host (Foster et al., 2005). They lack almost all biosynthetic pathways to produce amino acids *de novo* and retained only incomplete pathways for the synthesis of certain vitamins and cofactors such as nicotinamide adenine dinucleotide, biotin, lipoic acid, ubiquinone, folate, pyridoxal phosphate, and Coenzyme A, making them dependent on external sources (Slatko et al., 2010).

*Wolbachia* are predominantly found in the hypodermal cells of the lateral cords in both male and female nematodes as well as in all larval stages (Hoerauf et al., 2001). Their presence in oocytes, developing eggs and microfilariae indicates that the bacteria are maintained in the population by vertical transmission. *Wolbachia* are essential for worm development, fertility and survival (Bandi et al., 1998). In addition, they were shown to be a major driver of the inflammatory pathogenesis in filarial diseases (Tamarozzi et al., 2011).

Several studies have demonstrated that the depletion of *Wolbachia* by the antibiotics doxycycline and rifampicin leads to sterility and degeneration of adult worms, revealing
Wolbachia as an effective target for anti-filarial therapy (Hoerauf et al., 2000; Hoerauf et al., 2003; Volkmann et al., 2003; Specht et al., 2008) (Figure 3). As L. loa do not harbor Wolbachia endosymbionts, these antibiotics could be used in co-endemic areas without the risk of severe adverse reactions (Bockarie and Deb, 2010). Moreover, anti-wolbachial treatment decreases immune responses that appear when Wolbachia are released after death of filariae, thus having a beneficial effect on treated patients (Pfarr et al., 2009).

Figure 3: Impact of the depletion of endosymbiotic Wolbachia by doxycycline to Onchocerca volvulus (adapted from Hoerauf et al., 2000). A) A midbody cross-section of a female Onchocerca volvulus worm containing Wolbachia found mainly in the hypodermal chords and in embryos (Wolbachia are stained in red). B) Wolbachia are depleted after treatment with doxycycline and embryos are degenerated. h: hypodermal chords, c: cuticle, m: musculature, i: intestine, u: uterus epithelium, arrows: non-corpuscular, less intense staining possibly of nematode mitochondrial hsp-60.

Rifampicin is an essential back-up antibiotic for the treatment of tuberculosis, which is also endemic in many of the areas where filarial diseases occur, thus presenting a risk of selecting for rifampicin-resistant tuberculosis pathogens (Mycobacterium spp.) when broadly applied as an anti-wolbachial drug (Smits, 2009). The use of doxycycline in MDA programs is constrained by contraindications in children under eight years as well as pregnant or breast feeding women and the logistics of a relatively lengthy course of treatment (4–6 weeks) (Hoerauf et al., 2008; Taylor et al., 2014). However, doxycycline can be used for individual drug administration (Taylor et al., 2010). A recent clinical phase two pilot study suggests that the combination of doxycycline (200 mg/day 3 weeks) with ALB (800 mg/day 3 days) leads to an additive effect on top of that of doxycycline alone and might be a promising step forward to reduce treatment time (Klarmann-Schulz et al., 2017). Nevertheless, the development of substances suitable for short-term MDA and targeting all stages of the filarial worms is urgently needed.

Comparative genomics, bioinformatics and experimental analyses have identified a number of potential interactions which may be drug targets in Wolbachia including membrane proteins, ankyrins, lipoprotein biosynthesis, enzymes of undecaprenyl-pyrophosphoryl-
MurNAc-pentapeptide-GlcNAc (lipid II) biosynthesis, heme biosynthesis, the glycolytic enzymes pyruvate phosphate dikinase and cofactor-independent phosphoglycerate mutase (Slatko et al., 2010). For example, treatment with globomycin, which inhibits lipoprotein biosynthesis, led to a reduced Wolbachia load in an infected insect cell culture and significant reductions in motility and viability in B. malayi in vitro experiments (Johnston et al., 2010). The benzimidazole compound wALADin1 selectively targets the δ-aminolevulinic acid dehydratase of Wolbachia (wALAD), an enzyme of heme biosynthesis. wALADin1 also exhibits macrofilaricidal effects on Wolbachia-containing filarial worms in vitro (Lentz et al., 2013). Currently, the most promising drug is corallopyronin A, a non-competitive inhibitor of the bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase which is synthesized by Corallococcus coralloides (Irschik et al., 1985). In vivo, corallopyronin A depletes Wolbachia, resulting in impeded worm development (Schiefer et al., 2012). Resistance development in Staphylococcus aureus due to mutations were reported (Mariner et al., 2011). However, recombination rates were shown to be slow in Wolbachia from nematodes (Jiggins, 2002). Thus, corallopyronin A is an antibiotic to be developed further in clinical studies for filariasis elimination without concern for cross-resistance development in tuberculosis as this antibiotic has low efficacy against Mycobacterium spp. (Schäberle et al., 2014). The approach with an antibiotic-based therapy shows promising results in defeating filariasis and preventing the painful and disfiguring symptoms of elephantiasis (Rebollo and Bockarie, 2014; Walker et al., 2015).

1.4 Wolbachia as an intracellular model organism: the benefit of basic research to identify new targets against filariasis

Wolbachia pipiens is the most common bacterial infection in the animal world and has a vast influence on invertebrate reproduction, sex determination, speciation and behavior (LePage and Bordenstein, 2013). From a biodiversity perspective, Wolbachia infections are one of the great pandemics in the history of life (LePage and Bordenstein, 2013). The discoveries that Wolbachia-infected mosquitoes show lower susceptibility or even resistance to viruses causing dengue, chikungunya, yellow fever and zika as well as malaria-causing Plasmodium spp. create a potentially cheap and sustainable system in which this pandemic can be used as a tool to control vector-borne diseases (Moreira et al., 2009; Bian et al., 2010; Dutra et al., 2016). For instance, in an effort to eliminate dengue, a technology was developed with the stable introduction of W. pipiens into the mosquito Aedes aegypti to reduce its ability to transmit
dengue fever due to life shortening and inhibition of viral replication effects (Hoffmann et al., 2011). Other research areas have focused on the mutualistic role between Wolbachia and filarial nematodes aiming to eliminate the bacterial infection and thereby reducing the fitness of the worms that depend on it. The evolutionary distance of Wolbachia from mammals is far greater than that from nematodes, affording opportunities for treating filarial infections by specifically targeting its endosymbiont (Slatko et al., 2010).

Due to their obligate intracellular lifestyle and reduced genome, Wolbachia represent an organism in which essential processes like cell elongation and cell division are functionally organized in a minimal set-up. One of the most significant challenges to the experimental investigation of Wolbachia biology is the reliance on a eukaryotic host cell for bacterial proliferation (Rasgon et al., 2006). Attempts to establish a cell line containing nematode Wolbachia strains were not successful so far (Slatko et al., 2014), but Wolbachia-infected insect cell lines like Aedes albopictus Aa23 or C6/36 are established in vitro models to simulate filarial Wolbachia strains (O'Neill et al., 1997; Turner et al., 2006). Notably, insect W. pipientis strain A. albopictus B (wAlbB) can be purified from host cells and maintained extracellularly up to one week in a cell culture, but without replication (Rasgon et al., 2006). A better understanding of Wolbachia biology and particularly host-symbiont interactions is a key for future development of drugs against filarial diseases and therefore an excellent example of how basic research can be translated to biomedical science.

1.5 Bacterial cell wall

Free-living bacteria are dependent on a cell surrounding envelope which regulates bacterial size, shape, internal pressure and diffusion of molecules from the environment (Cloud-Hansen et al., 2006). The bacterial cell wall consists of a peptidoglycan polymer, which, as the name implies, is made of long linear glycan chains that are cross-linked by short peptides (Figure 4) (Höltje, 1998). The glycan chains are composed of alternating β-1,4 linked amino sugar units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc). Pentapeptides, usually consisting of the amino acids L-alanine (L-Ala), D-glutamic acid (D-Glu), meso-diaminopimelic acid (m-DAP) or L-lysine (L-Lys), and two terminal D-alanine (D-Ala), are attached to the carboxy-group of MurNAc (Schwechheimer and Kuehn, 2015). The amino acid m-DAP, an intermediate product of the bacterial lysine biosynthesis pathway, is typically found in the peptide chains of Gram-negative bacteria and the Gram-positive bacilli, while L-Lys is found in most Gram-positive bacteria (Schwechheimer and Kuehn, 2015). The terminal D-Ala of the pentapeptide is removed during the crosslinking transpeptidation process,
which takes place between the carboxyl group of the D-Ala at position four and the amino group of the m-DAP/L-Lys at position three of an adjacent peptide chain (Typas et al., 2012). Gram-positive bacteria have an inner membrane and are surrounded by several peptidoglycan layers of about 40–80 nm. The predominantly single-layered peptidoglycan of Gram-negative bacteria is much thinner at around 7–8 nm and located in the periplasm between the inner and the outer membrane (Malanovic and Lohner, 2016).

**Figure 4: Structure of peptidoglycan.** A) Simplified scheme of peptidoglycan consisting of linear glycan strands interlinked via peptide side chains. Green hexagons represent the sugar moiety N-acetylglucosamine (GlcNAc), blue hexagons represent N-acetylmuramic acid (MurNAc). Circles represent the amino acids L-alanine (L-Ala; yellow), D-glutamic acid (D-Glu; orange), L-lysine (L-Lys; red) or meso-diaminopimelic acid (m-DAP; red) and D-alanine (D-Ala; purple). B) Chemical structure of a peptidoglycan monomer unit composed of GlcNAc and MurNAc, and a pentapeptide containing L-Ala, D-Glu, L-Lys or m-DAP and two D-Ala (Olrichs, 2010).

1.5.1 Cell wall synthesis and breakdown in bacteria

Peptidoglycan biosynthesis is a multi-step process that takes place in three different cellular compartments: the cytoplasm, the cytoplasmic membrane and the periplasm (Figure 5) (Typas et al., 2012). It starts in the cytoplasm with the synthesis of uridine diphosphate N-acetyl-glucosamine (UDP-GlcNAc) by the conversion of fructose-6-phosphate via the activity of the enzymes GlmS, GlmM and GlmU (Misra et al., 2015). The precursor UDP-N-acetylmuramic acid pentapeptide (UDP-MurNAc-pentapeptide) is synthesized from UDP-GlcNAc and is catalyzed by the six enzymes MurA to MurF. Subsequently, the UDP-MurNAc-pentapeptide moiety is attached to the membrane-bound lipid carrier undecaprenyl phosphate (C\textsubscript{55}-P) by the enzyme MraY, yielding lipid I. The lipid I molecule
serves as a substrate for the enzyme MurG to add an UDP-GlcNAc molecule forming the final cell wall precursor lipid II (Typas et al., 2012). After synthesis, lipid II is flipped across the cytoplasmic membrane into the periplasm. To date, the identity of the enzyme translocating lipid II across the cell membrane remains a matter of debate. There are several candidates including MurJ, FtsW and RodA which might function as a flippase, but these are controversially discussed (Ruiz, 2016).

Figure 5: Peptidoglycan synthesis in Gram-negative bacteria. The peptidoglycan precursor lipid II is synthesized by the enzymes MurA-MurG and MraY. After translocation into the periplasm, lipid II is incorporated into the growing chain by various synthesizing and hydrolyzing enzymes building peptidoglycan.

Once in the periplasm, lipid II is incorporated into the growing peptidoglycan by a multi-enzyme complex, the elongasome, as exemplarily shown for the Gram-negative bacterium *Escherichia coli* (*E. coli*) (Typas et al., 2012) (Figure 6). The enzymes of the elongasome are highly regulated to avoid disturbing the equilibrium between synthesizing and hydrolyzing enzymes, which would ultimately lead to cell death if not tightly controlled.
Figure 6: Different peptidoglycan synthesis complexes are active during the cell cycle of *E. coli* (Typas et al., 2012). MreB and associated membrane proteins control the position and activity of peptidoglycan synthases PBP1A and PBP2 as well as so far unknown hydrolases (Hyd) during dispersed elongation. During a preseptal mode of elongation, which is located to the midcell, FtsZ forms the Z-ring and is associated with ZapA, ZipA, FtsA, FtsEX and FtsK. It is unknown whether MreB and associated proteins participate at this time point. The cell division complex contains essential, inner membrane-localized cell division proteins, the peptidoglycan synthases PBP1B and PBP3, lytic transglycosylases (LT) and amidase enzymes (Ami) with their activators as well as proteins of the Tol-Pal complex for constriction of the outer membrane.
The sugar moieties are linked to the nascent glycan chains by glycosyltransferases, while D-alanyl-D-alanine (DD)-transpeptidases catalyze the formation of peptide cross-links. The degree of cross-linking is regulated by DD-carboxypeptidases that cleave the terminal D-Ala of the pentapeptide side chains to maintain cell shape by controlling the amount of pentapeptide substrates available to the peptidoglycan synthetic DD-transpeptidases (Peters et al., 2016). The DD-transpeptidases and DD-carboxypeptidases belong to the family of penicillin-binding proteins (PBP) named after their capacity to covalently bind penicillin (Suginaka et al., 1972) (see chapter 1.5.2). The insertion of a new peptidoglycan strand into the existing sacculus requires the degradation of mature peptidoglycan by lytic enzymes referred to as cell wall hydrolases (Vollmer et al., 2008). Cell wall hydrolases such as lytic transglycosylases, endopeptidases and amidases are capable of cleaving different bonds within the net-like peptidoglycan structure. Lytic transglycosylases cleave the glycosidic bond between MurNAc and GlcNAc units, endopeptidases cut various amide bonds between the amino acids of the peptide chains and amidases hydrolyze the amide bond between MurNAc and the N-terminal L-Ala residue of the peptide chain (Vollmer et al., 2008). The degradation process is essential for proper cell division in which septal peptidoglycan needs to be cleaved but on the other hand also produced at the same time to allow separation of the daughter cells. This complex machinery, the divisome, consists of various synthesizing, hydrolyzing, cytoskeletal and regulating proteins as well as proteins of the Tol-Pal complex (Typas et al., 2012).

1.5.2 Penicillin-binding proteins (PBP)

PBPs belong to the protein family of acyl serine transferases and are essential enzymes for the final steps of peptidoglycan biosynthesis and are also required for proper cell division (Scheffers and Pinho, 2005). These enzymes play a crucial role in β-lactam susceptibility which is based on their high affinity for binding these antibiotics (Suginaka et al., 1972). Usually, PBPs have a PBP and serine/threonine kinase associated domain (PASTA) which forms a stable covalent adduct with β-lactam antibiotics (Yeats et al., 2002). Amino acid sequences of PBPs characteristically harbor the three conserved motifs SXXK, SX(D/N) and K(S/T)G with X denoting a variable amino acid residue. Occasionally, SXN is substituted by SXD and KTG is substituted by KSG, while SXXK is invariant (Goffin and Ghuysen, 2002). The SXXK motif contains the active site serine and is involved in binding of the substrate forming an acyl-enzyme intermediate and reacts with β-lactams. Subsequent deacylation is catalyzed by serine of the SX(D/N) motif and polarized by lysine of the K(S/T)G motif (Dougerty and
Pucci, 2011). Secondary and tertiary structures show that the SXXK motif is located in an α-helix, while SX(D/N) is in a loop connecting two α-helices and K(S/T)G is found in a β-sheet (Kelly and Kuzin, 1995; Goffin and Ghuysen, 1998). Four different physiological functions are assigned to PBPs (Egan et al., 2015) (Figure 7): first, transglycosylation, where PBPs catalyze the polymerization of disaccharide units with simultaneous removal of undecaprenyl pyrophosphate (C_{55}-PP; bactoprenol) probably leaving one C_{55}-PP at the terminal Mur\textsubscript{NAc} residue of the new glycan strand; second, DD-carboxypeptidation, where PBPs cleave the terminal D-Ala of a pentapeptide chain regulating the extent of peptidoglycan cross-linking; third, transpeptidation, in which PBPs catalyze the cross-linking of the peptide chains; and fourth, endopeptidation, in which PBPs hydrolyze the cross-linked peptide chains.

![Figure 7: Schematic presentation of identified PBP activities.](image)

**Figure 7: Schematic presentation of identified PBP activities.** PBPs can catalyze transglycosylation reactions to connect the sugar units with simultaneous removal of undecaprenyl pyrophosphate (C_{55}-PP) probably leaving one C_{55}-PP at the terminal Mur\textsubscript{NAc} residue of the new glycan strand (Egan et al., 2015). They can also exhibit DD-carboxypeptidase activity by cleaving the terminal D-Ala in a pentapeptide chain. PBPs can further act as DD-transpeptidases by cross-linking the peptide chains (with simultaneous DD-carboxypeptidase activity) or as endopeptidases by cleaving the cross-linked peptide chains. Green hexagons represent Glc\textsubscript{NAc}, blue hexagons Mur\textsubscript{NAc}. Circles represent the amino acids L-Ala (yellow), D-Glu (orange), L-Lys or m-DAP (red) and D-Ala (purple).

PBPs are divided into high molecular weight (HMW) PBPs and low molecular weight (LMW) PBPs (Sauvage et al., 2008). HMW-PBPs are usually anchored to the outer surface of the cytoplasmic membrane and are responsible for peptidoglycan polymerization (Goffin and Ghuysen, 1998; Born et al., 2006). Depending on their structure and activity, they are further classified into class A and class B PBPs. While the C-terminal domain of all HMW-PBPs shows DD-transpeptidase activity, the N-terminal domain of class A provides glycosyltransferase activity (Sauvage et al., 2008). Thus, they are bifunctional PBPs (Höltje, 1998). In class B, the
N-terminal domain is thought to be involved in maintaining cell shape by providing a recognition site for interaction with other proteins during the cell cycle (Den Blaauwen et al., 2008; Zapun et al., 2008). Class B PBPs in *E. coli* are monofunctional DD-transpeptidases (Sauvage et al., 2008). LMW-PBPs are described by the general term of class C PBPs. They are monofunctional and exhibit DD-carboxypeptidase or endopeptidase activity (Ghuysen, 1991; Massova and Mobashery, 1998). Bacteria have a variable number of PBPs which are historically numbered according to their migration on protein gels. For instance, *E. coli* have twelve known PBPs: PBP1a, PBP1b and PBP1c (class A HMW-PBPs); PBP2 and PBP3 (class B HMW-PBPs); PBP4a, PBP4b, PBP5, PBP6a, PBP6b, PBP7 and AmpH (class C LMW-PBPs) (Sauvage et al., 2008). Although the biochemical activities from of all these PBPs are well studied, control mechanisms and their exact roles within cells are not fully understood (Markovski et al., 2016).

1.5.3 Interaction between peptidoglycan and outer membrane proteins

In Gram-negative bacteria, the predominantly single-layered peptidoglycan sacculus is connected to the outer membrane by covalent and noncovalent interactions with various outer membrane proteins (Typas et al., 2010). The peptidoglycan-associated lipoprotein (Pal) is an outer membrane protein which specifically binds to uncross-linked m-DAP and is part of the membrane-spanning Tol-Pal complex (Parsons et al., 2006). The N-terminus of Pal containing the lipid moiety is anchored to the inner side of the outer membrane, with the C-terminus binding to peptidoglycan via a pocket for m-DAP residues (Bos et al., 2007). Pal interacts with the transmembrane protein TolA that, together with TolQ and TolR, forms a sub-complex in the inner membrane. TolB is a periplasmic protein which competes with peptidoglycan to bind Pal and thus regulates this association (Gerding et al., 2007). The Tol-Pal complex also interacts with other outer membrane proteins and builds a connection between the outer membrane, inner membrane and peptidoglycan layer facilitating membrane integrity (Godlewska et al., 2009). However, the Tol-Pal complex has not only been shown to play a role in cell wall stabilization but is also essential for proper constriction of the outer membrane during cell division (Gerding et al., 2007).

Apart from that, it was demonstrated in *E. coli* that certain outer membrane-anchored lipoproteins control peptidoglycan synthases (Paradis-Bleau et al., 2010; Typas et al., 2010). Each so-called Lpo protein stimulates the DD-transpeptidase activity of its cognate PBP by binding and inducing conformational changes (Egan et al., 2014; Markovski et al., 2016). Lpo proteins are limited to γ-proteobacteria (LpoA) and enterobacteria (LpoB). They evolved
independently and have no sequence homology (Typas et al., 2010). The additional level of regulation provided by Lpo proteins may enable niche-specific adaptation and other bacterial groups may have proteins with regulatory roles similar to Lpo proteins (Typas et al., 2012).

1.5.4 Host response to cell wall fragments

In **E. coli**, around 40–50% of the peptidoglycan sacculus is removed during each generation and either translocated to the cytoplasm or liberated into the environment (Typas et al., 2012). To keep resources, most of the degradation products are recovered, translocated into the cytoplasm via permeases and recycled by several enzymes to be available again for the synthesis of new peptidoglycan (Park and Uehara, 2008). The release of cell wall fragments has important messenger functions in bacterial communication and, in infections, liberated fragments can also be detected by the host leading to an immune response (Johnson et al., 2013; Wheeler et al., 2014). To identify pathogens, eukaryotes have evolved different pattern-recognition-receptors (PRRs). One group of PRRs are Toll-Like-Receptors (TLRs) which are part of the innate immune system and recognize pathogen-associated molecular patterns (PAMPs). TLRs sense a variety of PAMPs like bacterial lipopolysaccharides (TLR4), lipopeptides and peptidoglycan (TLR2, TLR6) (Kawai and Akira, 2007). Another group of PRRs are the nucleotide-binding oligomerization domain receptors (NOD). They sense bacterial cell wall fragments, i.e. anhydromuropeptides, and subsequently activate the transcription factor NFκB, which plays a key role in regulating the immune response to infection (Wheeler et al., 2014). NOD 1 has been shown to be specifically activated by m-DAP typically found in Gram-negative bacteria, while NOD 2 binds N-acetyl-muramyl-L-alanyl-D-glutamate (MurNAc-dipeptide) fragments of the cell wall from Gram-positive and Gram-negative bacteria (Lee et al., 2009). Hence, peptidoglycan and cell wall fragments are major players in pathogenesis by contributing to fever, sleepiness and loss of appetite that are symptomatic for many bacterial infections (Wheeler et al., 2014).

1.5.5 Cell wall biosynthesis as a target for antibiotics

Currently, cell wall biosynthesis inhibitors are the most clinically used antibiotics worldwide (Sarkar et al., 2017). The precursor lipid II is essential, highly conserved and difficult to modify, thus resistance to lipid II-targeting antibiotics develops more slowly compared to other antibiotics, e.g. protein biosynthesis inhibitors (Schneider and Sahl, 2010). In particular, easy access outside the cytoplasm makes lipid II and peptidoglycan attractive antibiotic targets from the early identification of penicillin to the recent discovery of teixobactin.
(Ling et al., 2015). For this reason, peptidoglycan synthesis is called the Achilles’ heel of bacteria (Schneider and Sahl, 2010).

1.6 Lipid II metabolism in *Wolbachia*

The genome of *Wolbachia* is highly reduced due to their obligate endosymbiotic lifestyle and it is hypothesized that retained genes and metabolic pathways are crucial for survival (Foster et al., 2005). The characterization of preserved pathways that are essential for *Wolbachia* is necessary to better understand *Wolbachia* biology and possibly their interaction with their different hosts. As for other intracellular bacteria, *Wolbachia* are protected by the host cell and therefore do not need peptidoglycan to withstand osmotic challenges. Interestingly, the *Wolbachia* genomes that have been sequenced and annotated encode all proteins required for the synthesis of lipid II, but endopeptidases and almost all peptidoglycan recycling enzymes are not annotated (Foster et al., 2005) (Figure 8). Also bifunctional PBPs with glycosyltransferase activity were not identified leading to the assumption that *Wolbachia* might have an unusual cell wall without connected glycan subunits (Vollmer et al., 2013). However, a cell wall has not been detected (Kozek, 1977; Louis and Nigro, 1989) and the question remains why *Wolbachia* should keep the high resource consuming process of lipid II synthesis. It has been shown that recombinant *Wolbachia* proteins and purified *Wolbachia* membranes synthesize lipid I and II, supporting the hypothesis that lipid II is required during cell division (Henrichfreise et al., 2009; Vollmer et al., 2013). When lipid II synthesis was blocked by the antibiotic fosfomycin, *Wolbachia* in a C6/36 insect cell culture could not separate properly resulting in enlarged cells (Vollmer et al., 2013). These findings indicate that *Wolbachia* might have kept the energy consuming process of lipid II synthesis, because cell wall biosynthesis and cell division are tightly connected and cannot be separately eliminated in the course of evolution. Additionally, it was demonstrated that *Wolbachia* lipid II likely contains D-Ala obtained by the racemase MetC (Vollmer et al., 2013). It is unclear whether lipid II is further processed and any attempts to detect peptidoglycan in *Wolbachia* have not been successful (Henrichfreise et al., 2009). Therefore, the exact composition of a possible *Wolbachia* cell wall is of great interest in order to find potential targets for the treatment of filarial diseases.
1.6.1 Retained lipid II processing enzymes in Wolbachia

Although almost all peptidoglycan recycling enzymes and glycosyltransferases are not annotated, there are still peptidoglycan synthesizing enzymes encoded in the genome of Wolbachia. PBP2 and PBP6a are found in filarial and insect Wolbachia, while PBP3 is only annotated in insect Wolbachia. PBP2 and PBP3 in free-living bacteria are known to provide DD-transpeptidase activity and catalyze the cross-linking of peptide stems, the DD-carboxypeptidase PBP6a regulates the degree of crosslinking by cleaving the terminal D-Ala of the pentapeptide (Höltje, 1998). The annotated genomes of Wolbachia from arthropods (e.g. wMel, Wolbachia from Drosophila melanogaster; wRi, Wolbachia from Drosophila simulans; wPiP, Wolbachia from Culex quinquefasciatus Pei) have retained one cell wall hydrolase that shows homology to the E. coli N-acetylmuramoyl-L-alanine-amidase.
AmiD. Vollmer et al. (2013) showed that lipid II processing enzymes are not only encoded in the wolbachial genome, but they are indeed expressed in wAlbB. However, the activity of these enzymes has not been studied in Wolbachia and it is unknown if and how lipid II is processed.

A new cell wall labeling technique revealed that obligate intracellular bacteria of the genus Chlamydia synthesize a peptidoglycan-like structure after decades of debates between scientists (Liechti et al., 2014). With the same technique, a peptidoglycan-like structure was also detected in free-living Planctomycetes for the first time and recently also in Orientia tsutsugamushi, which are closely related to Wolbachia also belonging to the order Rickettsiales (Atwal et al., 2017).

1.6.1.1 Penicillin-binding protein PBP2

PBP2 (synonyms: MrdA, ppaA) is a HMW class B PBP DD-transpeptidase involved in cell elongation and maintenance of cell shape. These proteins have an N-terminal, non-penicillin-binding domain, which might be involved in protein-protein interactions and a C-terminal domain with the active site motifs (Höltje, 1998). Inhibition of PBP2 by specific antibiotics, like mecillinam, leads to spherical cells instead of rods in E. coli (Spratt and Pardee, 1975). As shown for S. aureus, PBP2 localizes at the septum in the presence of lipid II. When the lipid II synthesis pathway is inhibited by the antibiotic D-cycloserine, PBP2 delocalizes from the septum (Pinho and Errington, 2005). PBP2 was also found in the lateral wall and at mid-cell during cell division suggesting that it might have an additional housekeeping role (Den Blaauwen et al., 2003). The filarial Wolbachia DD-transpeptidase homolog PBP2 from wBm was re-annotated on the database of the National Center for Biotechnology Information (NCBI) and is now listed as a putative PBP3, a monofunctional DD-transpeptidase involved in cell division. The characterization of this enzyme is part of this work.

1.6.1.2 Penicillin-binding protein PBP3

In free-living bacteria, PBP 3 (synonym: FtsI) is part of the divisome and responsible for correct septation (Goffin et al., 1996). In E. coli, the protein is a HMW class B PBP, which consists of an N-terminal non-penicillin-binding domain with a short intracellular part, a membrane anchor responsible for correct localization, and the C-terminal penicillin-binding domain which harbors the active site motifs (Goffin et al., 1996; Weiss et al., 1999). Up to now, no transpeptidation activity could be detected for PBP3 in vitro, but purified protein from E. coli has been shown to hydrolyze artificial thioester compounds, which might at least indicate the presence of an accessible active site (Adam et al., 1991; Egan et al., 2015). The specific inhibition of PBP3 by the antibiotic aztreonam leads to the arrest of cell division and a
filamentous phenotype which facilitates in vivo activity assays (Weiss et al., 1997). Filarial Wolbachia only harbor the putative monofunctional DD-transpeptidase PBP2 (see chapter 1.6.1.1), whereas Wolbachia residing in insect cells encode PBP2 and PBP3. The function of this additional PBP in Wolbachia biology is unknown. Thus, the putative PBP3 enzyme from wMel was investigated in this thesis.

1.6.1.3 Penicillin-binding protein PBP6a

The final reaction in cell wall synthesis is the cleavage of the terminal D-Ala residue accompanied by the formation of an interpeptide bridge. The degree of cross-linking is regulated by DD-carboxypeptidases which belong to LMW class C PBPs. In E. coli, three periplasmic monofunctional DD-carboxypeptidases have been identified: PBP5, PBP6a (synonym: DacC, formerly known as PBP6) and PBP6b (Peters et al., 2016). To date, the exact function of these proteins, especially PBP6a, is poorly understood. They seem to play a vital role in controlling cell diameter and septum formation as well as in modulating the mature peptidoglycan meshwork (Ghosh et al., 2008; Sarkar et al., 2011). DD-carboxypeptidases are dispensable for the survival of E. coli and the deletion of the corresponding genes does not affect cell growth or morphology except for PBP5, which is considered to act as the main DD-carboxypeptidase (Nelson and Young, 2001). Due to their high amino acid sequence similarity, a potential substitution of PBP5 by PBP6a was investigated, but PBP6a did not compensate growth defects of PBP5-lacking cells (Chowdhury et al., 2010). Additionally, PBP6 was shown to have an in vitro enzyme activity five times weaker than PBP5 (Chowdhury et al., 2010). Contrary to PBP5, which is produced primarily during early exponential growth in E. coli, PBP6a is highly expressed in the stationary phase (Baquero et al., 1996). This leads to the hypothesis of a functional difference between PBP5 and PBP6a in vivo, suggesting a role for the latter in the stabilization of peptidoglycan during the stationary phase (Van der Linden et al., 1992). Of note, overexpressed PBP6a from E. coli was able to restore cell division of a PBP3-repressed E. coli strain, which shows a filamentous phenotype when grown at the non-permissive temperature of 42 °C (Begg et al., 1990). This growth defect can be complemented by the overexpression of a DD-carboxypeptidase cleaving the terminal D-Ala of the pentapeptide chains. The subsequent cleavage of the tetrapeptides by a second carboxypeptidase (LD-carboxypeptidase A) results in increased levels of available tripeptide chains in peptidoglycan. These are the preferred substrates for the residual activity of the impaired PBP3 and cell division can be complemented partially (Botta and Park, 1981; Pisabarro et al., 1986; Begg et al., 1990; Dai et al., 1993). Restoration of growth in the same
PBP3-repressed *E. coli* strain has also been performed with PBP6 from *Chlamydia pneumoniae* and provides an established assay for the determination of *in vivo* DD-carboxypeptidase activity (Otten, 2014). The elucidation of the putative cell wall active enzyme PBP6a from *wBm* is part of this work.

**1.6.1.4 N-acetylmuramoyl-L-alanine-amidase AmiD**

In *E. coli*, four periplasmic N-acetylmuramoyl-L-alanine-amidases are described (Uehara and Park, 2007; Kerff et al., 2010). All of them are zinc-dependent and can be blocked by metal chelators like ethylenediaminetetraacetic acid (EDTA). AmiA, AmiB and AmiC belong to the amidase 3 family and play a role in septum cleavage leading to separation of the daughter cells at the end of cell division (Heidrich et al., 2001). These enzymes hydrolyze the amide bond between the MurNAc lactyl group and the L-alanine of the peptide but they have no activity when the MurNAc is in its anhydro form as a result of glycan chain cleavage by lytic transglycosylases (Heidrich et al., 2001). AmiD, the last N-acetylmuramoyl-L-alanine amidase identified in *E. coli*, is a periplasmic lipoprotein anchored in the outer membrane belonging to the amidase 2 family. It exerts its broader hydrolytic activity on the intact peptidoglycan and soluble fragments containing MurNAc regardless of its anhydro form (Uehara and Park, 2007). AmiD is not involved in cell separation during the bacterial division, and its exact role in the cell has not been identified (Kerff et al., 2010). It has been proposed that AmiD is part of a secondary strategy to prevent immune responses in the host organism by degrading cell wall fragments in the periplasm (Uehara and Park, 2007). The genomes of arthropod *Wolbachia* (e.g. *wMel*, *wRi*, *wPiP*) all contain only one predicted periplasmic cell wall hydrolase. Sequenced genomes of filarial *wBm* and *O. volvulus* (*wOv*) show that these strains have lost the ability to synthesize any of these enzymes, e.g. *wBm0682* might encode an amidase, but genome analysis has concluded that it is a pseudogene (Wu et al., 2004; Foster et al., 2005). Recently, the only identified chlamydial amidase AmiA has been shown to perform a novel bifunctional activity on lipid II as an amidase as well as a DD-carboxypeptidase *in vitro* and this amidase is essential for cell division (Klöckner et al., 2014). In this thesis, the putative hydrolyzing activity of AmiD from *wMel* was analyzed.

**1.6.2 Interaction of *Wolbachia* lipid II and outer membrane proteins**

Bioinformatic analysis of the *wBm* genome using distinct databases consistently identified two lipoproteins in the outer membrane: *Wolbachia* Pal and *Wolbachia* VirB6, which is a core component of the bacterial Type IV secretion system (Turner et al., 2009; Voronin et al., 2014). Analysis of the proteome of adult female *B. malayi* revealed that Pal is one of the
most abundant proteins in Wolbachia (Voronin et al., 2014). Wolbachia do not encode Tol genes located in the inner membrane. Only some of the annotated Wolbachia strains (e.g. \( w_{AlbB}, w_{Mel}, w_{Pip} \)) found in arthropods possess the gene for the periplasmic protein TolB which is assumed to modulate Pal by competing for peptidoglycan (Gerding et al., 2007). However, it is possible that Pal is necessary to connect the inner and outer membrane, especially during cell division, and this interaction partner might be lipid II (Vollmer et al., 2013). First evidence for this was demonstrated in fosfomycin-treated Wolbachia (blocking of lipid II synthesis) resulting in enlarged cells unable to divide and a perturbed localization of the lipoprotein Pal (Vollmer et al., 2013).

1.6.3 Host response to Wolbachia cell wall fragments

In filarial infections, the pro-inflammatory activity of \( B. \text{malayi} \) and \( O. \text{volvulus} \) is higher when Wolbachia are present, and lipoproteins have been identified as key ligands (Hise et al., 2007; Turner et al., 2009; Tamarozzi et al., 2011). It was shown that Wolbachia activate TLR 2/6 in filariosis, and Pal recruits neutrophils, macrophages and other innate immune cells, stimulating their activation and the production of an array of pro-inflammatory cytokines and mediators (Saint André et al., 2002; Hise et al., 2007; Tamarozzi et al., 2011). Additionally, Wolbachia lipoproteins also drive adaptive Th1 immunity through activation of dendritic cells (Turner et al., 2009). Thus, Pal is likely a major driver of Wolbachia-mediated inflammatory immunity. With protein extract of Litomosoides sigmodontis, a filarial nematode infecting rodents used as a mouse model for human filarial infections, it was demonstrated that both NOD 1 and NOD 2 receptors were activated in stimulated human embryonic kidney cells expressing the specific receptor (Ajendra et al., 2016). When Wolbachia residing in the nematodes were depleted by tetracycline, the receptors were not activated after incubation with \( L. \text{sigmodontis} \) extract. The activation of NOD 1 and NOD 2 receptors further confirm that at least cell wall precursors are synthesized by Wolbachia which likely contain m-DAP (Ajendra et al., 2016).
1.7 Objectives

Wolbachia endobacteria are not challenged by osmotic pressure and peptidoglycan has never been detected. Still, Wolbachia encode almost all genes required for the synthesis of the cell wall precursor lipid II, which has been shown to be synthesized and to be essential for cell division (Henrichfreise et al., 2009; Vollmer et al., 2013). However, it is unknown if and how lipid II is processed. The investigation of Wolbachia enzymes involved in lipid II metabolism and the exact composition of a putative Wolbachia cell wall not only provides insight into Wolbachia biology but might also identify novel targets for the development of antibiotics for use in depleting these essential endobacteria from filarial nematodes. Since the role of lipid II in Wolbachia biology is poorly understood, the function of the retained lipid II modifying enzymes in cell wall biosynthesis and cell separation were examined. The overall objective of the present thesis was to elucidate the processing of lipid II in Wolbachia. In particular, the functionality as well as antibiotic susceptibility of putative lipid II processing enzymes were investigated in vivo and in vitro. The main goals of the thesis were:

1. Characterization of the following proteins:
   (I) AmiD<sub>Wm</sub>, a putative N-acetylmuramoyl-L-alanine-amidase from Wolbachia endosymbionts of D. melanogaster
   (II) PBP2<sub>Wm</sub>, a putative DD-transpeptidase from Wolbachia endosymbionts of B. malayi
   (III) PBP3<sub>Wm</sub>, a putative DD-transpeptidase involved in cell division from Wolbachia endosymbionts of D. melanogaster
   (IV) PBP6<sub>Wm</sub>, a putative DD-carboxypeptidase from Wolbachia endosymbionts of B. malayi
   (V) Pal<sub>Wm</sub>, peptidoglycan-associated lipoprotein from Wolbachia endosymbionts of B. malayi
2. By labeling lipid II in vivo, it was investigated whether Wolbachia from an infected C6/36 insect cell culture have a peptidoglycan-like structure.
3. In interaction assays, it was examined in vitro whether Pal<sub>Wm</sub> interacts with lipid II and PBP2<sub>Wm</sub>.
4. An established cell-free Wolbachia culture was further studied and supplemented with substances in order to enhance stability and growth (Vollmer, 2012). Moreover, cell-free Wolbachia were incubated with different antibiotics to test the efficacy and impact on proliferation and morphology.
2 Materials and methods

2.1 Equipment and consumables

2.1.1 Chemicals and solvents

Table 1: List of chemicals used in this thesis.

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,10-Phenanthroline</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Anhydrotetracycline</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>(L-)Arginine</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>(L-)Ascorbic acid</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>β-Mercaptoethanol</td>
<td>Merck Millipore, Darmstadt, Germany</td>
</tr>
<tr>
<td>BCIP</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Betaine</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Biotin</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Biotin Blocking Buffer</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>Bovine Serum Albumin Fraction V</td>
<td>Fisher Scientific, Schwerte, Germany</td>
</tr>
<tr>
<td>Bradford reagent</td>
<td>Cytoskeleton, Denver, USA</td>
</tr>
<tr>
<td>Bromophenol blue</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>C₅₅-P</td>
<td>Larodan Fine Chemicals, Malmö, Sweden</td>
</tr>
<tr>
<td>CENTA™</td>
<td>Calbiochem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Chloroform</td>
<td>J.T. Baker, Griesheim, Germany</td>
</tr>
<tr>
<td>(D-)Desthiobiotin</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>DMF</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>DMSO</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>EDTA</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Merck Millipore, Darmstadt, Germany</td>
</tr>
<tr>
<td>Ethynyl-D-alanyl-D-alanine</td>
<td>Pepmic Co., Ltd., Suzhou, China</td>
</tr>
<tr>
<td>Ethynyl-L-alanyl-L-alanine</td>
<td>Pepmic Co., Ltd., Suzhou, China</td>
</tr>
<tr>
<td>Glycerol</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>HCl</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>KH₂PO₄</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>LE-Agarose</td>
<td>Biozym, Hamburg, Germany</td>
</tr>
<tr>
<td>(D-)Mannitol</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Methanol</td>
<td>J.T. Baker, Griesheim, Germany</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Midori Green Advanced</td>
<td>Nippon Genetics Europe, Düren, Germany</td>
</tr>
<tr>
<td>MOPS</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>NaOH</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Na₂HPO₄</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>NBT</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Novex™ sharp prestained protein ladder</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>PAGEruler prestained protein ladder 1kb</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>PAGEruler unstained protein ladder 1kb</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Perchloric acid 70 %</td>
<td>Merck Millipore, Darmstadt, Germany</td>
</tr>
</tbody>
</table>
### 2 Materials and methods

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraformaldehyde</td>
<td>Merck Millipore, Darmstadt, Germany</td>
</tr>
<tr>
<td>Quick-Load 1kb DNA ladder</td>
<td>New England Biolabs, Ipswich, USA</td>
</tr>
<tr>
<td>Remazol Brilliant Blue Dye</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>SDS</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Strep-Tactin® Sepharose</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>SYBR Green</td>
<td>Fermentas, St. Leon-Rot, Germany</td>
</tr>
<tr>
<td>TEMED</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>(D-)Trehalose</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Tri-Track loading dye</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Uridine 5′-diphospho-N-acetylglucosamine sodium salt</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Vectashield Mounting Medium</td>
<td>Vector Laboratories, Burlingame, USA</td>
</tr>
<tr>
<td>ZnCl₂</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
</tbody>
</table>

#### 2.1.2 Enzymes

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-Amylase from <em>Aspergillus oryzae</em></td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>α-Chymotrypsin</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Alkaline phosphatase conjugate</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>Benzonase</td>
<td>Novagen, Darmstadt, Germany</td>
</tr>
<tr>
<td>BamHI</td>
<td>New England Biolabs, Ipswich, USA</td>
</tr>
<tr>
<td>BsaI HF</td>
<td>New England Biolabs, Ipswich, USA</td>
</tr>
<tr>
<td>EcoRI HF</td>
<td>New England Biolabs, Ipswich, USA</td>
</tr>
<tr>
<td>NcoI HF</td>
<td>New England Biolabs, Ipswich, USA</td>
</tr>
<tr>
<td>D-amino acid oxidase (DAAO)</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Lysozyme</td>
<td>Novagen, Darmstadt, Germany</td>
</tr>
<tr>
<td>Phusion® HF Polymerase</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>T4 Ligase</td>
<td>New England Biolabs, Ipswich, USA</td>
</tr>
</tbody>
</table>

#### 2.1.3 Kits

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Click-iT® Cell Reaction Buffer Kit</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>HotStarTaq® DNA Polymerase Kit</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>LIVE/DEAD® BacLight™ Bacterial Viability Kit</td>
<td>Molecular Probes, Carlsbad, USA</td>
</tr>
<tr>
<td>Nucleospin Gel and PCR Clean-up Kit</td>
<td>Macherey Nagel, Düren, Germany</td>
</tr>
<tr>
<td>QIAamp DNA Mini Kit</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>QIAprep Spin Miniprep Kit</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>QIAquick PCR purification Kit</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>QuantaBlu™ Fluorogenic Peroxidase</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
</tbody>
</table>
2 Materials and methods

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substrate Kit</td>
<td>Agilent Technologies, Waldbronn, Germany</td>
</tr>
<tr>
<td>QuikChange Lightning Site-Directed Mutagenesis Kit</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>Strep Tactin Miniprep Spin Column Kit</td>
<td></td>
</tr>
</tbody>
</table>

2.1.4 Technical equipment

Table 4: List of technical equipment and devices used in this thesis.

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>96-well cell culture well plates, clear, flat bottom, with lid</td>
<td>Greiner, Frickenhausen, Germany</td>
</tr>
<tr>
<td>Bench-top centrifuge 5417R</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
<tr>
<td>Bench-top centrifuge Mikro 200</td>
<td>Hettich, Tuttingen, Germany</td>
</tr>
<tr>
<td>Biacore® T100</td>
<td>GE Healthcare, Chicago, USA</td>
</tr>
<tr>
<td>Binocular Leitz Diavert</td>
<td>Leitz, Wetzlar, Germany</td>
</tr>
<tr>
<td>BLItz® system device</td>
<td>Pall ForteBio, Fremont, USA</td>
</tr>
<tr>
<td>Borosilicate glass beads 3mm</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Cellstar standard cell culture flasks</td>
<td>Greiner, Frickenhausen, Germany</td>
</tr>
<tr>
<td>CM5 sensor chip</td>
<td>GE Healthcare, Chicago, USA</td>
</tr>
<tr>
<td>Corning cell lifter</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Electrophoresis power supply consort EV243</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Falcon™ Chambered Cell Culture Slides</td>
<td>BD Falcon, Corning, USA</td>
</tr>
<tr>
<td>FastGene Led Illuminator</td>
<td>Nippon Genetics Europe, Düren, Germany</td>
</tr>
<tr>
<td>Fraction Collector FC204</td>
<td>Gilson, Middleton, USA</td>
</tr>
<tr>
<td>Freeze dryer Alpha 2-4 LSC</td>
<td>Martin Christ, Osterode am Harz, Germany</td>
</tr>
<tr>
<td>Gel Doc™ EZ Imager</td>
<td>Bio-Rad, München, Germany</td>
</tr>
<tr>
<td>Heraeus Multifuge 1 S-R</td>
<td>Heraeus Instruments, Hanau, Germany</td>
</tr>
<tr>
<td>Hi-Trap DEAE FF column</td>
<td>Amersham Biosciences, Freiburg, Germany</td>
</tr>
<tr>
<td>HPLC</td>
<td>Gilson, Middleton, USA</td>
</tr>
<tr>
<td>Incubator Type B6120</td>
<td>Heraeus Instruments, Hanau, Germany</td>
</tr>
<tr>
<td>MicroPulser™</td>
<td>Bio-Rad, München, Germany</td>
</tr>
<tr>
<td>Mini-PROTEAN® 12 % Precast Gels</td>
<td>Bio-Rad, München, Germany</td>
</tr>
<tr>
<td>Mini-PROTEAN® Tetra Electrophoresis System</td>
<td>Bio-Rad, München, Germany</td>
</tr>
<tr>
<td>Nanophotometer TM 7122v1.6.1</td>
<td>Implen, München, Germany</td>
</tr>
<tr>
<td>Neubauer counting chamber improved</td>
<td>Laboroptik, Bad Homburg, Germany</td>
</tr>
<tr>
<td>Nitrocellulose blotting membrane</td>
<td>Amersham Biosciences, Freiburg, Germany</td>
</tr>
<tr>
<td>PCR cycler</td>
<td>MWG-Biotech, Ebersberg, Germany</td>
</tr>
<tr>
<td>Pierce™ Streptavidin Coated Plates</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Polypropylene column</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>QIAcube robotic workstation</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>Rotavapor RE11</td>
<td>Büchi Labortechnik, Flawil, Switzerland</td>
</tr>
<tr>
<td>Rotorgene 6000</td>
<td>Corbett Life Sciences, Sydney, Australia</td>
</tr>
<tr>
<td>Shaker MaxQ 5000 Mod4360</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Silica plate TLC Silica Gel 60</td>
<td>Merck Millipore, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sorvall Discovery M120 SE</td>
<td>Fisher Scientific, Schwerte, Germany</td>
</tr>
<tr>
<td>Sorvall Evolution EC Superspeed Centrifuge</td>
<td>Fisher Scientific, Schwerte, Germany</td>
</tr>
<tr>
<td>Spark™ 10M multimode microplate reader</td>
<td>Tecan, Männedorf, Switzerland</td>
</tr>
</tbody>
</table>
2 Materials and methods

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spectramax® 340PC</td>
<td>Molecular Devices, Biberach an der Riss, Germany</td>
</tr>
<tr>
<td>Streptavidin biosensors</td>
<td>Pall ForteBio, Fremont, USA</td>
</tr>
<tr>
<td>Sunrise™ microplate reader</td>
<td>Tecan, Mannendorf, Switzerland</td>
</tr>
<tr>
<td>Teflon tubes</td>
<td>Nalgene, Rochester, USA</td>
</tr>
<tr>
<td>Trans-Blot Turbo™ Transfer System</td>
<td>Bio-Rad, München, Germany</td>
</tr>
<tr>
<td>UviLine 9400 photometer</td>
<td>SI Analytics, Mainz, Germany</td>
</tr>
<tr>
<td>Vortexer RS-VA10</td>
<td>Phoenix Instruments, Garbsen, Germany</td>
</tr>
<tr>
<td>Zebra Spin Desalting Columns 7K MWCO</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>ZeissAxio VertA.1 Epifluorescence microscope</td>
<td>Carl Zeiss AG, Oberkochen, Germany</td>
</tr>
<tr>
<td>Zeiss Laser Scanning Microscope 710</td>
<td>Carl Zeiss AG, Oberkochen, Germany</td>
</tr>
</tbody>
</table>

2.1.5 Culture media and supplements

Table 5: Culture media and agar plates used in this thesis.

<table>
<thead>
<tr>
<th>Name</th>
<th>Composition/Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATCC medium: 200 YM medium</td>
<td>3 g yeast extract, 3 g malt extract, 10 g dextrose, 5 g peptone, ad 1 l aqua dest.; pH 6.2</td>
</tr>
<tr>
<td>L15 Leibovitz medium</td>
<td>Invitrogen, Darmstadt, Germany</td>
</tr>
<tr>
<td>Lysogeny broth (LB) medium</td>
<td>10 g tryptone, 5 g yeast extract, 10 g NaCl, ad 1 l aqua dest.; pH 7.5</td>
</tr>
<tr>
<td>LB agar</td>
<td>10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, ad 1 l aqua dest.; pH 7.5</td>
</tr>
<tr>
<td>Mueller-Hinton agar</td>
<td>Becton Dickinson GmbH, Heidelberg, Germany</td>
</tr>
<tr>
<td>Mueller-Hinton broth</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>NaCl-free LB broth</td>
<td>10 g tryptone, 5 g yeast extract, ad 1 l aqua dest.; pH 7.5</td>
</tr>
<tr>
<td>Super optimal broth (SOC) medium</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Tryptone soya broth (TSB)</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
</tbody>
</table>

Table 6: Culture media supplements used in this thesis.

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-cardiac actin from bovine cardiac muscle</td>
<td>Hypermol, Bielefeld, Germany</td>
</tr>
<tr>
<td>Bacto™-Yeast extract</td>
<td>Becton Dickinson, Heidelberg, Germany</td>
</tr>
<tr>
<td>Bacto™-Tryptone</td>
<td>Becton Dickinson, Heidelberg, Germany</td>
</tr>
<tr>
<td>Biotin</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Fetal Calf Serum (FCS)</td>
<td>PAA Laboratories, Colbe, Germany</td>
</tr>
<tr>
<td>Lipid Mixture</td>
<td>PeproTech Inc, Hamburg, Germany</td>
</tr>
<tr>
<td>MEM non-essential amino acids</td>
<td>PAA Laboratories, Colbe, Germany</td>
</tr>
<tr>
<td>Penicillin/Streptomycin</td>
<td>PAA Laboratories, Colbe, Germany</td>
</tr>
<tr>
<td>Sodium pyruvate</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Tryptose phosphate broth</td>
<td>PAA Laboratories, Colbe, Germany</td>
</tr>
</tbody>
</table>
2.1.6 Antibiotics

Table 7: Antibiotics used in this thesis.

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aztreonam</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>AppliChem GmbH, Darmstadt, Germany</td>
</tr>
<tr>
<td>Bocillin™ FL penicillin</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Alfa Aesar, Ward Hill, USA</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Calbiochem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>Infectopharm, Heppenheim, Germany</td>
</tr>
<tr>
<td>Mecillinam</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Penicillin G</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Polymyxin B</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Sulfamethoxazol</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
</tbody>
</table>

2.1.7 Antibodies and fluorophores

Table 8: Antibodies and fluorophores used in this thesis.

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexa Fluor® 488 azide</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Alexa Fluor® 594 azide</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>DAPI</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Goat anti-Rabbit IgG (H+L) secondary antibody, Alexa Fluor® 488 conjugate</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Goat anti-Rabbit IgG (H+L) secondary antibody, Alexa Fluor® 594 conjugate</td>
<td>Thermo Scientific, Waltham, USA</td>
</tr>
<tr>
<td>Nile red</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Rabbit wPAL anti-serum</td>
<td>Taylor Laboratory, Liverpool School of Tropical Medicine, Liverpool, UK</td>
</tr>
<tr>
<td>Rabbit Wolbachia FtsZ anti-serum</td>
<td>Sullivan Laboratory, University of California, Santa Cruz, USA</td>
</tr>
<tr>
<td>Strep-MAB-Immo monoclonal antibody</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
<tr>
<td>Strep-Tactin® Alkaline phosphatase conjugate</td>
<td>IBA Lifesciences, Göttingen, Germany</td>
</tr>
</tbody>
</table>
2 Materials and methods

2.2 Strains, expression vectors and primers

2.2.1 Cell lines, yeast and bacterial strains

Table 9: Cell lines, yeast and bacterial strains used in this thesis.

<table>
<thead>
<tr>
<th>Strain</th>
<th>Description</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Aedes albopictus</em> C6/36</td>
<td>Cell line</td>
<td>Turner, Langley et al. 2006</td>
</tr>
<tr>
<td><em>Aedes albopictus</em> C6/36 infected with <em>Wolbachia pipientis</em></td>
<td><em>Wolbachia pipientis</em> strain <em>Aedes albopictus</em> B (<em>w</em>AlbB)</td>
<td>Turner, Langley et al. 2006</td>
</tr>
<tr>
<td><em>Bacillus cereus</em> T</td>
<td>Indicator strain</td>
<td>Provided by AG Bierbaum, Bonn, Germany</td>
</tr>
<tr>
<td><em>Escherichia coli</em> (E. coli)</td>
<td><em>Δ amiA, amiB, amiC</em> amidase triple mutant, harboring pBAD33-amiCEc, glucose induced chain forming phenotype</td>
<td>Klöckner, Otten et al. 2014; Provided by AG Vollmer, Newcastle, UK</td>
</tr>
<tr>
<td>ADE24 +pBAD33</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>E. coli</em> C43</td>
<td>B F dcM ompT hsdS(BmB)</td>
<td>Lucigen, Middleton, USA</td>
</tr>
<tr>
<td><em>E. coli</em> JM83</td>
<td>rpsL ara Δ(lac-proAB)</td>
<td>DSM 3947</td>
</tr>
<tr>
<td><em>E. coli</em> MCI23</td>
<td>[araD139]B/r, leu-260::Tn10, ftsl23(ts), Δ(argF-lac)169, λ-, e14-, flhD5301, Δ(fruKyeiR) 725(fruA25), relA1, rpsL150(strR), rbsR22, Δ(fimBfimE) 632(::IS1), deoC1: FEGSC</td>
<td>CGSC; Provided by AG Henrichfreise, Bonn, Germany</td>
</tr>
<tr>
<td><em>E. coli</em> ML-35 pYC</td>
<td>ΔlacI, constitutive β-galactosidase expression, plasmid-encoded (pBR-22) β-lactamase, Amp&lt;sup&gt;8&lt;/sup&gt;</td>
<td>Lehrer, Barton et al. 1988</td>
</tr>
<tr>
<td><em>E. coli</em> W3110</td>
<td>Sex(Hfr,F+,F-,or F'): F-</td>
<td>DSM5911</td>
</tr>
<tr>
<td>One Shot TOP10® chemically</td>
<td></td>
<td>Invitrogen, Darmstadt, Germany</td>
</tr>
<tr>
<td>competent <em>E. coli</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Micrococcus flavus</em></td>
<td>Indicator strain</td>
<td>Provided by AG Schneider, Bonn, Germany</td>
</tr>
<tr>
<td><em>Rhodotorula minuta</em> var.</td>
<td>Yeast strain</td>
<td>ATCC, Manassas, USA; Phaff, Mrak et al. 1952</td>
</tr>
<tr>
<td><em>texensis</em></td>
<td></td>
<td>Sahl and Brandis 1981; Provided by AG Bierbaum, Bonn, Germany</td>
</tr>
<tr>
<td><em>Staphylococcus simulans</em> 22</td>
<td>Indicator strain</td>
<td></td>
</tr>
</tbody>
</table>
2.2.2 Expression vectors

pASK-IBA plasmids are Strep-tag II expression vectors manufactured by IBA Lifesciences, Germany. These vectors carry the promoter region from the tetA resistance gene in front of the multiple cloning site, thus overexpression of heterologous proteins can be induced by adding anhydrotetracycline (AHT) at a concentration that is antibiotic ineffective (200 ng/ml). Strep-tag II is a short peptide, which selectively binds to Strep-Tactin, an engineered streptavidin. In this thesis, four different pASK-IBA vectors were used (Table 10).

pASK-IBA2 contains an N-terminal OmpA leader-sequence for periplasmic overexpression of the target protein and a C-terminal Strep-tag II. In this work, both pASK-IBA2 and pASK-IBA2C were used, which encode an ampicillin or a chloramphenicol resistance gene, respectively.

pASK-IBA3 encodes a C-terminal Strep-tag II fused to the gene of interest, is used for cytoplasmic overexpression and contains an ampicillin resistance gene.

pASK-IBA6 harbors an N-terminal OmpA leader-sequence and Strep-tag II for periplasmic expression of the target protein. In this work pASK-IBA6C was used, which encodes a chloramphenicol resistance gene.
Table 10: List of pASK-IBA expression vectors used in this thesis.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Position (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promoter</td>
<td>37 to 72</td>
</tr>
<tr>
<td>Forward primer binding site</td>
<td>57 to 76</td>
</tr>
<tr>
<td>OmpA signal sequence</td>
<td>139 to 201</td>
</tr>
<tr>
<td>Multiple cloning site</td>
<td>202 to 282</td>
</tr>
<tr>
<td>Strep-tag®</td>
<td>283 to 312</td>
</tr>
<tr>
<td>Reverse primer binding site</td>
<td>308 to 384</td>
</tr>
<tr>
<td>F1 origin</td>
<td>397 to 835</td>
</tr>
<tr>
<td>AmpR resistance gene</td>
<td>984 to 1844</td>
</tr>
<tr>
<td>Tet-repressor</td>
<td>1854 to 2477</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feature</th>
<th>Position (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promoter</td>
<td>37 to 72</td>
</tr>
<tr>
<td>Forward primer binding site</td>
<td>57 to 76</td>
</tr>
<tr>
<td>OmpA signal sequence</td>
<td>139 to 201</td>
</tr>
<tr>
<td>Multiple cloning site</td>
<td>202 to 282</td>
</tr>
<tr>
<td>Strep-tag®</td>
<td>283 to 312</td>
</tr>
<tr>
<td>Reverse primer binding site</td>
<td>308 to 384</td>
</tr>
<tr>
<td>F1 origin</td>
<td>397 to 835</td>
</tr>
<tr>
<td>CamR resistance gene</td>
<td>957 to 1616</td>
</tr>
<tr>
<td>Tet-repressor</td>
<td>1629 to 2252</td>
</tr>
<tr>
<td>Col E1 origin</td>
<td>2405 to 2993</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feature</th>
<th>Position (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promoter</td>
<td>37 to 72</td>
</tr>
<tr>
<td>Forward primer binding site</td>
<td>57 to 76</td>
</tr>
<tr>
<td>OmpA signal sequence</td>
<td>139 to 201</td>
</tr>
<tr>
<td>Strep-tag®</td>
<td>244 to 273</td>
</tr>
<tr>
<td>Reverse primer binding site</td>
<td>329 to 345</td>
</tr>
<tr>
<td>F1 origin</td>
<td>358 to 796</td>
</tr>
<tr>
<td>AmpR resistance gene</td>
<td>945 to 1805</td>
</tr>
<tr>
<td>Tet-repressor</td>
<td>1815 to 2438</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feature</th>
<th>Position (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promoter</td>
<td>37 to 72</td>
</tr>
<tr>
<td>Forward primer binding site</td>
<td>57 to 76</td>
</tr>
<tr>
<td>OmpA signal sequence</td>
<td>139 to 201</td>
</tr>
<tr>
<td>Strep-tag®</td>
<td>232 to 243</td>
</tr>
<tr>
<td>Factor Xa cleavage site</td>
<td>232 to 243</td>
</tr>
<tr>
<td>Multiple cloning site</td>
<td>244 to 320</td>
</tr>
<tr>
<td>Reverse primer binding site</td>
<td>388 to 404</td>
</tr>
<tr>
<td>F1 origin</td>
<td>417 to 855</td>
</tr>
<tr>
<td>CamR resistance gene</td>
<td>977 to 1636</td>
</tr>
<tr>
<td>Tet-repressor</td>
<td>1649 to 2272</td>
</tr>
<tr>
<td>Col E1 origin</td>
<td>2425 to 3013</td>
</tr>
</tbody>
</table>
### 2.2.3 Primers

Table 11: Primers used for cloning into expression vectors and sequencing. Restriction sites are written in bold. Annealing temperatures used in PCRs and restriction enzymes are shown in the right column.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence (5’→3’)</th>
<th>Restriction enzyme/Annealing °T</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBA2C_amiD</td>
<td>ATGGTAGGTCTCAGGCCCAAATCCAATCTATCTA AAGTCAAC</td>
<td>BsaI/57 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA2_amiDΔSP</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/57 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA2C_pbp2</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/57.2 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA2C_pbp2ΔTM</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/57.2 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA2C_pbp6a</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>Necl/59 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA2C_pbp6aΔSP</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>Necl/59 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA3_amiD</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/57 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA6C_pbp2</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/57.2 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA6C_pbp2ΔTM</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/57.2 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA2C_pbp3</td>
<td>ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td>BsaI/58 °C</td>
</tr>
<tr>
<td></td>
<td>rev ATGGTAGGTCTCAGGCCCTCAAGCAATATCGAGA ATGATTTTCA</td>
<td></td>
</tr>
<tr>
<td>IBA_sequencing</td>
<td>GAGTTATTTTACCACTCCCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rev CGCAGTACCGTAAACG</td>
<td></td>
</tr>
</tbody>
</table>
Table 12: Primers used for mutagenesis of the active site residues. Mutated positions are underlined.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence (5’→ 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>amiD_mut1 (H79A)</td>
<td>forward GGTTATAGTTTCACGCAGACTGAACCATCAAC</td>
</tr>
<tr>
<td></td>
<td>reverse GTACCTTTTAGTGTGGGTGCCAGATTAACC</td>
</tr>
<tr>
<td>amiD_mut2 (S83A)</td>
<td>forward CACCATACTGAAAGCAACACTAAAAGGTAC</td>
</tr>
<tr>
<td></td>
<td>reverse GTACCTTTTAGTGTGGGTGCCAGATTAACC</td>
</tr>
<tr>
<td>amiD_mut3 (D207A)</td>
<td>forward GCTATACATGCTAAACCAGCCACAAATTTGTTTATTGG</td>
</tr>
<tr>
<td></td>
<td>reverse CAATCAAACATTTTGTGGGCTGGTGCTTTACGCACTTAACC</td>
</tr>
<tr>
<td>amiD_mut4 (S400A)</td>
<td>forward AGATATCGCATATGGTCGCCCTCTTATAACCATTTAAGG</td>
</tr>
<tr>
<td></td>
<td>reverse GTTAAAGTGTTTATAGAGGGCAGATATGCACTTAACC</td>
</tr>
<tr>
<td>pbp2_mut1 (S107A)</td>
<td>forward GTAACAAAACTCGGGAAAACAAAAATAACCGCTC</td>
</tr>
<tr>
<td></td>
<td>reverse GAGCGGTATTATTTGTTTTCCCGCATTTTTGTTAC</td>
</tr>
<tr>
<td>pbp2_mut2 (S265A)</td>
<td>forward CGTATCAAAATCCACTGCTGGCATATTAAAATAGGGT</td>
</tr>
<tr>
<td></td>
<td>reverse CAACTATTTTAAAATATCGTGGATTTTGCTGATAGC</td>
</tr>
<tr>
<td>pbp3_mut1 (S107A)</td>
<td>forward GAGTACTTACTGCCGAAAAGAAATTTGCTTGG</td>
</tr>
<tr>
<td></td>
<td>reverse CAATCAAACATTTTTGTTTTCCCGCATTTTTGTTAC</td>
</tr>
<tr>
<td>pbp3_mut2 (S256A)</td>
<td>forward GGGGTATATGAGATGGGGCCGGATATTAAAATACTTTAC</td>
</tr>
<tr>
<td></td>
<td>reverse GCTATGAAGTATTTTGGGCCTTTGAAAATAGATCC</td>
</tr>
<tr>
<td>pbp3_mut3 (S339A)</td>
<td>forward GCTATGAAGTATTTTGGGCCTTTGAAAATAGATCC</td>
</tr>
<tr>
<td></td>
<td>reverse GCTATGAAGTATTTTGGGCCTTTGAAAATAGATCC</td>
</tr>
<tr>
<td>pbp3_mut4 (S339A)</td>
<td>forward GCTATGAAGTATTTTGGGCCTTTGAAAATAGATCC</td>
</tr>
<tr>
<td></td>
<td>reverse GCTATGAAGTATTTTGGGCCTTTGAAAATAGATCC</td>
</tr>
<tr>
<td>pbp6a_mut1 (S48A)</td>
<td>forward GTTCATTTTTGAGCATAATGCCGACGAAAAGATGTCTCC</td>
</tr>
<tr>
<td></td>
<td>reverse GGAGACATCTTTTGGTCGCCATATTGCTCAAAAATGAC</td>
</tr>
<tr>
<td>pbp6a_mut2 (S56A)</td>
<td>forward CGAAAGATGTCTCTATCGCACATGAGCAAGCTATAGGAC</td>
</tr>
<tr>
<td></td>
<td>reverse GTCATTAGCTTGTGCTCAATTTTGCAGATGGAGACATCTTTCG</td>
</tr>
</tbody>
</table>

Table 13: Primers used for quantitative real-time PCR.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence (5’→ 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S rRNA-for</td>
<td>TTGCTATTAGATGAGCCTATATTAG</td>
</tr>
<tr>
<td>16S rRNA-rev</td>
<td>GTGTGGCTGATCATCCTCT</td>
</tr>
</tbody>
</table>

2.3 Microbiological methods

2.3.1 General cultivation of bacterial strains

Material from glycerol stocks (see chapter 2.3.5) was streaked out on LB agar plates with the appropriate antibiotic, incubated overnight at 30 °C or 37 °C and afterwards kept at 4 °C. For bacterial growth in liquid media, a single colony from an LB agar plate was inoculated in fresh LB medium containing the appropriate antibiotic and grown at 30 °C or 37 °C under shaking (120–180 rpm) overnight. To prepare a main culture, 1 % inoculum from the overnight culture was applied unless otherwise indicated. Selective media were supplemented with 30 µg/ml chloramphenicol or with 50 µg/ml ampicillin.
2.3.2 Preparation of competent *E. coli* cells

2.3.2.1 Chemically competent *E. coli* cells

50 ml TYM medium (Table 14) was inoculated with 2% of an *E. coli* C43, JM83 or W3110 overnight pre-culture in LB medium and incubated at 37 °C under shaking at 120 rpm until the optical density at 600 nm (OD\(_{600}\)) reached 0.6. Cells were kept cool for 10 min on ice, transferred into a pre-chilled 50 ml falcon tube and centrifuged (Heraeus Multifuge, HighConic Rotor, 2,500 rpm, 10 min, 4 °C). The cell pellet was resuspended in 5 ml cold TFB I buffer and centrifuged again. The pellet was resuspended in 2 ml cold TFB II buffer and cells were aliquoted in a final volume of 50 µl, shock frozen in liquid nitrogen and stored at -80 °C.

Table 14: Medium and buffers for the preparation of chemically competent cells.

<table>
<thead>
<tr>
<th>TYM medium</th>
<th>TFB I</th>
<th>TFB II</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 g Tryptone</td>
<td>30 mM KAc, pH 5.8</td>
<td>100 mM MOPS, pH 7</td>
</tr>
<tr>
<td>2.5 g Yeast extract</td>
<td>50 mM MnCl(_2)</td>
<td>7.5 mM CaCl(_2)</td>
</tr>
<tr>
<td>100 M NaCl</td>
<td>100 mM KCl</td>
<td>10 mM KCl</td>
</tr>
<tr>
<td>10 mM MgSO(_4)</td>
<td>10 mM CaCl(_2)</td>
<td>15% Glycerol</td>
</tr>
<tr>
<td>ad 500 ml Aqua dest.</td>
<td>ad 250 ml Aqua dest.</td>
<td>ad 250 ml Aqua dest.</td>
</tr>
</tbody>
</table>

2.3.2.2 Electro-competent *E. coli* cells

500 ml LB medium was inoculated with 1% of an overnight *E. coli* MCI23 pre-culture and incubated at 30 °C and 120 rpm until OD\(_{600}\) = 0.5. Cells were chilled for 15 min on ice and afterwards harvested by centrifugation (Sorvall Evolution, Rotor SLC 4000, 6,000 rpm, 4 °C, 15 min). The pellet was resuspended in 150 ml ice-cold sterile distilled water. After a second centrifugation step, the pellet was resuspended in 10 ml ice-cold water with 10% sterile glycerol (v/v) and transferred into a cold 50 ml falcon tube. The pellet was again harvested by centrifugation and finally resuspended in 800 µl ice-cold distilled water with 10% sterile glycerol (v/v). Aliquots of 50 µl were prepared, frozen in liquid nitrogen and stored at -80 °C.

2.3.3 Transformation of chemically competent *E. coli* cells

A 50 µl aliquot of chemically competent cells was thawed on ice and mixed with 100 ng of plasmid DNA. The mixture was incubated for 30 min on ice, subsequently heat-shocked for 30 s at 42 °C and immediately cooled on ice for 5 min. Cells were mixed with 950 µl of SOC medium and incubated at 37 °C and 120 rpm for 2 h. Afterwards, cells were spread on LB plates containing the desired antibiotic and incubated overnight at 37 °C.
2.3.4 Transformation of electro-competent *E. coli* cells

Transformation of plasmid DNA into *E. coli* MCI23 using electroporation instead of a heat-shock was necessary due to high temperature-sensitivity of the strain. Electro-competent cells were thawed on ice, mixed with 100 ng of plasmid DNA and incubated for 1 min on ice. The suspension was transferred into a pre-cooled 2 mm electroporation cuvette and placed into an electroporation apparatus (MicroPulser™, Bio-Rad). Cells were pulsed for 5 ms, immediately mixed with 950 µl of pre-warmed SOC medium and incubated for 2 h at 30 °C under shaking at 120 rpm. Cells were spread on fresh LB plates containing the desired antibiotic and incubated at 30 °C overnight.

2.3.5 Preparation of glycerol stocks

For long term storage of bacterial strains and clones, 5 ml LB medium containing the appropriate antibiotic was inoculated with a single colony and grown overnight under shaking. The next day, 800 µl of the suspension was mixed with 200 µl of sterile glycerol and subsequently stored in cryovials at -80 °C.

2.3.6 *In vivo* activity assays

2.3.6.1 *In vivo* complementation assay of *E. coli* MCI23 with AmiD<sup>WMel</sup>, PBP2<sup>Bm</sup>, PBP3<sup>WMel</sup> and PBP6a<sup>Bm</sup>

One colony of *E. coli* MCI23 containing a pASK-IBA vector with amidi<sup>WMel</sup>, pBP2<sup>Bm</sup>, pBP3<sup>WMel</sup> or pBP6a<sup>Bm</sup> was inoculated in 5 ml LB medium with the desired antibiotic and grown at 30 °C and 120 rpm overnight. The next day, 2 % of the culture was transferred into fresh LB medium supplemented with antibiotic and grown at 30 °C and 120 rpm until OD<sub>600</sub> = 0.4. 100 ng/ml tetracycline dissolved in ethanol was added inducing expression of the pASK-IBA vector and the culture was split into two conical flasks. One culture was further incubated at 30 °C, the other one transferred to 42 °C where *E. coli* MCI23 cannot divide anymore as the activity of its essential cell division protein PBP3 is repressed at that temperature (Begg et al., 1990; Dai et al., 1993). *E. coli* MCI23 expressing the empty vector or pal<sup>Bm</sup> served as controls. 120 min after induction, 1 µl of the culture was applied to a 1 % agarose slide and complementation was monitored by microscopy. Five randomly chosen pictures were taken from each sample and cell size was measured using ImageJ (Version 2.0.0-rc-43/1.50e, https://imagej.nih.gov/ij/). Cells were categorized in single/dividing cells (< 7 µm<sup>2</sup>) and elongated cells (≥ 7 µm<sup>2</sup>).
2.3.6.2 In vivo complementation assay of *E. coli* ADE24 ΔamiABC with AmiD<sup>wMel</sup>

To investigate whether AmiD<sup>wMel</sup> is involved in cell separation, complementation assays were carried out using the *E. coli* ADE24 ΔamiABC- triple knockout mutant (kindly provided by AG Vollmer, Newcastle, UK, Table 9). This mutant harbors an arabinose-inducible pBAD33 plasmid with amiC from *E. coli* (Klöckner et al., 2014). By adding 0.8 % glucose, the expression of AmiC is repressed and the *E. coli* cells cannot separate any longer resulting in long chains (Guzman et al., 1995). 10 ml LB with the appropriate antibiotic were inoculated with a 2 % overnight culture of *E. coli* ADE24 ΔamiABC harboring amiD<sup>wMel</sup> in pASK-IBA2, pASK-IBA2C or pASK-IBA3. 100 ng/ml tetracycline were added to induce AmiD<sup>wMel</sup> expression and cells were grown at 30 °C to the exponential phase (OD<sub>600</sub> = 0.5). 1 µl of the culture was applied on 1 % agarose slides and visualized under a microscope (ZeissAxio VertA.1, Carl Zeiss AG). *E. coli* ADE24 ΔamiABC expressing the empty vector served as a control.

2.3.6.3 Growth kinetics

*E. coli* cultures harboring pASK-IBA expression vectors were grown in LB medium supplemented with the desired antibiotic at 25 °C and 120 rpm. Protein expression was induced with 200 ng/ml AHT at OD<sub>600</sub> = 0.6 and the optical density was measured hourly after induction. Growth was recorded to control the viability of the production strain after the induction of protein expression.

2.3.6.4 In vivo complementation assay with PBP2<sup>wBm</sup> and PBP3<sup>wMel</sup> in the presence of antibiotics

Inhibition of PBP2 by the β-lactam mecillinam leads to spherical cells instead of rods in *E. coli* (Spratt and Pardee, 1975). Aztreonam is a β-lactam with high affinity for PBP3 leading to arrested cell division and a filamentous phenotype (Georgopapadakou et al., 1982). To investigate if these antibiotics affect PBP2<sup>wBm</sup> and PBP3<sup>wMel</sup>, *E. coli* MCI23 were prepared as described (see chapter 2.3.6.1) and 30 min after induction, the appropriate antibiotic was added (PBP2<sup>wBm</sup>: 16 µg/ml mecillinam; PBP3<sup>wMel</sup>: 8 µg/ml aztreonam). The cultures were further incubated at 30 °C (PBP3<sup>wMel</sup>) or 42 °C (PBP2<sup>wBm</sup>) for 120 min and subsequently visualized via microscopy. Uninduced *E. coli* MCI23 as well as cultures with the induced empty vector supplemented with aztreonam or mecillinam served as controls.

2.3.7 Preparation of Remazol Brilliant Blue (RBB)-peptidoglycan sacculi

To analyze if AmiD<sup>wMel</sup> is capable of cleaving polymeric peptidoglycan, Remazol Brilliant Blue (RBB)-dyed peptidoglycan was used as a substrate. During the reaction, which
takes place in an alkaline environment at elevated temperature, the vinylsulphone function of
the dye reacts with free hydroxyl groups of peptidoglycan (Broadbent, 2001). When used in
enzyme assays, the subsequent cleavage of N-acetyl-anhydromuramoyl-L-alanine bonds within
RBB-peptidoglycan by an amidase releases stained fragments of different lengths, which are
visible with the naked eye and can be quantified at 595 nm (Figure 9).

Figure 9: Reaction of Remazol Brilliant Blue (RBB) with peptidoglycan (PG) building an RBB-PG complex.
This complex can be cleaved by enzymes, e.g. N-acetyl-anhydromuramoyl-L-alanine amidases releasing stained
fragments of different lengths, which can be quantified at 595 nm.

An E. coli W3110 overnight pre-culture was inoculated 1 % in 2 l LB medium and
incubated at 37 °C and 130 rpm until OD$_{600}$ = 0.6. The culture was harvested (Sorvall Evolution,
Rotor SLC 4000, 6,000 rpm, 4 °C, 12 min) and the pellet was resuspended in 20 ml phosphate
buffered saline (PBS) (4 mM KH$_2$PO$_4$, 16 mM Na$_2$HPO$_4$, 115 mM NaCl, pH 7.4). The mixture
was transferred to an 80 ml boiling 5 % sodium dodecyl sulfate (SDS)-solution and incubated
for 30 min under stirring. Afterwards, the mixture was further incubated overnight at room
temperature (RT) under stirring to completely lyse bacterial cells. To separate peptidoglycan
sacculi from other cell components and to remove SDS, the mixture was centrifuged (Sorvall
Discovery, Rotor S80-AT3, 12,600 rpm, 20 min, RT) and washed three times with 1 ml distilled
water. The sacculi were further incubated with 300 µg/ml α-chymotrypsin overnight at 37 °C.
Then, 250 µl of a 5 % SDS-solution was added and the mixture was incubated for 2 h at 95 °C.
Sacculi were centrifuged (Sorvall Discovery, Rotor S80-AT3, 21,000 rpm, 20 min, RT) and
washed three times with 2 ml distilled water. The sacculi were incubated with 200 µg/ml α-
amylase for 2 h at 37 °C, centrifuged (Sorvall Discovery, Rotor S80-AT3, 21,000 rpm, 20 min,
RT) and washed two times with 1 ml distilled water. E. coli W3110 sacculi were stained with
20 mM RBB and 250 mM NaOH in PBS buffer at 37 °C overnight. To adjust the RBB-
peptidoglycan to pH 7, 1 M HCl was added. The dyed sacculi were centrifuged (Sorvall
Discovery, Rotor S80-AT3, 21,000 rpm, 20 min, RT) and washed several times with distilled
water until the supernatant was completely colorless. Then, the pellet was resuspended in 1 ml
Materials and methods

2.4 Molecular Biological Methods

2.4.1 Isolation of genomic and plasmid DNA

Genomic DNA (gDNA) from wBm (NCBI RefSeq NC_006833.1) was kindly provided by Dr. Kenneth Pfarr (IMMIP). gDNA from wMel (NCBI RefSeq NC_002978) was kindly provided by Dr. Benjamin Makepeace, Liverpool School of Tropical Medicine, UK and by Dr. Benjamin Loppin, Université de Lyon, France. gDNA from the C6/36 insect cell culture infected with W. pipiensis strain A. albopictus B (wAlbB) (NCBI RefSeq NZ_CAGB00000000.1, Table 9) was extracted using the QIAamp DNA Mini Kit (Qiagen) following the manufacturer’s instructions for DNA purification from blood or body fluids with an adjusted elution volume of 50 µl. Plasmid DNA was purified using the QIAprep® Miniprep-Kit (Qiagen) according to the manufacturer’s instructions with an adjusted elution volume of 30 µl. Genomic and plasmid DNA of multiple samples was extracted using a QIAcube robotic workstation (Qiagen).

2.4.2 Polymerase chain reaction (PCR)

The polymerase chain reaction (PCR) is a broadly-used standard technique to produce high amounts of any desired DNA sequence in vitro (Mullis et al., 1986). The reaction needs a DNA template, a thermo-stable DNA polymerase (e.g. Taq or Pfu), two primers binding on the opposite strands on the regions outside the target DNA sequence, magnesium chloride, and deoxynucleotides (dNTPs). The reaction includes several cycles and each cycle consists of three steps. First step is the denaturation of the double stranded DNA by increasing the temperature up to 98 °C. Second, the temperature is decreased enabling the primers to anneal to the DNA template. Last step is extension, where temperature is increased to 72 °C, which is the optimal temperature for the polymerase to synthesize the new filament of DNA. Here, PCR was used to amplify wBm or wMel genes for further cloning into an expression vector, the corresponding primers with annealing temperatures are listed in Table 11. The standard reaction mixture and PCR cycling parameters are shown in Table 15.
2 Materials and methods

Table 15: PCR reaction mixture and cycling parameters.

<table>
<thead>
<tr>
<th>Component</th>
<th>Volume [µl]</th>
<th>1x PCR reaction mixture</th>
<th>PCR cycling parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>5x Reaction buffer (including MgCl₂)</td>
<td>10</td>
<td></td>
<td>1 cycle 98 °C 5 min</td>
</tr>
<tr>
<td>dNTP-mix (10 mM)</td>
<td>1</td>
<td></td>
<td>98 °C 10 s</td>
</tr>
<tr>
<td>Primer forward (10 µM)</td>
<td>2.5</td>
<td>30 cycles</td>
<td>Table 11 30 s</td>
</tr>
<tr>
<td>Primer reverse (10 µM)</td>
<td>2.5</td>
<td></td>
<td>72 °C 30 s/kb</td>
</tr>
<tr>
<td>gDNA (100 ng)</td>
<td>X</td>
<td></td>
<td>1 cycle 72 °C 10 min</td>
</tr>
<tr>
<td>Phusion® HF (2 U/µl)</td>
<td>0.5</td>
<td></td>
<td>8 °C ∞</td>
</tr>
<tr>
<td>Ultrapure water</td>
<td>ad 50</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.4.3 Agarose gel electrophoresis

Agarose gel electrophoresis is a method to separate nucleic acid fragments by their length. In an agarose gel, the negatively charged DNA fragments migrate along an applied electrical field from the cathode to the anode and the speed of migration depends on the fragment’s size (Sambrook et al., 1989). The gels used in this study contained 1% agarose and Midori Green advanced, which allows visualization of DNA bands under UV light. Agarose gels were placed into a running chamber containing 0.5x TBE buffer (Table 16). DNA samples were mixed with Tri-Track loading dye and applied to the gel. Agarose gels were run at 120 V for 45 min and subsequently visualized using an automated gel imaging instrument (Gel Doc™ EZ Imager, Bio-Rad). The length of the analyzed DNA fragments was determined with a 1kb DNA ladder.

Table 16: 0.5x TBE buffer used for agarose gel electrophoresis.

<table>
<thead>
<tr>
<th>Component</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris base</td>
<td>4.45 mM</td>
</tr>
<tr>
<td>Boric acid</td>
<td>44.5 mM</td>
</tr>
<tr>
<td>Na₂EDTA·2H₂O</td>
<td>1.25 mM</td>
</tr>
<tr>
<td>Aqua dest.</td>
<td>ad 1 liter</td>
</tr>
</tbody>
</table>

2.4.4 Quantitative real-time PCR

Quantitative real-time PCR (qPCR) is an established method to amplify specific parts of DNA and to quantify the products at the same time using a fluorescent dye or a fluorescent reporter. The principle of DNA amplification is identical to a standard PCR reaction (see chapter 2.4.2), but with an additional fluorophore in the reaction mixture. Here, SYBR Green was used which intercalates in double-stranded DNA emitting fluorescent light that is detectable in the appropriate channel of a thermal cycler (Rotorgene 6000, Corbett Life Sciences). wAlbB cell numbers were calculated by the quantification of 16S rRNA gene copies by qPCR as previously described (Makepeace et al., 2006) using the HotStar Taq Polymerase.
Kit (Qiagen). A qPCR reaction contained 1 x HotStar Taq polymerase buffer, 3 mM MgCl₂, 200 µM dNTPs, 0.2 µl SYBR Green 1:1000 dilution in dimethyl sulfoxide (DMSO), 0.5 µM 16S rRNA gene specific forward and reverse primers (see Table 13), 0.5 U HotStar Taq polymerase and 2 µl of extracted gDNA. Standard qPCR cycling conditions are shown in Table 17. Melt curve analysis confirmed a specific peak for all positive samples. Data were analyzed using Rotorgene 6000 software version 1.7.

Table 17: qPCR cycling parameters.

<table>
<thead>
<tr>
<th>Cycles</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>95 °C</td>
<td>15 min</td>
</tr>
<tr>
<td>45</td>
<td>95 °C</td>
<td>10 s</td>
</tr>
<tr>
<td></td>
<td>55 °C</td>
<td>15 s</td>
</tr>
<tr>
<td></td>
<td>72 °C</td>
<td>20 s</td>
</tr>
<tr>
<td>1</td>
<td>72 °C</td>
<td>10 min</td>
</tr>
</tbody>
</table>

2.4.5 Cloning

AmiD<sub>wMel</sub>, PBP2<sub>wBm</sub>, PBP3<sub>wMel</sub> and PBP6<sub>a</sub><sup>wBm</sup> were amplified from gDNA of wBm or wMel, with specific primers (see Table 11). Primers were designed following the manufacturer’s instructions using the software “Primer D’Signer” (IBA Lifesciences). During the PCR, BsaI or NcoI restriction sites were added at the 5' and 3'-ends of the respective products. The amplified products were controlled for correct size and purity by agarose gel electrophoresis, purified and cloned into pASK-IBA expression vectors (see Table 10). Correct cloning of the inserts into the vectors was confirmed by sequencing (Microsynth Seqlab, Göttingen, Germany). Wolbachial PBPs were only cloned into vectors which encode a chloramphenicol resistance cassette as ampicillin is a β-lactam and might interfere with the PBPs when added to the LB medium during expression.

2.4.5.1 Purification of DNA fragments

To remove compounds from the reaction mixtures and other contaminants, DNA fragments were purified after PCR (see chapter 2.4.2), after restriction digest (see chapter 2.4.5.2) and after dephosphorylation (see chapter 2.4.5.3) with a Nucleospin Gel and PCR Clean-up Kit following the manufacturer’s instructions (Macherey Nagel).

2.4.5.2 Restriction digest

Restriction enzymes are endonucleases which recognize specific sites in DNA and degrade it by the hydrolysis of the phosphate backbone producing double-stranded fragments with either blunt or sticky ends with terminally unpaired bases (Pham et al., 1998). The
restriction enzymes BsaI and NcoI used in this work produce sticky-ends which facilitates the correct insertion of the DNA fragments into the vector during the ligation process. The reaction scheme is summarized in Table 18. The vector and the PCR product were digested by incubating the mixture for 60 min at 37 °C and subsequently incubating for 20 min at 65 °C (BsaI) or 80 °C (NcoI) to heat-inactivate the restriction enzyme. After restriction digest, the gene of interest was purified (see chapter 2.4.5.1), while the vector was dephosphorylated (see chapter 2.4.5.3).

Table 18: Restriction digest mixture.

<table>
<thead>
<tr>
<th>Components</th>
<th>Volume [µl]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 µg purified PCR product/vector DNA</td>
<td>X</td>
</tr>
<tr>
<td>10x CutSmart buffer</td>
<td>5</td>
</tr>
<tr>
<td>Restriction enzyme</td>
<td>1</td>
</tr>
<tr>
<td>Aqua dest.</td>
<td>ad 50</td>
</tr>
</tbody>
</table>

2.4.5.3 Dephosphorylation

To avoid re-ligation of the restricted and linearized vector, the phosphate of the 5’ ends can be removed by a phosphatase. Here, 5 µl of 10x Phosphatase reaction buffer and 1 µl of Antarctic Phosphatase were applied to the 50 µl restriction mixture of the vector and incubated for 1 h at 37 °C. Subsequently, the dephosphorylated vector was purified (see chapter 2.4.5.1).

2.4.5.4 Ligation

The ligation step inserts the gene of interest into the vector building a construct that can be transformed into E. coli cells (see chapter 2.3.3 and 2.3.4). A ligase catalyzes the formation of the phosphodiester bond between the 3’ hydroxyl group of the sugar and the 5’ phosphate group of two adjacent DNA strands (Sambrook et al., 1989). The T4 ligase used in this work catalyzes the reaction of both blunt-ended and sticky-ended DNA fragments (Rusche and Howard-Flanders, 1985). The molar ratio of insert:plasmid was 3:1, the standard reaction is shown in Table 19. The ligation mixture was either incubated for 15 min at RT or overnight at 16 °C and subsequently heat inactivated at 70 °C for 5 min.

Table 19: Scheme of the ligation reaction mixture.

<table>
<thead>
<tr>
<th>Components</th>
<th>Volume [µl]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insert</td>
<td>X</td>
</tr>
<tr>
<td>50 ng Vector</td>
<td>X</td>
</tr>
<tr>
<td>10x T4 ligase Buffer</td>
<td>2</td>
</tr>
<tr>
<td>T4 DNA ligase</td>
<td>1</td>
</tr>
<tr>
<td>Aqua dest.</td>
<td>ad 50</td>
</tr>
</tbody>
</table>
2.4.5.5 Suicide cut

Restriction with BsaI or NcoI removes the multiple cloning site from the pASK-IBA vector and during ligation, the desired gene is inserted. To further decrease the level of false positive clones caused by undigested re-ligated empty vectors, they were cut with a suitable restriction enzyme after ligation. BamHI was selected as a suitable restriction enzyme for AmiD<sup>WMel</sup>, which targets a recognition site in the multiple cloning site of pASK-IBA vectors, but not in the sequence of AmiD<sup>WMel</sup>. For PBP2<sup>WBM</sup> and PBP6a<sup>WBM</sup>, EcoRI was used. The ligation mixture was supplemented with 5.6 µl CutSmart buffer and 1 µl BamHI/EcoRI and incubated for 1 h at 37 °C. EcoRI was inactivated at 65 °C for 20 min (not required for BamHI) and 5 µl of the mixture were used for transformation in chemically competent <i>E. coli</i> cells (see chapter 2.3.3).

2.4.6 Site-directed mutagenesis

Putative active site motifs in the gene sequences of wolbachial AmiD and PBPs were changed using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). This technique is used to specifically introduce point mutations into a gene of interest. Two complementary primers harboring the mutation bind to the plasmid and are amplified in a PCR with a PfuUltra high-fidelity DNA polymerase leading to the formation of a mutated and non-methylated version of the vector. DpnI digestion of the amplification products cuts the original plasmid in contrast to the newly synthesized mutated one due to missing methylation (Figure 10). In this thesis, primers were designed using the software "PrimerX automated design of mutagenic primers for site-directed mutagenesis" (http://www.bioinformatics.org/primerx/) according to the manufacturer’s guidelines for primer design. The site-directed mutagenesis was performed following the manufacturer’s instructions (Tables 20 and 21) with one modification. Instead of using the provided chloramphenicol resistant <i>E. coli</i> XLGold cells, 5 µl of the mixture was transformed into <i>E. coli</i> TOP10 cells since the used pASK-IBA vectors harbor a chloramphenicol selection marker. After transformation, correct base changes were confirmed by sequencing (see Table 11).
### 2.5 Biotechnological methods

#### 2.5.1 Overproduction using Strep-tagged proteins

##### 2.5.1.1 Overproduction pre-tests

By carrying out pre-tests, the optimal conditions for protein overexpression were determined for each protein used in this study. Overproduction was tested in different *E. coli* strains (C43, JM83 and W3110), different temperatures (25 °C and 30 °C), time points of induction (OD\textsubscript{600} = 0.5 and OD\textsubscript{600} = 1.2) and length of expression (4 h and overnight). Overproduction pre-tests were performed in 50 ml LB medium containing chloramphenicol. Medium was inoculated with 1 % of an *E. coli* overnight culture containing a pASK-IBA vector with the gene of interest. 1 ml samples were collected before induction of protein expression with 200 ng/ml AHT and after 4 h or overnight expression. The samples were lysed (see chapter 2.5.1.3) and analyzed via SDS-PAGE and Western Blot (see chapter 2.6). Cells containing the induced empty vector served as a control.

##### 2.5.1.2 Small-scale co-solvent screen

The substitution of NaCl in LB medium with co-solvents has been shown to improve production, folding and stability of proteins expressed in the periplasm (Otten et al., 2015). Therefore, it was tested if co-solvent assisted overproduction also had positive effects on the
proteins investigated in this thesis. To prevent osmotic stress, the amount of co-solvent was adjusted to an osmotic pressure elicited by 10 g/l NaCl. 171 mM NaCl which are equivalent to 342 osm/l of dissociated Na⁺ and Cl⁻ ions were replaced by 342 mM of non dissociating co-solvents (equivalent to 342 osm/l) (Otten et al., 2015). All co-solvents had a final concentration of 342 mM, except for arginine, which was observed to be toxic for bacteria in high concentrations. Thus, arginine was used in a final concentration of 100 mM. After addition of co-solvents to the NaCl-free LB medium, the pH was adjusted to 7.5 and the medium was sterile filtered. After optimal expression conditions were determined (see chapter 2.5.1.1), 50 ml NaCl-free LB medium was supplemented with different co-solvents (Table 22), inoculated with 1 % from an overnight E. coli culture, grown until OD₆₀₀ = 0.5 and then induced with 200 ng/ml AHT. The harvested pellets were lysed and analyzed by SDS-PAGE and Western Blot (see chapter 2.5.1.3 and 2.6).

Table 22: Used co-solvents for the substitution of NaCl.

<table>
<thead>
<tr>
<th>Co-solvent</th>
<th>Molecular mass [g/mol]</th>
<th>Amount [g/l]</th>
<th>Molarity [mM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-Arginine</td>
<td>174.20</td>
<td>17.42</td>
<td>100</td>
</tr>
<tr>
<td>Betaine</td>
<td>117.15</td>
<td>40.09</td>
<td>342</td>
</tr>
<tr>
<td>Glycerol</td>
<td>92.09</td>
<td>31.52</td>
<td>342</td>
</tr>
<tr>
<td>D-Mannitol</td>
<td>182.17</td>
<td>62.34</td>
<td>342</td>
</tr>
<tr>
<td>Sucrose</td>
<td>342.30</td>
<td>117.15</td>
<td>342</td>
</tr>
<tr>
<td>D-Trehalose</td>
<td>342.30</td>
<td>117.15</td>
<td>342</td>
</tr>
</tbody>
</table>

2.5.1.3 Protein overproduction and purification

NaCl-free LB medium containing the appropriate antibiotic and co-solvent was inoculated with 1 % from an overnight culture and grown under the optimal induction conditions as determined previously (see chapter 2.5.1.1 and 2.5.1.2).

Purification of Strep-tagged proteins was performed according to the manufacturer’s instructions (IBA Lifesciences) with slight adjustments. Cell pellets were resuspended in 10 ml Buffer P per liter E. coli culture, supplemented with 1 mg/ml lysozyme (Table 23) and lysed for 30 min at 4 °C under gentle rotation. For PBP2ʷBm with its native transmembrane domain, 2 % Tween 200 was added to the lysis Buffer P as a detergent to increase solubility. To reduce viscosity, benzonase (20 U/ml) and MgCl₂ (3 mM) were added and the suspension was incubated for additional 15 min on ice. Cleared lysate containing soluble proteins was prepared by centrifugation (38,800 g, 15 min, 4 °C) and Strep-tagged proteins were purified by gravity flow chromatography at 4 °C. For this, 1 ml Strep-Tactin® Sepharose was applied to a 1 ml polypropylene column and equilibrated with 2 ml Buffer W (Table 23). The cleared lysate was loaded onto the column and washed five times with 1 ml Buffer W. Finally, the proteins were
eluted eight times with 0.5 ml Buffer E (Table 23). As AmiD<sup>mMel</sup> is a putative metalloprotein, adjusted buffers were used following the manufacturer's recommendations. Briefly, ethylenediaminetetraacetic acid (EDTA) in Buffer P was substituted by 2 mg/ml polymyxin B, while Buffer W and Buffer E were prepared without EDTA. To test if amidase activity of AmiD<sup>mMel</sup> is decreased in the presence of EDTA, some batches of overexpressed protein were prepared with EDTA. Purified proteins were kept at 4 °C for up to five days and, in case of AmiD<sup>mMel</sup>, for long-time storage in 50 % sterile glycerol at -20 °C.

Table 23: Buffers used for cell lysis and purification of Strep-tagged proteins.

<table>
<thead>
<tr>
<th>Buffer P</th>
<th>Buffer W</th>
<th>Buffer E</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mM TrisHCl, pH 8</td>
<td>150 mM NaCl</td>
<td>100 mM TrisHCl, pH 8</td>
</tr>
<tr>
<td>500 mM Sucrose</td>
<td>1 mM EDTA</td>
<td>100 mM TrisHCl, pH 8</td>
</tr>
<tr>
<td>1 mg/ml Lysozyme</td>
<td>2.5 mM D-Desthiobiotin</td>
<td></td>
</tr>
</tbody>
</table>

2.6 Electrophoretic methods

2.6.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins equivalent to their molecular weight, based on their differential rates of migration through a sieving matrix under the influence of an applied electrical field (Laemmli and Favre, 1970). Proteins are denaturated by the addition of a loading buffer containing β-mercaptoethanol as a reducing agent and by heating. The internal charge, which is a consequence of the different properties of the contained amino acids, is overlaid by the association of negatively charged SDS. The intensity of this constant negative charge is proportional to the length of the peptide chain and therefore indirectly to molecular weight of the polypeptides (Laemmli and Favre, 1970). Polyacrylamide polymerization results in a matrix in which the denaturated protein samples can be separated driven by an electric field. Protein samples are concentrated first in an upper stacking gel with large pores in the matrix due to a lower concentration of acrylamid. In the lower separation gel protein samples are fragmented by their molecular weight. In this thesis, Mini-PROTEAN® Stain-free™ 12 % Precast Gels (Bio-Rad) were used. Alternatively, self-made gels were prepared. A 4 % stacking gel contained 3 ml distilled water, 1.25 ml upper buffer (0.5 M Tris-HCl, 0.4 % SDS, pH 6.8) and 750 µl acrylamide/bisacrylamide. Polymerization was initiated by adding 15 µl 10 % ammonium persulphate (APS) and 10 µl Tetramethylethylenediamine (TEMED). TEMED induces free radical formation from APS which transfers electrons to the acrylamide/bisacrylamide...
monomers causing a vinyl addition and resulting in a polyacrylamide chain. For a 12.5 % separation gel, 4 ml of lower buffer (1.5 M Tris-HCl, 0.4 % SDS, pH 8.8) were mixed with 5.3 ml distilled water and 6.7 ml acrylamide/bisacrylamide, 80 µl of 10 % APS and 8 µl TEMED. 5 µl of 5x SDS sample buffer was added to 20 µl of the sample (Table 24). Samples were mixed, heated 10 min at 70 °C and subsequently applied to the SDS gel. The SDS gel was run at 160 V for 45 min in buffer (25 mM Tris-HCl, 192 mM glycine, 0.1% SDS, pH 8.3).

Table 24: 5x SDS sample buffer.

<table>
<thead>
<tr>
<th>Component</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris-HCl, pH 6.8</td>
<td>25 mM</td>
</tr>
<tr>
<td>Glycerol</td>
<td>25 %</td>
</tr>
<tr>
<td>SDS</td>
<td>7.5 %</td>
</tr>
<tr>
<td>Bromophenol blue</td>
<td>0.04 %</td>
</tr>
<tr>
<td>β-Mercaptoethanol</td>
<td>12.5 %</td>
</tr>
</tbody>
</table>

2.6.2 Western Blot

Western Blot is a technique to transfer proteins from a polyacrylamid gel to a membrane to specifically visualize tagged proteins (Renart et al., 1979). Western Blots can be detected with chemiluminescent, colorimetric or fluorescent methods. Here, Strep-tagged proteins were visualized using a colorimetric method. After separating proteins by SDS-gel electrophoresis (see chapter 2.6.1), they were transferred to a nitrocellulose membrane. The nitrocellulose membrane and blotting paper were pre-wetted in Towbin running buffer (25 mM Tris Base, 192 mM glycine, 20 % methanol, pH 8.3). For blotting, the Trans-Blot® TurboTM Transfer System (Bio-Rad) was used for 80 min at 15 V. Chromogenic detection of Strep-tagged proteins with Strep-Tactin Alkaline Phosphatase (AP) conjugate was performed following the manufacturer’s instructions (IBA Lifesciences, Figure 11). Briefly, the membrane was incubated in 20 ml PBS blocking buffer (4 mM KH₂PO₄, 16 mM Na₂HPO₄, 115 mM NaCl, pH 7.4, with 3 % bovine serum albumin (w/v, BSA) and 0.5 % Tween 20 (v/v)) for 1 h at RT under gentle shaking. PBS-blocking buffer was removed by washing three times with 20 ml PBS-Tween buffer (PBS buffer with 0.1 % Tween 20 (v/v)) for 5 min at RT and gentle shaking. After the last washing step, 10 ml PBS-Tween buffer plus 10 µl of Biotin blocking buffer were added to the membrane to block

![Figure 11: Detection of recombinant Strep-tagged fusion proteins (IBA Lifesciences).](image-url)
endogenously biotinylated proteins of the expression strain. 5 µl Strep-Tactin alkaline phosphatase conjugate (1:2000) was added and incubated for 1 h and subsequently washed two times with PBS-Tween buffer for 1 min. After washing, the membrane was transferred to 20 ml reaction buffer (100 mM NaCl, 5 mM MgCl₂, 100 mM Tris-HCl, pH 8.8). Specific staining of Strep-Tactin motifs of recombinant proteins was visualized by addition of 10 µl 7.5 % nitro blue tetrazolium (w/v, NBT) solution and 60 µl of 5 % 5-bromo-4-chloro-3-indolyl-phosphate (w/v, BCIP) solution. The reaction was stopped with tap water.

2.7 Biochemical methods

2.7.1 Protein determination via Bradford assay

The Bradford assay is a quantitative method to determine the protein concentration in a solution (Bradford, 1976). Coomassie Brilliant Blue G-250 dye builds complexes with cationic and unpolar side chains of polypeptides in an acidic environment shifting the absorption maximum of the dye from 465 to 595 nm. Using a BSA standard curve with known concentrations allows determination of the relative protein concentration of the samples. Quantification is based on the positive correlation of the absorption rate of the dye and the amount of protein in the samples. In this thesis, a standard curve with defined concentrations of BSA between 7.5 µg/ml up to 2 mg/ml was used. 3 µl of protein samples were applied in triplicates to a 96-well plate and 300 µl of 1x Bradford reagent was added to each sample. The plate was subsequently measured in a photometric plate-reader at 595 nm (Spectramax® 340PC, Molecular Devices) and analyzed with Softmax® Pro Version 6.3.

2.7.2 In vitro DD-carboxy- and DD-transpeptidase activity assays using lipid II as a substrate

Lipid II is the precursor of peptidoglycan and the natural substrate of PBPs. To perform in vitro assays, lipid II containing either m-DAP or Lys was synthesized (see chapter 2.9) and used to study wolbachial protein activity.

Standard in vitro activity assays for wolbachial PBPs were carried out in a final volume of 70 µl containing 0.5 nmol purified protein, 2 nmol lipid II, 50 mM MES (pH 5.5), 2 mM MgCl₂ and 20 % DMSO. The reaction mixture was incubated for 4 h or overnight at 30 °C. To test the impact of β-lactam antibiotics on PBP activity, penicillin G or ampicillin were added to the reaction mixture in a molar ratio of 1:10. Reaction products were extracted with 70 µl of n-butanol/pyridine acetate (2:1, v/v, pH 4.2). For the extraction solution, 6 M glacial acetic acid
was adjusted to pH 4.2 by the addition of pyridine and mixed with two volumes of n-butanol according to Anderson (1967). The mixture was vortexed for 1 min and centrifuged (21,000 g, 5 min, RT). The upper phase containing lipids was analyzed via TLC and MALDI-TOF (see chapter 2.7.5 and 2.8.1) as described previously (Klöckner et al., 2014). For DD-transpeptidase activity assays, TLC bands were quantified by Image Quant™ TL (GE Healthcare).

Standard in vitro activity assay mixtures for AmiD wMel contained 4 µg purified protein, 2 nmol lipid II, 50 mM Tris (pH 7.5) and 5 % DMSO in a volume of 40 µl and were incubated for 4 h at 30 °C. Reaction products were extracted with 40 µl of n-butanol/pyridine acetate (2:1, v/v, pH 4.2), centrifuged (21,000 g, 5 min, RT) and analyzed by TLC and MALDI-TOF (see chapter 2.7.5 and 2.8.1). To inhibit amidase activity of AmiD wMel, the protein was lysed and purified in the presence of 1 mM of the non-specific metal chelator EDTA (see chapter 2.5.1.3). As a second approach, 5 mM of the zinc-specific inhibitor 1,10-phenanthroline was added to the reaction mixtures of the activity tests.

2.7.3 *In vitro* activity of AmiD wMel using peptidoglycan as a substrate

For the RBB-PG dye-release assay, 20 µl of stained peptidoglycan sacculi (see chapter 2.3.7) were incubated at 30 °C overnight with 4 µM of purified AmiD wMel in a final volume of 200 µl containing 50 mM Tris (pH 7.5) and 5 % DMSO. Samples were centrifuged (20,000 g, 20 min, RT) and absorbance of the supernatants was measured at 595 nm in a nanophotometer (TM 7122v1.6.1, Implen).

2.7.4 Cleavage of anhydromuropeptides by AmiD wMel

The cleavage of anhydromuropeptides was performed by the research group of Prof. Vollmer, University of Newcastle, United Kingdom. Briefly, *E. coli* sacculi were prepared as described previously (Glauner et al., 1988). Peptidoglycan (750 µg) was digested with the lytic transglycosylase Slt (1 µM) in a final volume of 210 µl containing 10 mM HEPES (pH 7.5) and 150 mM NaCl for 18 h at 37 °C. The reaction mixture was heated for 10 min at 100 °C and centrifuged for 20 min. The supernatant containing the 1,6-anhydro-muropeptides was collected and stored at 2–8 °C. 1,6-anhydro-muropeptides (15 µl) were incubated with AmiD wMel (2 µM) in a final volume of 50 µl containing 50 mM Tris (pH 7.5) and 5 % DMSO for 4 h at 30 °C. Samples were boiled for 10 min and centrifuged for 20 min, and the supernatant was recovered. The pH of the supernatant was adjusted to pH 4 with 20 % phosphoric acid. HPLC analysis was carried out as described previously (Glauner et al., 1988) and selected peaks were collected and analyzed by mass spectrometry (Bui et al., 2009).
2.7.5 Thin layer chromatography (TLC)

Thin layer chromatography (TLC) is a method to separate mixtures of non-volatile compounds according to their different solubility in a mobile and a stationary phase (Gordon et al., 1943). The various applications of TLC include the determination of the purity of samples, the identification of compounds and the examination of reactions. The mobile phase (a solvent) moves by capillary action along the stationary phase (silica plate) transporting the compounds. Here, the upper phase of lipid extracts was spotted onto a silica plate and dried. The TLC plate was placed in a glass chamber containing chlorophorm:methanol:water:ammonia (88:48:10:1, v/v/v/v) as the mobile phase according to Rick (1998). After separating the compounds up to 60 min, the plate was removed and dried. To visualize lipid bands, the TLC plate was dipped into a phosphomolybdic acid (PMA) staining solution (2.5 % phosphomolybdic acid (w/v), 1 % ceric IV sulfate (w/v), 6 % sulfuric acid (v/v)) and dried again. The silica plate was developed at 140 °C in an oven until stained blue bands were visible.

2.8 Instrumental methods

2.8.1 Matrix assisted laser desorption/ionization (MALDI)

Matrix assisted laser desorption/ionization (MALDI) is routinely used for the analysis of biomolecules (e.g. DNA, proteins, peptides and sugars) and large organic molecules (e.g. polymers, dendrimers and other macromolecules) (Karas et al., 1987). The target molecules are embedded in a defined matrix and ionized via a pulse laser. In this thesis, MALDI was combined with a time-of-flight detector (MALDI-TOF). For detection of reaction products from AmiD^{WMel} and PBP6a^{VBlm} activity assays using lipid II (see chapter 2.7.2), 1 µl of the sample was placed onto a ground steel MALDI-TOF target plate and dried at RT. Each sample was then overlaid with 1 µl of matrix (saturated solution of 6-Aza-2-thiothymine in 50 % ethanol/20 mM diammonium citrate or alpha-cyano-cinnamic acid in 33 % acetonitril/0.1 % trifluoroacetic acid) and air dried at RT again. Spectra were recorded in the reflector negative mode on a Biflex III mass spectrometer (Bruker Daltonik). MALDI-TOF measurements were performed by Michaele Josten, AG Schneider, IMMIP, University of Bonn.

2.8.2 Biomolecular binding interaction studies

Surface plasmon resonance (SPR) and Biolayer interferometry (BLI) are two established techniques for label-free measurement of biomolecular binding interactions. SPR
and BLI use light to measure the interaction between two molecules in real-time. In this thesis, both techniques were used to examine interactions between wobachial proteins and lipid II.

2.8.2.1 Surface plasmon resonance (SPR)

SPR is a method to determine specificity, affinity and kinetic parameters of the interaction between two macromolecules for example protein-protein, protein-DNA or lipid membrane-protein (Karlsson et al., 1991; Nguyen et al., 2015). This optical technique measures the refractive index changes in the vicinity of metal layers, i.e. a gold layer in a sensor chip, in response to biomolecular interactions (Figure 12). The sensor chip consists of a glass surface coated with a thin layer of gold. This is the basis for a range of specialized surfaces designed to optimize the binding of a variety of molecules. One of the interaction partners, the ligand, is coupled to the surface of a sensor chip. The analyte, the potential interaction partner of the ligand, is dissolved in running buffer and flows over the sensor surface continuously. Binding between the ligand and the analyte changes the detectable resonance signal; when molecules in a solution bind to a target molecule the mass increases, when they dissociate the mass falls. This principle forms the basis of the sensorgram, which monitors the association and dissociation of the interacting molecules in real-time. The sensorgram provides quantitative information on specificity of binding, kinetics and affinity. In this thesis, the interaction between Pal wBm and lipid II with either m-DAP or Lys was investigated using a Biacore® T100 (GE Healthcare). Purified Pal wBm was immobilized on a CM5 sensor chip using a Strep-tag II specific Strep-MAB-Immo monoclonal antibody (IBA Lifesciences) following the manufacturer's protocol. As CM5 sensor chips have a carboxy-methylated dextran matrix attached to a gold layer, molecules can be covalently coupled to the sensor surface via amine, thiol, aldehyde or carboxyl groups. StrepMAB-Immo antibody nearly irreversibly captures Strep-tag® II fusion proteins on solid phases. Lipid II (0–12.5 µM) dissolved in HBS-EP running buffer (Table 25) was used as the analyte of the binding reaction. Data were analyzed using the provided Biacore® T100 software.

Figure 12: Principle of surface plasmon resonance (SPR) (University of Chicago, USA). SPR detects changes in the refractive index at the surface of a sensor which is comprised of a glass substrate and a thin gold coating.
Table 25: Biacore HBS-EP running buffer.

<table>
<thead>
<tr>
<th>Component</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEPES, pH 7.4</td>
<td>10 mM</td>
</tr>
<tr>
<td>NaCl</td>
<td>150 mM</td>
</tr>
<tr>
<td>EDTA</td>
<td>3 mM</td>
</tr>
<tr>
<td>Surfactant P20</td>
<td>0.005 % v/v</td>
</tr>
</tbody>
</table>

2.8.2.2 Biolayer interferometry (BLI)

BLI is a label-free technology for measuring biomolecular interactions (Cooper, 2006). The binding between a ligand immobilized on a biosensor surface and an analyte in solution produces an increase in optical thickness at the biosensor resulting in a wavelength shift (Figure 13). Any changes in the number of molecules bound to the biosensor can be measured in real-time, whereas unbound molecules or changes in the refractive index of the surrounding medium do not affect the interference pattern. This feature of BLI allows application of crude samples for protein-protein interaction, quantitation, affinity and kinetic measurements. In this thesis, a BLItz® system device (Pall ForteBio) was used to measure interactions between PalwBm and PBP2wBm. 50 µg PalwBm was biotinylated and purified using Zeba Spin Desalting Columns (Thermo Scientific) according to the manufacturer’s instructions. In a basic kinetic assay, biotinylation was confirmed. For interaction measurements, a streptavidin sensor (Pall ForteBio) was incubated with 1 µl biotinylated PalwBm (ligand) for 1 min. The sensor was measured in analysis buffer for 30 s to get a baseline before starting the interaction measurements. 1 µl PBP2wBm (analyte) or the empty vector, which served as a negative control, were applied and measured for 2 min. The sensor was incubated with analysis buffer for 1 min to measure dissociation. Data were analyzed using the provided BLItz® Pro software (version 1.2.0.49).

2.9 Chromatographic methods

2.9.1 Lipid II Synthesis

2.9.1.1 Isolation of UDP-MurNAc-pentapeptide substrate

UDP-MurNAc-pentapeptide is a cytoplasmic, soluble precursor of peptidoglycan (see chapter 1.5.1), which can be accumulated and subsequently purified. In this thesis,
**2 Materials and methods**

*Staphylococcus simulans* 22 and *Bacillus cereus* T were used to accumulate and isolate UDP-MurNAc-pentapeptide with either Lys or m-DAP at position three of the pentapeptide side chain for lipid II synthesis. 4 l Mueller-Hinton broth was inoculated with 1 % of *S. simulans* 22 or *B. cereus* T overnight cultures and incubated at 37 °C and 120 rpm until \( \text{OD}_{600} = 0.75 \). To inhibit protein biosynthesis, 130 µg/ml chloramphenicol was added for 15 min. Chloramphenicol prevents the *de novo* synthesis of enzymes that may interfere, e.g. through induction of cellular autolysis, with the accumulation of the UDP-linked peptidoglycan precursor in the cytoplasm (Dai and Ishiguro, 1988). Afterwards, the 10x minimal inhibitory concentration of vancomycin (*S. simulans* 22: 5 µg/ml, *B. cereus* T: 10 µg/ml) was added. Vancomycin binds to the terminal D-alanyl-D-alanine (D-Ala-D-Ala) residues of the pentapeptide and therefore blocks the regeneration of the lipid-carrier C\(_{55}\)-P, leading to an accumulation of the UDP-MurNAc-pentapeptide in the cytoplasm (Anderson et al., 1967). After 1 h of incubation, cells were harvested (Sorvall Evolution, Rotor SLC-4000, 10 min, 8,000 rpm, 4 °C) and the pellet was resuspended in 20 ml distilled water. The suspension was slowly transferred to 80 ml boiling distilled water under stirring in a 500 ml Erlenmeyer flask. After 15 min boiling, the suspension was chilled on ice and centrifuged again (Sorvall Evolution, Rotor SS-34, 18,000 rpm, 30 min, 4 °C) to remove insoluble cell parts. The supernatant containing the UDP-MurNAc-pentapeptide substrate was shock frozen with liquid nitrogen, lyophilized in a freeze dryer and stored at -20 °C. For lipid II synthesis, UDP-MurNAc-pentapeptide was resolved in 4 ml distilled water and added to the reaction mixture (see chapter 2.9.1.3).

**2.9.1.2 Membrane preparation**

As the enzymes MraY and MurG are necessary to build lipid II (see chapter 1.5.1), the membranes of *Micrococcus flavus* were isolated as described previously (Schneider et al., 2004). Briefly, 2 l TSB were inoculated with 1 % of an overnight culture of *M. flavus* and incubated at 37 °C and 120 rpm overnight. The next morning, cells were harvested (Sorvall Evolution, Rotor SLC 4000, 7,500 rpm, 15 min, 4 °C), the pellet was washed in 700 ml Tris-buffer (50 mM Tris-HCl, 10 mM MgCl\(_2\), pH 7.5) and centrifuged again. The pellet was resuspended in the Tris-buffer containing 800 µg/ml lysozyme and 80 µg/ml benzonase and incubated on ice for 60 min. The suspension was heated up in a water bath to 35 °C and afterwards cooled again on ice. Membranes were obtained through centrifugation (Sorvall Evolution, Rotor SLC 4000, 13,000 rpm, 20 min, 4 °C). Finally, pellets were resuspended in 8 ml Tris-buffer and stored at -80 °C until further use.
2.9.1.3 *In vitro* lipid II-synthesis

To synthesize lipid II *in vitro*, the isolated membranes from *M. flavus* were incubated with UDP-MurNAc-pentapeptide from *S. simulans* or *B. cereus* T, C\textsubscript{55}-P and UDP-GlcNAc. For every synthesis, the optimal conditions had to be titrated in an analytical assay before preparing lipid II in a larger scale for purification. Lipid II was obtained by mixing 20–30 µl isolated membranes (see chapter 2.9.1.2), 7.5–15 µl UDP-MurNAc-pentapeptide (see chapter 2.9.1.1), 5 nmol C\textsubscript{55}-P, 1 mM UDP-GlcNAc, 5 mM MgCl\textsubscript{2}, 60 mM Tris-HCl (pH 7.5), 0.5 % Triton X-100 (v/v) in a final volume of 75 µl. C\textsubscript{55}-P (dissolved in 10 µl chloroform/methanol, 1:1, v/v) was vacuum-dried in a dessicator and subsequently re-dissolved by adding 0.5 % Triton X-100 and vortexed vigorously. The remaining components were added and the mixture was incubated for 4 h at 30 °C and under shaking. To verify that lipid II was synthesized, bactoprenol-containing products were extracted and visualized via TLC (see chapter 2.7.5). Lipid II synthesis in a larger scale was achieved by using the 200-fold volume of the optimal analytical scale. Extraction was done in two steps by first extracting the lipids in 15 ml and then in 10 ml of n-butanol/pyridine acetate (2:1, v/v, pH 4.2). The two upper phases containing soluble lipids were combined and washed with ice-cold, acidic ultrapure water (1:1, v/v, pH 4.2). The mixture was centrifuged (Heraeus Multifuge, HighConic Rotor, 10.000 rpm, 10 min, 4 °C) and the upper phase was used for HPLC purification of lipid II.

2.9.1.4 Purification of lipid II via high performance liquid chromatography (HPLC)

High performance liquid chromatography (HPLC) is a separation technique for chemical and biological compounds which is mainly used to identify, quantify or purify compounds from a mixture (Horvath and Lipsky, 1966; Jadaun et al., 2017). HPLC pumps a liquid mobile phase through a stationary phase, usually a column, which separates the sample components. During the chromatographic separation, a pump can either deliver a constant mobile phase composition (isocratic) or an increasing mobile phase composition (gradient). In this thesis, the liquid mixture containing *in vitro* synthesized lipid II was applied to a 5 ml HiTrap DEAE FF-Agarose-column with Buffer A (Table 26) and a flow rate of 3 ml/min for 1 h. Lipid II was eluted by creating a linear ammonium bicarbonate gradient flow with up to 25 % Buffer B (Table 26) and a flow rate of 5 ml/min for 3 h. Fractions of 5 ml were collected in glass tubes and the ones containing purified lipid II were identified via TLC (see chapter 2.7.5). These fractions were combined and separated from the organic solvents with a rotating evaporator (Büchi Labortechnik). The remaining solution was transferred to a teflon tube, dried in an exsiccator to remove chloroform, then frozen with liquid nitrogen and lyophilized.
overnight. The dried material was resolved in 500 µl chloroform/methanol (1:1, v/v) and centrifuged (Eppendorf 5417R, Rotor FA45-24-11, 10 min, 5,000 rpm, RT) to remove salts. The supernatant was applied to a glass tube and stored at -20 °C. Lipid II concentration was determined by its phosphate content (see chapter 2.9.1.5).

Table 26: Buffers used for HPLC purification of lipid II.

<table>
<thead>
<tr>
<th>Buffer</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buffer A</td>
<td>Chloroform, methanol, ultrapure aqua dest. (2:3:1, v/v/v)</td>
</tr>
<tr>
<td>Buffer B</td>
<td>Chloroform, methanol, 300 mM ammonium bicarbonate (2:3:1, v/v/v)</td>
</tr>
</tbody>
</table>

2.9.1.5 Determination of phosphate concentration

As lipid II contains two phosphate residues, the amount synthesized in vitro can be quantified by determination of the phosphate concentration. In this thesis, the method according to Rouser (1970) was used. This assay is based on the principle that free inorganic phosphate (Pi) is released when phospholipids are hydrolyzed. In an acidic environment, Pi binds to molybdate resulting in yellowish phosphomolybdic acid. Ascorbic acid reduces phosphomolybdic acid to molybdenum blue which can be measured at 797 nm. To determine the phosphate concentration of the synthesized lipid II, two different volumes (5 µl and 10 µl) were applied to clean and phosphate-free glass tubes, 0–90 nmol Pi of 1 mM monopotassium phosphate (KH₂PO₄) served as a standard. The tubes were dried at 140 °C for 20 min and afterwards 300 µl of 70–72 % perchloric acid (HClO₄) was added to each tube. The mixture was incubated for 3 h at 180 °C to hydrolyze the lipid II or the standard and afterwards cooled down to RT. 1 ml phosphate-free ultrapure water, 400 µl of 1.25 % ammonium heptamolybdate and 400 µl of 5 % ascorbic acid were added, the mixture was vigorously vortexed and boiled for 5 min in a water bath. The absorption was measured at 797 nm (UviLine 9400, Schott Instruments) and the concentration of lipid II was calculated based on the standard curve.

2.10 Fluorometric methods

2.10.1 QuantaBlu assay

To examine whether wolbachial PBPs or AmiD exhibit DD-carboxypeptidase activity in vitro, a fluorescent-linked enzyme assay to detect free D-Ala was performed using QuantaBlu Substrate solution (Thermo Scientific). Free D-Ala, which is released through the activity of a DD-carboxypeptidase, can be converted into pyruvate, ammonia and hydrogen peroxide by a D-amino acid oxidase (DAAO). The hydrogen peroxide can be used by horseradish peroxidase (HRP) to oxidize a suitable fluorogenic substance. In this thesis, the substrate from QuantaBlu
Substrate solution (QBS) was converted into a chromophore detectable at 420 nm following the reaction scheme:

\[
\begin{align*}
D-\text{Ala} + O_2 & \xrightarrow{\text{DAAB}} \text{Pyruvate} + \text{NH}_3 + H_2O_2 \\
2H^+ + H_2O_2 + \text{QBS} & \xrightarrow{\text{HPP}} 2H_2O + \text{QBS}^{2+} (A_{420})
\end{align*}
\]

Purified protein was incubated with synthesized lipid II (see chapter 2.9). A DD-carboxypeptidase (VanY) from \textit{S. aureus} served as a positive control and the pASK-IBA empty vector as a negative control. After overnight incubation, every sample was supplemented with 150 pmol D-Ala due to the detection limit of this assay and the reaction was stopped by adding 360 µl of a detection mixture (55 mg/ml ampicillin, 10 µl QuantaBlu substrate solution, 2.78 µg/ml FAD, 100 mM Tris-HCl, 1U HRP and 0.06 U DAAO). The samples were further incubated for 1 h at RT and subsequently measured (excitation/emission 325/420 nm) in a luminescence photometer (Spark™ 10M, Tecan).

2.10.2 \textit{In vivo} β-lactamase activity assay

To examine whether wobachial PBPs or AmiD possess β-lactamase activity, an assay using CENTA™ as a substrate was performed. CENTA™ is a chromogenic β-lactamase substrate suitable for both Gram-positive and Gram-negative bacteria (Jones et al., 1982). The hydrolysis of the β-lactam ring causes a shift in absorption maxima (\(\lambda_{\text{max}}\)) from 340 nm to 405 nm. Permeabilization of the outer membrane with the pore forming compound polymyxin B enables the substrate access to the enzyme and vice versa. \textit{E. coli} ML-35 pYC constitutively expressing a β-lactamase served as a positive control (Lehrer et al., 1988). PBP2\textsuperscript{wBm} and PBP6a\textsuperscript{wBm} were expressed in \textit{E. coli} JM83 and PBP3\textsuperscript{wMel} was expressed in \textit{E. coli} C43, two strains deficient in native β-lactamases. Fresh LB medium supplemented with chloramphenicol was inoculated with 2 % of the respective \textit{E. coli} pre-culture harboring a pASK-IBA expression vector with a wobachial PBP or AmiD. Cells were grown at 30 °C until OD\textsubscript{600} = 0.4 and then induced with 200 ng/ml AHT. After 4 h of expression, cells were diluted 1:10 and supplemented with 150 µM CENTA™ (dissolved in DMSO) and 1 µg/ml polymyxin B (dissolved in ultrapure water) in 200 µl LB medium in a flat bottom 96-well plate. The mixture was incubated for 16 h in a plate reader (Tecan Sunrise™, Tecan) at 30 °C and \(\lambda_{405}\) was measured every 10 min. All samples were prepared in duplicates, the empty vector served as a negative control.

2.10.3 Penicillin-binding assay

To test whether \textit{Wolbachia} AmiD or PBPs bind to penicillin, the fluorescent derivative Bocillin™ FL was used (Zhao et al., 1999). 4 µg purified protein, 10 µM Bocillin™ FL, 20 mM
potassium phosphate, pH 7.5 and 140 mM NaCl in a total volume of 20 µl were incubated in the dark at 20–35 °C for 30 min up to 16 h. Afterwards, SDS-PAGE was performed (see chapter 2.6.1) and the protein bound to Bocillin™ FL was visualized with a FastGene Led Illuminator (Nippon Genetics Europe GmbH).

2.11 Cell biological methods

2.11.1 C6/36 insect cell culture

Culture experiments were performed with an A. albopictus C6/36 insect cell line uninfected or stably infected with wAlbB (Turner et al., 2006). Cells were grown at 26 °C and split every seven days as described previously (Turner et al., 2006; Henrichfreise et al., 2009). Culture medium consisted of L15 Leibovitz medium supplemented with 5 % fetal calf serum (FCS), 2 % tryptose phosphate broth, 1 % MEM non-essential amino acids and 1 % penicillin/streptomycin. In later experiments, the standard 5 % FCS in the culture media was switched to 20 % as this was shown to increase the percentage of infected cells by Wolbachia (Clare et al., 2015).

2.11.2 Isolation of wAlbB from C6/36 insect cells

Wolbachia wAlbB were purified from infected C6/36 cells as described (Vollmer, 2012). Briefly, cells were grown to ~90 % confluence, harvested in 10 ml cell culture medium and lysed by vortexing with 100 sterile 3 mm borosilicate glass beads (Sigma-Aldrich) for 5 min. Cell debris was removed by centrifugation at 2,500 g for 10 min at 4 °C and the supernatant was filtered through a 5 µm syringe filter. The number of Wolbachia was determined by qPCR of the Wolbachia 16S rRNA single copy gene (see chapter 2.4.4).

2.11.3 Cell-free wAlbB culture

The cell-free wAlbB culture consisted of culture medium (see chapter 2.11.1), isolated wAlbB (see 2.11.2) and fractionated insect cell lysate from uninfected C6/36 cells (Vollmer, 2012). The amount of uninfected insect cells was calculated using a Neubauer counting chamber. Subsequently, uninfected cells were lysed by vortexing with 100 sterile 3 mm borosilicate glass beads for 5 min. Cell debris was removed by centrifugation at 2,500 g for 10 min at 4 °C and the supernatant was filtered through a 5 µm syringe filter. Additionally, the uninfected insect cell lysate was centrifuged at 20,000 g, 4 °C for 30 min. The supernatant containing cytosol, microsomes and plasma membranes was retained and used to prepare cell-
free wAlbB cultures. The final concentration of insect cell lysate fraction added to the culture was equivalent to $0.95 \times 10^6$ insect cells/ml. Purified *Wolbachia* were added in a final concentration of $0.5–1 \times 10^3$ 16S rRNA gene copies/µl. Prepared cell-free *Wolbachia* cultures of 200 µl were incubated in triplicates in 96-well plates for twelve days at 26 °C. *Wolbachia* numbers were calculated by qPCR on day 0 and then every three days by harvesting three wells.

2.11.4 Cell-free wAlbB with modified growth conditions

As *Wolbachia* are obligate intracellular bacteria, there is a high dependence on substances from their hosts to ensure survival and proliferation (see chapter 1.3). Isolated cell-free wAlbB were incubated with culture medium and additionally supplemented with insect cell lysate (see chapter 2.11.3), which has been shown to facilitate growth (Vollmer, 2012). However, the cell-free wAlbB culture decreased after twelve days as shown in qPCR and thus likely needs modified growth conditions to keep viable and to proliferate (Vollmer, 2012). In this work, several conditions were tested whether they could enhance growth and stability of the culture. Apart from that, cell-free wAlbB were incubated with different antibiotics to test the efficacy and impact on proliferation and morphology.

2.11.4.1 Incubation in a lowered oxygen environment

As shown for other intracellular bacteria, culturing in a lowered oxygen environment can increase cell-free growth (Omsland et al., 2009). Here, a carbonic gas chamber with 3 % oxygen, 5 % carbonic gas and 77 % nitrogen was used to examine whether proliferation of cell-free *Wolbachia* could be enhanced under these conditions. Cells were prepared as described in chapter 2.11.3 and fresh gas was applied every three days after harvesting three samples.

2.11.4.2 Incubation of cell-free wAlbB on actin-coated streptavidin plates

Pal"wBm" specifically binds to actin filaments of *B. malayi* and might be crucial in maintenance of endosymbiosis (Melnikow et al., 2013). As cell-free wAlbB show no adherence in the 96-well plate (J. Vollmer, pers. communication), culturing on a plate with actin was used to examine if the bacteria bind to the substrate to facilitate medium change. Here, a streptavidin plate was coated with biotin-labeled α-cardiac actin from bovine cardiac muscle according to the manufacturer’s protocol (Hypermol). Briefly, biotin-labeled actin was adjusted to 10 µg/ml with wash buffer (25 mM Tris, 150 mM NaCl; pH 7.2, 0.1% BSA (w/v), 0.05% Tween 20 (v/v)). Each well of the streptavidin plate was washed three times with 200 µl wash buffer and was then incubated with 100 µl of biotin-labeled actin for two hours under shaking at RT. The plates were washed three times with 200 µl wash buffer and subsequently washed three times
with 200 µl Leibovitz medium. Cell-free wAlbB were prepared (see chapter 2.11.3) and medium change was performed on day six.

2.11.4.3 Supplementation of cell-free wAlbB culture medium

An optimized culture medium was designed for cell-free growth of the obligate endobacteria Coxiella burnetii (Omsland et al., 2009). The cell-free wAlbB standard medium was compared to the medium for C. burnetii. Substances, which were only present in the medium for C. burnetii were supplemented to the cell-free wAlbB medium including biotin, cystine, glucose, pyridoxal 5-phosphate (PLP) and sodium bicarbonate (Table 27). Moreover, insufficient amounts of cholesterol were considered being a potential limiting factor of cell-free growth. Wolbachia do not synthesize lipid A and it was proposed that cholesterol might be necessary to promote membrane stability as a substitute for lipopolysaccharide (Lin and Rikihisa, 2003; Wu et al., 2004). Therefore, cholesterol was also added to the cell-free wAlbB standard medium. Lipid Mixture Solution (PeproTech) contains non-animal-derived fatty acids and lipids to improve cell growth in serum-free media, but the exact formulation is proprietary of PeproTech. The lipid mixture solution was added to the cell-free wAlbB culture to examine any beneficial effects regarding proliferation.

Table 27: Supplements tested in cell-free wAlbB culture.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration</th>
<th>Solvent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotin</td>
<td>25 mg/l</td>
<td>1N NaOH (adjusted to pH 7)</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>0.1 mg/l and 1 mg/ml</td>
<td>H₂O</td>
</tr>
<tr>
<td>D-Glucose</td>
<td>500 mg/l</td>
<td>H₂O</td>
</tr>
<tr>
<td>L-Cystine</td>
<td>30 mg/l</td>
<td>1M HCl (adjusted to pH 7)</td>
</tr>
<tr>
<td>Lipid mixture</td>
<td>1x, 2.5x and 5x</td>
<td>H₂O</td>
</tr>
<tr>
<td>PLP</td>
<td>0.247 mg/l</td>
<td>H₂O</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>250/500/2500 mg/l</td>
<td>H₂O</td>
</tr>
</tbody>
</table>

2.11.4.4 Growth of cell-free wAlbB co-cultured with yeast

B. malayi and B. pahangi infective-stage larvae co-cultured in vitro with the yeast Rhodotorula minuta have been shown to support consistent and reproducible molting to the fourth larval stage (Smith et al., 2000). It was assumed that the larvae are benefiting from an unknown secreted product of the yeast. R. minuta were cultured in YM medium (see Table 5) at 24 °C. Cell-free Wolbachia were prepared (see chapter 2.11.3) and co-cultured with different concentrations of R. minuta ranging from 10⁴–10⁷ cells/ml. Proliferation rates were examined via qPCR (see chapter. 2.4.4).
2.11.4.5 Antibiotic treatment

Cell-free \( w\)AlbB were prepared (see chapter 2.11.3) and additionally treated with antibiotics (Table 28). All antibiotics were applied freshly every three days during the assay, except for fosfomycin, which had to be given daily due to its short half-life in solution (Kirby, 1977). Growth was detected via qPCR every three days and changes in morphology were examined using immunohistochemistry (see chapter 2.12.1).

Table 28: Antibiotics tested in the cell-free \( w\)AlbB culture.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Antibiotic class</th>
<th>Target</th>
<th>Concentration</th>
<th>Solvent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin</td>
<td>( \beta)-lactam</td>
<td>Cell wall synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>( H_2O )</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>Cyclic peptide</td>
<td>Cell wall synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>( H_2O )</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Fluoroquinone</td>
<td>DNA synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>0.1 M HCl</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Lincosamide</td>
<td>Protein synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>( H_2O )</td>
</tr>
<tr>
<td>Corallopyronin A</td>
<td>Alpha-pyrone</td>
<td>RNA synthesis</td>
<td>1 ( \mu)g/ml</td>
<td>DMSO</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Tetracycline</td>
<td>Protein synthesis</td>
<td>4 ( \mu)g/ml</td>
<td>( H_2O )</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>Phosphonic</td>
<td>Cell wall synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>( H_2O )</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Ansamycin</td>
<td>RNA synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>( Ethanol )</td>
</tr>
<tr>
<td>Sulfamethoxazol</td>
<td>Sulfonamide</td>
<td>Folic acid synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>( Ethanol )</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>Sulfonamide</td>
<td>Folic acid synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>DMSO</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Glycopeptide</td>
<td>Cell wall synthesis</td>
<td>512 ( \mu)g/ml</td>
<td>DMSO</td>
</tr>
</tbody>
</table>

2.12 Immunohistochemistry

2.12.1 Fluorescence microscopy of antibiotic treated cell-free \( w\)AlbB

For viability assays, \( Wolbachia \) were pelleted by centrifugation at 18,400 \( g \) for 5 min and suspended in ultrapure water, PBS or Leibovitz medium, respectively. To test for lysozyme sensitivity, isolated \( w\)AlbB were resuspended in 5 \( mg/ml \) lysozyme. Bacteria were stained with the LIVE/DEAD\( ^{\text{\textregistered}} \) BacLight\( ^{\text{\textTM}} \) Bacterial Viability Kit (Molecular Probes) as previously described (Rasgon et al., 2006) and examined with a fluorescence microscope (ZeissAxio VertA.1, Carl Zeiss AG).

To test the effect of antibiotics on growth of cell-free \( w\)AlbB, cultures were prepared (see chapter 2.11.3), cultured in 96-well plates and treated with the respective antibiotic for twelve days (see chapter 2.11.4.5). Cell-free \( w\)AlbB were stained with the LIVE/DEAD\( ^{\text{\textregistered}} \) BacLight\( ^{\text{\textTM}} \) Bacterial Viability Kit as described previously (Rasgon et al., 2006). Additionally, cell-free \( w\)AlbB were fixed, stained and visualized as described for C6/36 \( w\)AlbB infected cells (Vollmer et al., 2013). Briefly, 50 \( \mu l \) \( w\)AlbB were dried on a microscope slide and fixed in ice-cold 4 \% paraformaldehyde \( (w/v) \) for 15 min. Then, samples were washed three times with 1x PBS (137 \( mM \) NaCl, 2.7 \( mM \) KCl, 10 \( mM \) Na\( _2 \)HPO\( _4 \), 2 \( mM \) KH\( _2 \)PO\( 4 \), pH 7.4) and cells were
2 Materials and methods

permeabilized with 1x PBS + 0.25 % Triton X-100 (v/v) for 15 min. Subsequently, slides were washed three times and blocked with 1x PBS + 10 % BSA (w/v) for 1 h at RT. Samples were washed again three times with 1x PBS and incubated with a Wolbachia-specific FtsZ/Pal antibody diluted 1:1000 in PBS overnight at 4 °C in a humid chamber. The next day, samples were washed three times with 1x PBS and incubated with secondary antibody conjugated to Alexa Fluor® 488 diluted 1:200 in PBS for 1 h at RT in the dark. After three washing steps with 1x PBS, 0.25 µg/ml DAPI was applied and incubated for 10 min at RT. Cells were washed again three times with 1x PBS and stored at 4 °C until fluorescence microscopy was performed.

2.12.2 Lipid II labeling of wAlbB

Liechti et al. (2014) developed a novel peptidoglycan labeling approach that bypasses the bacterial Ddl enzyme using D-Ala-D-Ala dipeptide analogues modified with alkyne functional groups (Ethynyl-D-alanyl-D-alanine; EDA-DA) and click chemistry. With this technique, a peptidoglycan-like structure was revealed for the first time in intracellular Chlamydia trachomatis, in free-living Planctomycetes and in the closely to Wolbachia-related O. tsutsugamushi (Liechti et al., 2014; Jeske et al., 2015; Van Teeseling et al., 2015; Atwal et al., 2017). Here, the labeling technique was applied to the C6/36 wAlbB infected culture to investigate if Wolbachia residing in insect cells also have a peptidoglycan-like structure. Cells were harvested, counted in a Neubauer chamber and inoculated to a final concentration of 50,000 cells/ml in chamber slides. To block lipid II synthesis, 512 µg/ml fosfomycin was applied daily for 12 days to the C6/36 wAlbB infected culture before harvesting and seeding the cells to chamber slides. Cells were incubated with 1 mM EDA-DA or ELA-LA (synthesized by Pepmic Co., Ltd.) for 72 h and subsequently prepared for fluorescence microscopy. Cells were fixed in ice-cold 4 % paraformaldehyde (w/v) for 15 min, washed three times with 1x PBS (136 mM NaCl, 2.68 mM KCl, 10 mM Na₂HPO₄·2H₂O, 1.98 mM KH₂PO₄, pH 7.4) and were incubated for 10 min with 1x PBS + 0.15 % Tween 20 (v/v). Cells were washed again three times and blocked with 1x PBS + 3 % BSA (w/v) for 1 h at RT. Click chemistry was performed using the Click-iT® Cell Reaction Buffer Kit (Thermo Scientific) following the manufacturer’s instructions with a concentration of 10 mM Alexa Fluor® 594 azide. Cells were washed again three times with 1x PBS and incubated with a Wolbachia-specific FtsZ or Pal antibody diluted 1:1000 in PBS overnight at 4 °C in the dark. The next day, samples were washed three times with 1x PBS and incubated with secondary antibody conjugated to Alexa Fluor® 488 diluted 1:200 in PBS for 1 h at RT in the dark. After three washing steps with 1x PBS, 0.25 µg/ml DAPI was applied and incubated for 10 min at RT. Cells were washed again three times with
1x PBS and observed with a fluorescence microscope (ZeissAxio VertA.1, Carl Zeiss AG). Fosfomycin treated cells were visualized using a confocal microscope (Zeiss LSM710, Carl Zeiss AG).

2.13 Bioinformatics

2.13.1 In silico analyses

BLAST analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to identify sequences similar to Wbm0075 (pal), Wbm0152 (php2), Wbm0290 (php6a), WD1073 (amiD) and WD1273 (php3) and the sequence alignment tool Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) to align wolbachial and E. coli sequences. The presence of transmembrane domains and a signal peptide for secretion in the periplasm was predicted using TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM/) and SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/). Protein structure prediction of the proteins was generated by Phyre² (protein homology/analogy recognition engine V2.0) based on secondary structure prediction by recognition of similar sequences and related 3D structures (www.sbg.bio.ic.ac.uk). Potential ligand binding sites were predicted by 3DLigandSite (http://www.sbg.bio.ic.ac.uk/~3dligandsite/) (Wass et al., 2010). 3D-models of the proteins with highlighted putative active sites were illustrated using Jmol 14.28.3 (http://jmol.sourceforge.net/).

2.13.2 Statistical analyses

For statistical analyses, GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, USA) was used. Normality tests were performed using Shapiro-Wilk tests. For normal distributed data, parametric t-tests were applied (comparison of two groups), whereas non-parametric data were analyzed using Mann-Whitney tests (comparison of two groups) or Kruskal-Wallis tests (comparison of more than two groups) with subsequent Dunn’s comparison post-hoc test with a significance level of P < 0.05.
3 Results

3.1 Functional analysis of PBP6a<sub>wBm</sub>

3.1.1 Primary structure analysis of PBP6a<sub>wBm</sub>

The genome of <i>wBm</i> encodes the putative DD-carboxypeptidase PBP6a<sub>wBm</sub> (NCBI: WP_041571552.1) which consists of 370 amino acids with a predicted molecular mass of 42.21 kDa. PBP6a<sub>wBm</sub> shares 84% sequence similarity with PBP6a from <i>wMel</i> (NCBI: AAS13855.1) having identical conserved PBP active site motifs SXXX, SX(D/N) and K(S/T)G (Supplementary Figure 1). PBP6a<sub>wBm</sub> and PBP6a from <i>E. coli</i> (NCBI: WP_032169860.1) have 35% sequence identity (Figure 14). Notably, the wolbachial PBP6a has one more SXXK motif which might harbor the active site serine than its <i>E. coli</i> homolog, but only the second SXXK (K<sup>56</sup>MSK), SXN (K<sup>116</sup>GN) and the KTG (K<sup>218</sup>TG) motifs align to <i>E. coli</i> PBP6a. PBP6a<sub>wBm</sub> has a predicted signal peptide ranging from amino acid 1–22, but no predicted transmembrane domain suggesting the enzyme being localized in the periplasm (Supplementary Figure 2).

![Primary structure and amino acid alignment of PBP6a<sub>wBm</sub> and <i>E. coli</i> PBP6a.](image-url)
3.1.2 Secondary structure analysis of PBP6α\textsuperscript{wBm}

To get a deeper insight into the putative active site of PBP6α\textsuperscript{wBm}, secondary structure analysis was performed. Based on sequence alignments to \textit{E. coli}, the conserved active site motifs found in PBP6α\textsuperscript{wBm} were localized (Figure 15). The first SXXK motif (S\textsuperscript{48}DEK) was predicted to be located on a loop, while the second SXXK motif (S\textsuperscript{56}MSK) is putatively found in an α-helix. S\textsuperscript{116}GN is likely localized in an α-helix and loop, whereas K\textsuperscript{218}TG is found in a β-sheet. The results of the structure analysis indicated that PBP6α\textsuperscript{wBm} has a catalytic center and might be an active DD-carboxypeptidase. The gene \textit{pbp6a} from \textit{w}Bm was cloned into pASK-IBA2C, transformed into different \textit{E. coli} strains and tested in \textit{in vivo} and \textit{in vitro} activity assays.

![Secondary structure of PBP6α\textsuperscript{wBm} as predicted by Phyre²](image)

**Figure 15**: Secondary structure of PBP6α\textsuperscript{wBm} as predicted by Phyre². S\textsuperscript{48}DEK or S\textsuperscript{56}MSK (blue) might, together with S\textsuperscript{116}GN (green) and K\textsuperscript{218}TG (red), build the catalytic center of the enzyme. The molecular structure of PBP6α\textsuperscript{wBm} was illustrated by Jmol.

3.1.3 Characterization of PBP6α\textsuperscript{wBm} \textit{in vivo}

The characterization of DD-carboxypeptidases \textit{in vivo} is challenging as depletion in \textit{E. coli} does not lead to an aberrant phenotype (Nelson and Young, 2001). However, the activity of DD-carboxypeptidases can be measured indirectly by complementation of \textit{E. coli} MCI23. This strain encodes a temperature sensitive version of the essential cell division DD-transpeptidase PBP3 resulting in a filamentous phenotype when grown at the non-permissive temperature of 42 °C (Begg et al., 1990; Dai et al., 1993). This growth defect can be complemented by the overexpression of a DD-carboxypeptidase cleaving the terminal D-Ala of the pentapeptide chains of peptidoglycan. The subsequent cleavage of the tetrapeptides by the LD-carboxypeptidase A results in increased levels of available tripeptide
chains in peptidoglycan (Begg et al., 1990). These are the preferred substrates of PBP3 (Botta and Park, 1981; Pisarro et al., 1986). This is sufficient to partially restore cell division by the residual activity of PBP3 (Begg et al., 1990). To test the in vivo activity of the putative DD-carboxypeptidase PBP6a\textsubscript{wBm}, the encoded \textit{php6a} gene from \textit{wBm} was cloned into the expression vector pASK-IBA2C. The native signal sequence of \textit{php6a} was replaced by the \textit{ompA} signal peptide of the expression vector pASK-IBA2C. Successful cloning was confirmed by sequencing (Supplementary Figure 3) and the construct was transformed into \textit{E. coli} MCI23 and ready-to-use for in vivo assays. \textit{E. coli} MCI23 expressing recombinant PBP6a\textsubscript{wBm} showed short and dividing cells at 30 °C and PBP6a\textsubscript{wBm} overproduction at the non-permissive temperature of 42 °C partially restored cell division (Figure 16A). Additional staining with DAPI displayed distinct DNA separation of PBP6a\textsubscript{wBm} expressing cells, thus confirming the restoration of cell division in the temperature sensitive \textit{E. coli} MCI23 strain. \textit{E. coli} MCI23 with the induced empty vector pASK-IBA2C incubated at 30 °C had a normal phenotype with only single and dividing cells, whereas bacteria grown at 42 °C were unable to divide resulting in elongated cells (Figure 16B). In accordance, no partition of DNA was monitored in DAPI-stained cells. Consequently, each filament represents one viable elongated cell. Experiments were repeated six times and in each experiment five randomly chosen pictures were taken for quantitative analysis of cells at the non-permissive temperature. \textit{E. coli} MCI23 expressing PBP6a\textsubscript{wBm} were statistically shorter than and cells expressing the empty vector control at 42 °C (Figure 16C). In \textit{E. coli} MCI23 expressing recombinant PBP6a\textsubscript{wBm} at 42 °C, a mixed set of phenotypes was observed with 36.3 % (± 25.6 standard deviation (SD)) elongated cells and 63.7 % (± 25.6 SD) short cells able to divide (Figure 16D). \textit{E. coli} MCI23 expressing the empty vector pASK-IBA2C at 42 °C resulted in 97.8 % (± 2.6 SD) elongated bacteria and only 2.2 % (± 2.6 SD) short single and dividing cells. In conclusion, these results give a first hint that PBP6a\textsubscript{wBm} might act as a DD-carboxypeptidase in vivo.
Figure 16: PBP6a\textsuperscript{wBm} rescues cell division in a temperature sensitive \textit{E. coli} MCI23 mutant. \textit{E. coli} MCI23 were grown in LB medium containing chloramphenicol until OD$_{600}$ = 0.4. PBP6a\textsuperscript{wBm} expression was induced with 100 ng/ml tetracycline and cells were incubated for 120 min at 30 °C (endogenous PBP3 is expressed, cells divide normally; permissive temperature) or 42 °C (endogenous PBP3 is not expressed, cells do not divide normally and form long, filamentous strands; non-permissive temperature). A) \textit{E. coli} MCI23 expressing recombinant PBP6a\textsuperscript{wBm} complement cell division at 30 °C and partially at the non-permissive temperature of 42 °C, scale bar = 20 µm. DAPI staining confirmed septa formation in \textit{E. coli} MCI23 expressing PBP6a\textsuperscript{wBm}, scale bar = 5 µm. B) \textit{E. coli} MCI23 expressing the empty vector pASK-IBA2C have short, single cells at 30 °C, but are not able to divide at 42 °C showing a filamentous phenotype. DAPI staining confirmed that septa were absent in cells with the empty vector control. C) At least 938 cells from 30 randomly chosen pictures taken from six independent assays per sample at 42 °C were measured by Image J. Boxes extend from the 25\textsuperscript{th} to the 75\textsuperscript{th} percentile. The line in the middle of the box is plotted at the median. Whiskers represent 1\textsuperscript{st} and 99\textsuperscript{th} percentiles, dots represent outliers. Statistical analysis was performed using Mann-Whitney test. *** = P ≤ 0.001. D) Columns represent mean ± SD of relative occurrence of different phenotypes at 42 °C from 30 randomly chosen pictures in six independent experiments.

3.1.4 Active site analysis of PBP6a\textsuperscript{wBm} \textit{in vivo}

The serine of the SXXK motif catalyzes the enzymatic reaction of PBPs and the mutagenesis of SXXK motifs in PBP6 from \textit{C. pneumoniae} was shown to inhibit DD-carboxypeptidase activity \textit{in vitro} (Otten, 2014). Since PBP6a\textsuperscript{wBm} contains two SXXK motifs, it was tested which of the serine residues from the conserved SXXK motifs is essential
for enzyme activity. Mutagenesis PCRs were performed to exchange serine from both SXXK motifs to alanine (S48A and S56A) (Figure 17). Successful mutagenesis was confirmed by nucleotide sequencing (Supplementary Figure 4).

Figure 17: Primary structure of PBP6a\(^{wBm}\) in pASK-IBA2C after site-directed mutagenesis. Serine residues from SXXK motifs were substituted by alanine (red bold letters). The predicted native signal peptide (highlighted gray) was removed and replaced by OmpA from the pASK-IBA2C vector. The amino acid sequence is shown in single-letter code.

E. coli MC123 cultures expressing mutated PBP6a\(^{wBm}\) were tested for their ability to rescue division at 42 °C. In control assays with E. coli MC123 expressing recombinant PBP6a\(^{wBm}\) S48A, S56A or S48A-S56A at 30 °C, all cells were short and dividing (data not shown). Expression at 42 °C of PBP6a\(^{wBm}\) with one mutated SXXK motif (S48A or S56A) resulted in a mixed set of phenotypes similar to the expression of unmutated PBP6a\(^{wBm}\) at 42 °C (see chapter 3.1.1). In contrast, the expression of PBP6a\(^{wBm}\) S48A-S56A predominantly resulted in elongated cells (Figure 18A-C). Analysis of six independent experiments confirmed these observations showing that cells with only one SXXK mutation were significantly shorter than the double SXXK mutant (Figure 18D). Expression of single SXXXK mutants resulted in 61.3 % (± 29.5 SD) (PBP6a\(^{wBm}\) S48A) and 59.7 % (± 31.2 SD) (PBP6a\(^{wBm}\) S56A) short cells able to divide (Figure 18E) similar to the unmutated PBP6a\(^{wBm}\) (see chapter 3.1.1). Expression of PBP6a\(^{wBm}\) S48A-S56A resulted in an increase of elongated cells to 91 % (± 8.1 SD) with a concomitant decrease of short, single and dividing cells to 9 % (± 8.1 SD).
Figure 18: Complementation assay to test for the ability of PBP6a<sup>W18M</sup> active site mutants to rescue cell division in a temperature sensitive <i>E. coli</i> MCI23 mutant. Cultures were grown in LB medium containing chloramphenicol at 30 °C and protein expression was induced with 100 ng/ml tetracycline at OD<sub>600</sub> = 0.4. Cells were further incubated for 120 min at the non-permissive temperature of 42 °C. Phase-contrast micrographs show that <i>E. coli</i> MCI23 expressing A) PBP6a<sup>W18M</sup>S48A and B) PBP6a<sup>W18M</sup>S56A partially rescue cell division, while C) expression of PBP6a<sup>W18M</sup>S48A-S56A leads to elongated cells unable to divide. Scale bars = 20 µm. D) At least 683 cells from 30 pictures taken from six independent assays per sample were measured by Image J. Boxes extend from the 25<sup>th</sup> to the 75<sup>th</sup> percentile. The line in the middle of the box is plotted at the median. Whiskers represent 1<sup>st</sup> and 99<sup>th</sup> percentiles. Statistical analysis was performed using Kruskal-Wallis test and Dunn’s comparison post-hoc test. ns = not significant, *** = P ≤ 0.001. E) Columns represent mean ± SD of relative occurrence of different phenotypes at 42 °C from 30 randomly chosen pictures in six independent experiments.

Growth of <i>E. coli</i> was monitored to exclude that the different observed phenotypes resulted from potential cell arrests induced by protein induction. In three independent measurements, all cultures grew exponentially after induction (Figure 19).

Figure 19: Growth kinetics of <i>E. coli</i> MCI23 during periplasmic expression of PBP6a<sup>W18M</sup>. Protein expression was induced at OD<sub>600</sub> = 0.4 with 100 ng/ml tetracycline. OD<sub>600</sub> was measured every hour. Each point represents mean ± SD (n = 3).
As the number of single and dividing cells in PBP6a\textsuperscript{wBm} S48A-S56A (9 \%) was still higher than cells expressing the empty vector (2.2 \%), further control experiments with \textit{E. coli} MCI23 expressing Pal\textsuperscript{wBm} were performed. This protein is not expected to have any DD-carboxypeptidase or DD-transpeptidase activity and was an appropriate control to exclude potential false positive results caused by expression stress of proteins after induction which could also contribute to reduced cell size. In six independent assays, cells expressing Pal\textsuperscript{wBm} were significantly shorter than the empty vector control, but only 8.32 \% (± 2.42 SD) of cells were single and dividing, whereas 91.68 \% (± 2.42 SD) of cells were elongated (Figure 20). This explains the apparent remaining activity of the PBP6a\textsuperscript{wBm} S48A-S56A which is likely caused by expression stress of the bacteria.

![Figure 20: Lack of complementation of cell division defect of \textit{E. coli} MCI23 with Pal\textsuperscript{wBm}. A) The phase-contrast micrograph shows that \textit{E. coli} MCI23 expressing Pal\textsuperscript{wBm} predominantly have elongated cells unable to divide. Scale bar = 20 µm. B) At least 351 cells from 30 pictures taken from six independent assays per sample were measured by Image J. Boxes extend from the 25th to the 75th percentile. The line in the middle of the box is plotted at the median. Whiskers represent 1\textsuperscript{st} and 99\textsuperscript{th} percentiles. Statistical analysis was performed using Kruskal-Wallis test and Dunn’s comparison post-hoc test. *** = P ≤ 0.001. C) Columns represent mean ± SD of relative occurrence of different phenotypes at 42 °C from 30 randomly chosen pictures in six independent experiments.](image)

In conclusion, the results from the \textit{in vivo} complementation assays in \textit{E. coli} indicate that the serines in both SXXK motifs of PBP6a\textsuperscript{wBm} are most likely responsible for catalytic activity in this enzyme.

### 3.1.5 Periplasmic expression and purification of recombinant PBP6a\textsuperscript{wBm}

As previous attempts to obtain purified recombinant PBP6a\textsuperscript{wBm} by cytoplasmic overexpression were not successful (data not shown), \textit{php6a} was cloned into pASK-IBA2C with \textit{ompA} substituting the native signal peptide for periplasmic expression. This method has been shown to improve protein yields of expressed recombinant PBPs from intracellular bacteria of the genus \textit{Chlamydia} (De Benedetti et al., 2014; Klöckner et al., 2014; Otten et al., 2015). For small-scale overexpression pre-tests, pASK-IBA2C containing \textit{php6a} was transformed into the \textit{E. coli} strains C43, JM83 and W3110. Pre-tests were carried out to identify conditions that facilitate the production of recombinant PBPs and yield the highest amounts of
soluble protein. PBP6α\textsuperscript{wBm} was expressed in all three strains and *E. coli* JM83 was chosen to be used for further overexpression as this strain yielded highest protein amounts. PBP6α\textsuperscript{wBm} overproduction was additionally optimized by co-solvent supplementation. Co-solvent assisted overproduction has been established for heterologous expression of recombinant proteins from intracellular *Chlamydia* (Otten et al., 2015). The co-solvent test revealed that 4 h expression at 25 °C in the presence of arginine resulted in the highest amount of soluble protein. Subsequently, the expression culture was scaled-up to 4 l and recombinant protein was purified using Strep-tag chromatography. Protein concentration of each eluate was measured (80–120 µg/ml) and purity of PBP6α\textsuperscript{wBm} was confirmed by Western Blot analysis (Figure 21). As a negative control, a mock purification of the empty vector pASK-IBA2C was performed, which is exemplarily shown in chapter 3.4.1.1.

![Figure 21: Overexpressed and purified PBP6α\textsuperscript{wBm} in pASK-IBA2C.](image)

3.1.6 Activity of PBP6α\textsuperscript{wBm} *in vitro* using lipid II as a substrate

The arginine-assisted overproduction of recombinant PBP6α\textsuperscript{wBm} yielded in soluble protein accessible to biochemical characterization. The protein was incubated with the cell wall precursor lipid II for 4 h or overnight at 30 °C. To exclude false positive results from potentially contaminating *E. coli* DD-carboxypeptidases, the corresponding eluate of the overexpressed and purified empty vector pASK-IBA2C served as a negative control. The DD-carboxypeptidase VanY from *S. aureus* served as a positive control and was incubated with lipid II for 1 h. After incubation of PBP6α\textsuperscript{wBm} with lipid II for 4 h and separation of the reaction mixture by TLC, a lipid II band at the normal running level was detected. However, after overnight incubation, two bands at different levels were observed (Figure 22A). The lower band represents lipid II with a tetrapeptide, which is generated when the terminal D-Ala is cleaved.
from the pentapeptide chain. This band was also detected when lipid II was incubated with VanY from *S. aureus*. The upper band represents lipid II with a pentapeptide, which was also observed in the empty vector. MALDI-TOF analysis of the reaction products confirmed the TLC results (Figure 22B). Lipid II (L-Lys) has a mass of around 1875 Da, which was detected in the empty vector control. When incubated with PBP6a<sub>Wm</sub>, a mass of 1805 Da was measured due to the cleavage of the terminal D-Ala from the pentapeptide side chain. The enzyme activity of PBP6a<sub>Wm</sub> was slower compared to VanY from *S. aureus*. Nevertheless, TLC as well as MALDI-TOF analysis of the reaction products indicated *in vitro* DD-carboxypeptidase activity of PBP6a<sub>Wm</sub>.

![Figure 22: In vitro activity of PBP6a<sub>Wm</sub>](image)

The overexpressed recombinant PBP6a<sub>Wm</sub> showed DD-carboxypeptidase activity on lipid II. A) TLC comparing DD-carboxypeptidase activity of PBP6a<sub>Wm</sub> after 4 h and overnight (o/n) incubation with lipid II. The DD-carboxypeptidase VanY (*S. aureus*) was used as a positive control, the empty vector pASK-IBA2C served as a negative control. B) MALDI-TOF analysis of the lipid II reaction products after incubation with PBP6a<sub>Wm</sub> and the empty vector pASK-IBA2C. Cleaving of terminal D-Ala from the pentapeptide side chain of lipid II (mass: 1875 Da) resulted in the formation of lipid II-tetrapeptide (mass: 1805 Da). MALDI-TOF analysis was performed by M. Josten, IMMIP.
3.1.7 Active site analysis of PBP6a\textsuperscript{wBm} \textit{in vitro}

The expressed and purified PBP6a\textsuperscript{wBm} S48A-S56A protein, in which both active site serine residues of the SXXK motifs were replaced by alanine, was not capable of cleaving the terminal D-Ala from lipid II as shown by TLC and MALDI-TOF (Figure 23). The mass of the reaction products after overnight incubation of PBP6a\textsuperscript{wBm} S48A-S56A with lipid II was around 1877 Da, which corresponds to the mass of lipid II (L-Lys) with a pentapeptide confirming no DD-carboxypeptidase activity of the active site mutant.

![Figure 23: In vitro activity of PBP6a\textsuperscript{wBm} S48A-S56A active site mutant. TLC and MALDI-TOF analysis of the lipid II reaction products after incubation with overexpressed recombinant PBP6a\textsuperscript{wBm} S48A-S56A active site mutant did not reveal DD-carboxypeptidase activity on lipid II. MALDI-TOF analysis was performed by M. Josten, IMMIP.](image)

3.1.8 Resistance of PBP6a\textsuperscript{wBm} to β-lactam antibiotics \textit{in vitro}

As PBPs usually show a high penicillin-binding affinity, antibiotic susceptibility tests using β-lactam antibiotics were performed. These antibiotics bind to the active site serine in the SXXXK motif of PBPs and inhibit cell wall synthesis by the formation of an acyl-enzyme complex due to structural similarity to the natural substrate D-Ala-D-Ala (Sauvage and Terrak, 2016). Neither penicillin G nor ampicillin abolished the DD-carboxypeptidase activity of PBP6a\textsuperscript{wBm} after incubation overnight in a molar ratio of 1:10 (Figure 24). A Bocillin\textsuperscript{TM} FL-binding assay confirmed that penicillin did not bind to the protein \textit{in vitro} (Supplementary Figure 5). Additionally, a more sensitive assay with radiolabeled penicillin also did not reveal any binding to PBP6a\textsuperscript{wBm} (data not shown). Altogether, these results indicate that PBP6a\textsuperscript{wBm} is resistant to β-lactam antibiotics.
3.1.9 *In vivo* β-lactamase activity assay of PBP6a\(^{wBm}\)

DD-carboxypeptidases and β-lactamases are members of the so-called serine proteases and have high structural similarities (Smith et al., 2013). Serine-β-lactamases hydrolyze the lactam ring by an active serine residue resulting in resistance to β-lactam antibiotics. A bifunctional DD-carboxypeptidase and β-lactamase activity was demonstrated in PBP5 from *Pseudomonas aeruginosa* explaining β-lactam resistance of these bacteria (Smith et al., 2013). As penicillin G and ampicillin were not able to inhibit PBP6a\(^{wBm}\) activity *in vitro* and penicillin-binding was not observed (see chapter 3.1.7), a β-lactamase assay was performed to examine if PBP6a\(^{wBm}\) cleaves β-lactam antibiotics. For this, PBP6a\(^{wBm}\) was expressed in *E. coli* JM83 cultures supplemented with CENTA\(^{TM}\) as a substrate and incubated for 16 h. Analysis of absorbance measurements of six independent assays showed an increase of λ\(_{405}\) from 0.48 (± 0.04 standard error of the mean (SEM)) to 1.36 (± 0.15 SEM) in cultures containing the positive control *E. coli* ML-35 pYC indicating successful CENTA\(^{TM}\) hydrolysis (Figure 25). In contrast, constant absorbance values around λ\(_{405}\) = 0.38 (± 0.02 SEM) were observed in cells expressing PBP6a\(^{wBm}\) in eight independent assays. Cultures expressing the empty vector control showed slightly increased λ\(_{405}\) levels from 0.4 (± 0.03 SEM) to 0.58 (± 0.07 SEM) after 16 h incubation in six independent assays. In conclusion, no β-lactamase activity for PBP6a\(^{wBm}\) was detected under the conditions tested.
Figure 25: β-lactamase activity assay of PBP6a<sub>wBm</sub> <i>in vivo</i>. <i>E. coli</i> JM83, carrying PBP6a<sub>wBm</sub> in pASK-IBA2C were induced with 200 ng/ml AHT. β-lactamase activity was detected at λ<sub>405</sub> using the chromogenic cephalosporin CENTA™ as a substrate. <i>E. coli</i> ML35-pYC constitutively expressing a periplasmic β-lactamase were used as a positive control, pASK-IBA2C (empty vector) served as a negative control. PBP6a<sub>wBm</sub> data represent means from eight independent assays, the positive and negative control were tested in six independent assays. Error bars represent ± SEM.

3.1.10 <i>In silico</i> binding of PBP6a<sub>wBm</sub> to cefoxitin

<i>In silico</i> analysis predicted a binding of the β-lactam antibiotic cefoxitin to PBP6a<sub>wBm</sub>, including the serine of the second SXXK motif S56 (Figure 26). Contrary to PBP6a from <i>E. coli</i>, PBP6a<sub>wBm</sub> has two SXXK motifs allowing the enzyme to be active even when bound to a β-lactam. As the first SXXK serine is not involved in binding and <i>in vivo</i> assays indicate that SXXK motifs can substitute each other (see chapter 3.1.4), PBP6a<sub>wBm</sub> might still be a functional DD-carboxypeptidase in the presence of a β-lactam.

Figure 26: PBP6a<sub>wBm</sub> bound to cefoxitin as predicted by 3DLigandSite. The residues S55, S56, K59, S93, S116, N118, S157, P160, K204, T219, Y221, T222 putatively involved in binding to cefoxitin (green) are labeled in red, their corresponding structures are marked in blue. The arrow points to the active site serine S56 of the SXXK motif predicted to be involved in binding.
3.2 Functional analysis of PBP2\textsuperscript{wBm}

3.2.1 Primary structure analysis of PBP2\textsuperscript{wBm}

In rod-shaped \textit{E. coli}, PBP2 is an essential compound of the peptidoglycan biosynthesis multi-enzyme complex and promotes cell elongation as well as shape maintenance (Typas et al., 2012). The annotated wolbachial DD-transpeptidase homolog PBP2\textsuperscript{wBm} (NCBI: WP_011256277) investigated in this thesis consists of 520 amino acids with an estimated size of 58 kDa. It harbors one predicted N-terminal transmembrane domain ranging from amino acids 1–35, but no signal peptide for periplasmic secretion (Supplementary Figure 6). PBP2\textsuperscript{wBm} contains two SXXK, four SX(D/N) and one K(S/T)G motif. \textit{E. coli} PBP2 (NCBI: WP_000776176.1) has only one SXXK motif, but four SX(D/N) and one KSG motif. A glycosyltransferase activity site was not identified in PBP2\textsuperscript{wBm}, thus it might be a monofunctional DD-transpeptidase like \textit{E. coli} PBP2 (Sauvage et al., 2008). PBP2\textsuperscript{wBm} was re-annotated on NCBI and is now listed as a putative PBP3, a DD-transpeptidase involved in cell division. PBP2\textsuperscript{wBm} shares 28\% sequence identity with \textit{E. coli} PBP2 and 24\% with \textit{E. coli} PBP3 (NCBI: ARB43848.1) (Figure 27). Sequence alignment of PBP2\textsuperscript{wBm} with PBP2\textsuperscript{wMel} and PBP3\textsuperscript{wMel} revealed a high similarity around 84\% to PBP2\textsuperscript{wMel} and only 18\% to PBP3\textsuperscript{wMel} (Supplementary Figures 7, 8). Thus, the term PBP2\textsuperscript{wBm} was kept in this thesis as a description for this enzyme. However, the question remained whether this enzyme is involved in cell elongation or whether it is part of the cell division complex.
### Results

<table>
<thead>
<tr>
<th>PBP2</th>
<th>E. coli</th>
<th>PBP3</th>
<th>E. coli</th>
</tr>
</thead>
<tbody>
<tr>
<td>wBm</td>
<td>--------</td>
<td>wBm</td>
<td>--------</td>
</tr>
<tr>
<td>PBP2</td>
<td>M-WKKNKVFNRRAF-ILGQIGLTSTIFSRCLYLQIRNRQKYEKLAD</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>E. coli</td>
<td>MKLQNSFRTDAEALVFYRRL-VAFGLILLLTTGTVIYLAQLYNLTVFQVTDYQTRSN</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>PBP3</td>
<td>MKAAATQKFKRQEEEHANSWRFALLGCQLLALFLGRVAVLQVSDMVLWEGD</td>
<td>58</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 27:** Primary structure analysis and amino acid alignment of PBP2<sup>wBm</sup> and E. coli PBP2 and PBP3. PBP2<sup>wBm</sup> (WP_011256277.1) shares 28% sequence identity to E. coli PBP2 (WP_000776176.1) and 24% identity to E. coli PBP3 (ARB43848.1). Conserved SXXK, SX(D/N) and K(S/T)G motifs found in PBP2<sup>wBm</sup> are written in bold letters, motifs which align to E. coli PBP2 and PBP3 are additionally framed in black. The predicted N-terminal transmembrane domain is highlighted gray.

* fully conserved residue; : conservation between groups of strongly similar properties; : conservation between groups of weakly similar properties.
3.2.2 Secondary structure analysis of PBP2\textsuperscript{wBm}

To get a deeper insight into the putative active site of PBP2\textsuperscript{wBm}, secondary structure analysis was performed. Here, the three conserved motifs were localized based on sequence alignments to \textit{E. coli}. Secondary structure analysis predicted that the first SXXK motif (S\textsuperscript{107}ETK) is outside the predicted catalytic center (Figure 28). The second motif (S\textsuperscript{265}IFK), which was found to be conserved in the \textit{E. coli} PBP2, is probably localized in an $\alpha$-helix and thus might comprise the active site with S\textsuperscript{320}CN ($\alpha$-helix and loop) and K\textsuperscript{465}TG ($\beta$-sheet). The results of the structure analysis indicated that PBP2\textsuperscript{wBm} has a catalytic center and might be an active DD-transpeptidase. The gene \textit{pbp2} from wBm was cloned into pASK-IBA expression vectors, transformed into different \textit{E. coli} strains and tested in \textit{in vivo} and \textit{in vitro} activity assays.

![Figure 28: Secondary structure of PBP2\textsuperscript{wBm} as predicted by Phyre\textsuperscript{2}. S\textsuperscript{265}IFK (blue) might, together with S\textsuperscript{320}CN (green) and K\textsuperscript{465}TG (red), build the catalytic center of the enzyme, while S\textsuperscript{107}ETK is predicted to be located outside the active site (blue). The molecular structure of PBP2\textsuperscript{wBm} was illustrated by Jmol.]

3.2.3 Characterization of PBP2\textsuperscript{wBm} \textit{in vivo}

To gain a first insight into the function of the putative wolbachial DD-transpeptidase PBP2\textsuperscript{wBm}, \textit{in vivo} complementation assays were performed with the PBP3 temperature sensitive \textit{E. coli} MCI23 strain. As PBP2 and PBP3 have clearly distinct tasks in other bacteria like \textit{E. coli}, a complementation of cell division deficiency would only be expected if PBP2\textsuperscript{wBm} was involved in cell division. PBP2\textsuperscript{wBm} with and without its predicted N-terminal transmembrane domain (PBP2\textsuperscript{wBm}\text{ΔTM\textsuperscript{wBm}}) was cloned into pASK-IBA6C and transformed into \textit{E. coli} MCI23. Successful cloning and transformation were confirmed by sequencing (Supplementary Figures 9,10).
Additionally, *E. coli* MCI23 were transformed with the empty vector as a control for *in vivo* assays. *E. coli* MCI23 expressing recombinant PBP2ΔTM<sup>BM</sup>, PBP2<sup>BM</sup> or the empty vector control at 30 °C only had short and dividing cells (data not shown). At the non-permissive temperature of 42 °C, *E. coli* MCI23 expressing recombinant PBP2ΔTM<sup>BM</sup> were mainly short and dividing (Figure 29A), whereas *E. coli* MCI23 overexpressing PBP2<sup>BM</sup> and the empty vector control did not rescue cell division (Figure 29B,C). Analysis of six independent assays confirmed the observed results (Figure 29D,E). *E. coli* MCI23 expressing recombinant PBP2ΔTM<sup>BM</sup> were significantly shorter than PBP2<sup>BM</sup> and the empty vector control with 85.7 % (± 7.6 SD) short and dividing cells at 42 °C and 14.3 % (± 7.6 SD) elongated cells at 42 °C. In contrast, *E. coli* MCI23 overexpressing PBP2<sup>BM</sup> did not restore cell division with only 6 % (± 5.2 SD) short and 94 % (± 5.2 SD) elongated cells observed. Cells expressing the empty vector had 95.3 % (± 5.9 SD) filamentous and 4.6 % (± 5.9 SD) short cells. Possibly, the soluble PBP2ΔTM<sup>BM</sup> replaced the impaired *E. coli* PBP3 on the division site, while PBP2<sup>BM</sup> with its native transmembrane domain was not recruited to the divisome. In conclusion, the *in vivo* results indicated that PBP2<sup>BM</sup> might be an active DD-transpeptidase.

![Image](image-url)
3.2.4 Active site analysis of PBP2ΔTM\textsuperscript{wBm} \textit{in vivo}

The serine of the SXXK motif catalyzes the enzymatic reaction of PBPs and the mutagenesis of SXXK motifs in PBP3 from \textit{C. pneumoniae} was shown to inhibit enzyme activity (Otten, 2014). Thus, the active site serine of both SXXK motifs in PBP2ΔTM\textsuperscript{wBm} were changed to alanine (S107A and S265A) by mutagenesis PCR (Figure 30), successful amino acid substitution was confirmed by nucleotide sequencing (Supplementary Figure 11).

![Figure 30: Primary structure analysis of PBP2ΔTM\textsuperscript{wBm} in pASK-IBA6C after site-directed mutagenesis.](image)

Serine residues from SXXK motifs were substituted by alanine (red bold letters). The predicted transmembrane domain (highlighted gray) was removed to increase solubility of the protein. The amino acid sequence is shown in single-letter code.

The plasmid containing mutated PBP2ΔTM\textsuperscript{wBm} was transformed into \textit{E. coli} MCI23 and activity assays were performed (see chapter 3.2.3). \textit{E. coli} MCI23 expressing PBP2ΔTM\textsuperscript{wBm} S107A, S265A or S107A-S265A were exclusively short or dividing at 30 °C (data not shown). At 42 °C, single mutation of the SXXK motifs did not impair PBP2ΔTM\textsuperscript{wBm} activity, still restoring division in 84.1 % (± 14.3 SD) (S107A) and 82.3 % (± 21.7 SD) (S265A) of cells (Figure 31). Expression of a PBP2ΔTM\textsuperscript{wBm} double active site mutant (S107A-S265A) revealed functional dependency of at least one functional serine of the SXXK motif as an increase to 72.5 % (± 13.6 SD) of elongated cells unable to divide was observed.
Figure 31: Complementation assay to test for the ability of PBP2ΔTM<sup>wBm</sup> active site mutants to rescue cell division in a temperature sensitive <i>E. coli</i> MC123 mutant. Phase-contrast micrographs shows <i>E. coli</i> MC123 expressing PBP2ΔTM<sup>wBm</sup> active site mutants A) PBP2ΔTM S107A and B) PBP2ΔTM S265A partially rescue cell division, while C) PBP2ΔTM S107A-S265A cannot restore growth defects resulting in elongated cells. Scale bars = 20 µm. D) At least 652 cells from 30 pictures taken from six independent assays per sample were measured by Image J. Boxes extend from the 25<sup>th</sup> to the 75<sup>th</sup> percentile. The line in the middle of the box is plotted at the median. Whiskers represent 1<sup>st</sup> and 99<sup>th</sup> percentiles. Statistical analysis was performed using Kruskal-Wallis test and Dunn’s comparison post-hoc test. * = P ≤ 0.05, *** = P ≤ 0.001. E) Columns represent mean ± SD relative occurrence of different phenotypes at 42 °C from five randomly chosen pictures in each experiment (n = 6).

Growth of <i>E. coli</i> was monitored to exclude that the different observed phenotypes resulted from potential cell arrests induced by protein induction. In three independent measurements, all cultures grew exponentially after induction (Figure 32).

Figure 32: Growth kinetics of <i>E. coli</i> MC123 during periplasmic expression of PBP2<sup>wBm</sup>. Protein expression was induced at OD<sub>600</sub> = 0.4 with 100 ng/ml tetracycline. OD<sub>600</sub> was measured every hour. Each point represents mean ± SD (n = 3).
3.2.5 Mecillinam treatment of PBP2<sup>wBm</sup> in vivo

Specific inhibition of PBP2 by the β-lactam mecillinam leads to spherical cells instead of rods in *E. coli* (Spratt and Pardee, 1975). Thus, the potential sensitivity of PBP2<sup>ΔTM<sup>wBm</sup></sup> to this antibiotic was examined. *In vivo* complementation assays using *E. coli* MCI23 at the non-permissive temperature of 42 °C were conducted (see chapter 3.2.3) in the presence of mecillinam in six independent assays. *E. coli* MCI23 overexpressing PBP2<sup>ΔTM<sup>wBm</sup></sup> were mainly short and rod-shaped indicating that mecillinam did not affect the activity of this enzyme (Figure 33A). Control cultures with uninduced PBP2<sup>ΔTM<sup>wBm</sup></sup> had spherical cells due to the inhibition of PBP2 from *E. coli* by mecillinam (Spratt and Pardee, 1975) (Figure 33B). Cultures overexpressing the empty vector showed an altered phenotype with elongated, but also spherical cells in the presence of mecillinam (Figure 33C). *E. coli* MCI23 with the uninduced empty vector served as a further control resulting in spherical cells after mecillinam treatment (Figure 33D). These results suggest that PBP2<sup>wBm</sup> is not inhibited by mecillinam.

![Figure 33](image-url)

**Figure 33**: Cell division of *E. coli* MCI23 expressing PBP2<sup>ΔTM<sup>wBm</sup></sup> is not inhibited by mecillinam, a specific inhibitor of PBP2. A) *E. coli* overexpressing PBP2<sup>ΔTM<sup>wBm</sup></sup> complement cell division in the presence of mecillinam, while B) uninduced cells show a spherical phenotype. C) *E. coli* expressing the empty vector pASK-IBA6C are partially elongated, but also show a spherical phenotype. D) Uninduced cultures harboring the empty vector are spherical after mecillinam treatment.
3.2.6 Periplasmic expression and purification of recombinant PBP2\textsuperscript{wBm}

As previous attempts to get soluble protein by cytoplasmic overexpression in pET vectors were unsuccessful (data not shown), the PBP2\textsuperscript{wBm} encoding gene was cloned into pASK-IBA vectors for co-solvent assisted periplasmic expression (Otten et al., 2015). Ppb2 was cloned with and without its predicted transmembrane domain (ΔTM). This modification was performed to allow the protein to accumulate in the periplasm in a soluble and correctly folded state. In the following step, small-scale overexpression pre-tests in different \textit{E. coli} strains (C43, JM83 and W3110) and in the presence of different co-solvents were carried out to identify conditions that facilitate the production of recombinant PBP2\textsuperscript{wBm} and yield the highest amounts of soluble protein. Taken together, the overproduction and purification conditions were optimized regarding expression strain, addition of co-solvents and detergents, and recombinant PBP2\textsuperscript{wBm} was successfully purified for the first time (Figure 34). Although the largest proportion of recombinant protein was found in flow-through and wash fractions, mannitol-assisted overproduction in \textit{E. coli} JM83 for 4 h at 25 °C resulted in soluble PBP2ΔTM\textsuperscript{wBm}. By adding the detergent Tween 20 to the lysis Buffer P, also soluble PBP2\textsuperscript{wBm} with its native transmembrane domain was purified. Protein concentrations of single elution fractions were around 100 μg/ml (PBP2\textsuperscript{wBm}) or 200 μg/ml (PBP2ΔTM\textsuperscript{wBm}) respectively, which was sufficient for biochemical characterization.

![Figure 34: Purification of PBP2ΔTM\textsuperscript{wBm} and PBP2\textsuperscript{wBm} via Strep-Tactin affinity chromatography. Western Blot analysis shows recombinant protein from different steps of the purification procedure of A) PBP2ΔTM\textsuperscript{wBm}, the empty vector pASK-IBA2C and B) PBP2\textsuperscript{wBm}. L = Ladder, E = Elution fractions, F = Flow through, W = Wash Fraction, F empty = Flow through of the empty vector control, W empty = Wash fraction of the empty vector control. Arrows point to expected protein size.](image-url)
3.2.7 Characterization of PBP2\textsuperscript{\textit{wBm}} \textit{in vitro}

3.2.7.1 DD-transpeptidase activity test using lipid II as a substrate

The cross-linking of lipid II stem peptide moieties by monofunctional DD-transpeptidases is poorly characterized \textit{in vitro} even in well investigated bacteria due to a lack of established assays (Dougherty and Pucci, 2011). Still, the presence or absence of monomeric lipid II on a TLC plate can indicate DD-transpeptidation since polymerized lipid II cannot be extracted by butanol-pyridine acetate and is consequently not detectable on the TLC plate. PBP2\textsuperscript{\textit{wBm}} was incubated with 2 nmol synthesized lipid II overnight and reaction products were analyzed by TLC. The corresponding elution fraction of the empty vector served as a negative control, PBP2 from \textit{S. aureus}, which is a bifunctional PBP with DD-transpeptidase and glycosyltransferase activity, served as a positive control. In first assays, a bright lipid II band was detectable on the TLC plate after overnight incubation with PBP2\textsuperscript{\textit{wBm}} (Figure 35). In the positive control with PBP2 from \textit{S. aureus}, no lipid II was detectable indicating polymerization of lipid II. In contrast, the lipid II band was still present after incubation with the empty vector elution fraction, implying that lipid II was not polymerized in this sample.

![Figure 35: In vitro activity assay of PBP2\textsuperscript{\textit{wBm}}](image)

These observations were confirmed by quantification of the bands (Image Quant\textsuperscript{TM} TL). As a reference, 2 nmol pure lipid II were applied to the TLC. Based on the intensity of this band, the amount of monomeric lipid II in the other samples was calculated. The mixture with the positive control PBP2 from \textit{S. aureus} had 0.18 nmol residual lipid II after overnight incubation. In the PBP2\textsuperscript{\textit{wBm}} containing sample, 0.78 nmol lipid II were detected, while the mixture with the empty vector contained 1.43 nmol lipid II. Assays were repeated under different conditions (time, temperature, pH, increased protein concentration), but none of them resulted in increased extinction of the lipid II band in the presence of PBP2\textsuperscript{\textit{wBm}}.
3.2.7.2 Penicillin-binding assays

Penicillin-binding was tested by incubating cleared lysates, wash fractions and elution fractions of overexpressed PBP2\textsuperscript{wBm} with Bocillin\textsuperscript{TM} FL. While 4 µg of purified PBP2 from \textit{S. aureus} (positive control) was sufficient to observe a distinct fluorescent band, no bands were detectable in lanes containing PBP2\textsuperscript{wBm} (Supplementary Figure 5). Further, a more sensitive assay using radiolabeled penicillin also did not reveal binding to PBP2\textsuperscript{wBm} (data not shown). These results indicate that PBP2\textsuperscript{wBm} might not bind to β-lactam antibiotics.

3.2.8 \textit{In vivo} β-lactamase activity assay of PBP2\textsuperscript{wBm}

As PBP2\textsuperscript{wBm} was resistant to mecillinam \textit{in vivo} (see chapter 3.2.5) and no penicillin-binding of was observed \textit{in vitro} (see chapter 3.2.7.2), a potential β-lactamase activity of PBP2\textsuperscript{wBm} was examined using CENTA\textsuperscript{TM} as a substrate. PBP2\textsuperscript{wBm} and PBP2\textsuperscript{ΔTM wBm} were expressed in \textit{E. coli} JM83, supplemented with CENTA\textsuperscript{TM} and incubated for 16 h. In six independent experiments, absorbance $\lambda_{405}$ increased of from 0.48 (± 0.04 SEM) to 1.36 (± 0.15 SEM) in cultures containing the positive control \textit{E. coli} ML-35 pYC indicating CENTA\textsuperscript{TM} hydrolysis (Figure 36). Cultures expressing PBP2\textsuperscript{wBm} only slightly increased from $\lambda_{405} = 0.4$ (± 0.02 SEM) to 0.54 (± 0.04 SEM) in seven independent assays. Similar values were observed in cells expressing PBP2\textsuperscript{ΔTM wBm} with a slight increase from $\lambda_{405} = 0.4$ (± 0.02 SEM) to 0.52 (± 0.05 SEM) in seven experiments. Cultures expressing the empty vector control slightly increased from $\lambda_{405} = 0.4$ (± 0.03 SEM) to 0.58 (± 0.07 SEM) in six independent assays. No β-lactamase activity of PBP2\textsuperscript{wBm} or PBP2\textsuperscript{ΔTM wBm} was detected under these conditions.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure36.png}
\caption{\textit{β-lactamase activity assay of PBP2\textsuperscript{wBm} \textit{in vivo}. E. coli JM83 with PBP2\textsuperscript{wBm} in pASK-IBA6C or PBP2\textsuperscript{ΔTM wBm} in pASK-IBA2C were induced with 200 ng/ml AHT. β-lactamase activity was detected at $\lambda_{405}$ using CENTA\textsuperscript{TM} as a substrate. \textit{E. coli} ML35-pYC were used as a positive control, pASK-IBA2C (empty vector) served as a negative control. PBP2\textsuperscript{wBm} and PBP2\textsuperscript{ΔTM wBm} data represent means from seven independent assays, the positive and negative control were tested in six independent assays. Error bars represent ± SEM.}}
\end{figure}
3.2.9 *In silico* modeling of PBP2\textsuperscript{wBm}

*In silico* analysis predicted a binding of the β-lactam antibiotic cefoxitin, including the serine of the second SXXK active site motif S265 (Figure 37). As the first SXXK motif is not involved in binding, PBP2\textsuperscript{wBm} might still be active in the presence of a β-lactam with inactivated S265 as indicated by *in vivo* assays (see chapter 3.2.2 and 3.2.3).

![Figure 37: 3D structure of PBP2\textsuperscript{wBm} bound to cefoxitin as predicted by 3DLigandSite.](image)

The residues S265, K268, L303, S320, N322, 389, T452, T466, G467, T468, E470, A503, P504 putatively involved in binding to cefoxitin (green) are marked in blue. The arrow points to the active site serine S265 of the SXXK motif.

3.3 Functional analysis of Pal\textsuperscript{wBm}

3.3.1 Primary structure analysis of Pal\textsuperscript{wBm}

Peptidoglycan-associated lipoprotein Pal\textsuperscript{wBm} is among the most abundant proteins in *Wolbachia* (Voronin et al., 2014). Pal\textsuperscript{wBm} (NCBI: AAW70743.1) consists of 159 amino acids with a predicted molecular mass of 18.5 kDa and shares 37 % sequence identity with *E. coli* Pal (NCBI: WP_001560401.1) (Figure 38). Pal\textsuperscript{wBm} contains a signal peptide ranging from amino acid 1–24 suggesting the enzyme being localized in the periplasm (Supplementary Figure 12). Fosfomycin treatment of *Wolbachia* (blocking of lipid II synthesis) results in enlarged cells and a perturbed localization of wolbachial Pal indicating that this protein is necessary to connect the inner and outer membrane, in particular during cell division (Vollmer et al., 2013). The interaction partner of Pal might be lipid II. In *E. coli*, outer membrane-anchored lipoproteins control PBP activity by binding and inducing conformational changes (Paradis-Bleau et al.,
Thus, a potential binding between Pal$^{wBm}$ and PBP2$^{wBm}$ as well as Pal$^{wBm}$ and lipid II were investigated in *in vitro* experiments in this thesis.

**Figure 38:** Amino acid alignment of Pal$^{wBm}$ and *E. coli* Pal. Pal$^{wBm}$ (AAW70743.1) shares 37% sequence identity with *E. coli* Pal (WP_001560401.1). The predicted signal peptide ranges from amino acids 1–24 (highlighted gray). * fully conserved residue; : conservation between groups of strongly similar properties; . conservation between groups of weakly similar properties.

### 3.3.2 Pal$^{wBm}$ interaction with PBP2$^{wBm}$

To measure a potential interaction between Pal$^{wBm}$ and PBP2$^{wBm}$ *in vitro*, biolayer interferometry was performed. Biotinylated Pal$^{wBm}$ was immobilized on a streptavidin biosensor. Purified PBP2$^{\Delta TM}$ was used as the analyte and applied to the biosensor. Here, a concentration-dependent interaction of PBP2$^{\Delta TM}$ with Pal$^{wBm}$ was observed, but not from supernatant of the overexpressed empty vector control, as exemplarily shown (Figure 39). In five independent assays using purified protein from two different expressions, the interaction of Pal$^{wBm}$ and PBP2$^{\Delta TM}$ had a dissociation constant with a mean of 12.1 (±3.4 nM SD), indicating a high affinity between the proteins.

**Figure 39:** Interaction between PBP2$^{\Delta TM}$ and Pal$^{wBm}$ detected by biolayer interferometry (BLI). Biotinylated Pal$^{wBm}$ was immobilized on a streptavidin biosensor PBP2$^{\Delta TM}$ (29.5 nM – 118 nM) was used as an analyte. Calculated dissociation constant in this assay was 9.7 nM. The empty vector served as a negative control. The graph is representative for five experiments using purified PBP2$^{\Delta TM}$ from two different expressions.
3.3.3 Pal\(^{wBm}\) interaction with lipid II

Surface plasmon resonance was used to measure a possible protein-lipid II interaction between Pal\(^{wBm}\) and lipid II (either mDAP or L-Lys). Pal\(^{wBm}\) was immobilized on a CM5 chip using a strep-tag II specific monoclonal antibody. Lipid II was dissolved in running buffer and used as the analyte of the binding reaction. Pal\(^{wBm}\) showed a higher affinity for lipid II with an mDAP residue at position 3 in the pentapeptide side chain typically found in Gram-negative bacteria compared to lipid II with an L-Lys residue at position 3 typically found in Gram-positive bacteria (Figure 40).

![Figure 40: Binding of Pal\(^{wBm}\) to lipid II. Pal\(^{wBm}\) has a higher affinity for A) lipid II with an mDAP residue compared to B) lipid II with an L-Lys residue at position 3 in the pentapeptide side chain as revealed by surface plasmon resonance. Pal\(^{wBm}\) was immobilized on a CM5 chip using a strep-tag II specific monoclonal antibody. Lipid II dissolved in running buffer (0–12.5 µM) was used as the analyte of the binding reaction.](image)

3.4 Functional analysis of AmiD\(^{wMel}\)

3.4.1 Primary structure analysis of AmiD\(^{wMel}\)

The genomes of insect Wolbachia such as wMel encode a putative peptidoglycan hydrolase, the N-acetylmuramoyl-L-alanine amidase AmiD, although a functional cell wall has not been detected. AmiD\(^{wMel}\) (NCBI: AAS14728) has 497 amino acids and is almost double the size of AmiD from E. coli (NCBI: NP_415388) with 257 amino acids (Kerff et al., 2010) (Figure 41). Sequence alignments with periplasmic E. coli AmiA, AmiB, AmiC and AmiD reveal the highest homology to E. coli AmiD with 27% sequence identity. AmiD\(^{wMel}\) contains an N-terminal predicted signal sequence from amino acids 1–30 for the transport into the periplasm (Supplementary Figure 13). However, the signal sequence lacks a typical lipobox
3 Results

motif with a conserved cysteine residue for lipidation and insertion into the outer membrane suggesting that AmiD<sup>W</sup><sub>Mel</sub> is not a lipoprotein. A putative amidase catalytic site with three conserved zinc-binding residues is present (H<sup>79</sup>, H<sup>187</sup> and D<sup>207</sup>). Additionally, two SXXK, two SX(D/N) and one K(S/T)G motif are conserved in AmiD<sup>W</sup><sub>Mel</sub>.

Figure 41: Sequence alignment of AmiD<sup>W</sup><sub>Mel</sub> with <i>E. coli</i> AmiD. AmiD<sup>W</sup><sub>Mel</sub> (AAS14728) shares 27 % sequence identity to <i>E. coli</i> AmiD (NP_415388). The signal peptide of AmiD<sup>W</sup><sub>Mel</sub> (highlighted gray) was predicted by SignalP and lacks a cysteine-containing lipobox motif that mediates the insertion into the outer membrane as found in <i>E. coli</i> (LAGC, underlined). The three conserved zinc-coordinating residues of the amidase active site are shaded in black. AmiD<sup>W</sup><sub>Mel</sub> additionally contains two SXXK, two SX(D/N) and one K(S/T)G motif (bold letters).

3.4.2 Secondary structure analysis of AmiD<sup>W</sup><sub>Mel</sub>

The active site of AmiD<sup>W</sup><sub>Mel</sub> comprises three conserved zinc-coordinating residues (H79, H187, D207). In silico analysis of AmiD<sup>W</sup><sub>Mel</sub> predicted that these residues indeed bind to zinc, thus it is highly possible that they are essential for N-acetylmuramoyl-L-alanine amidase activity (Figure 42). However, the modeling was incomplete because it was based on homologies to the presumed <i>E. coli</i> ortholog which is half the size of AmiD<sup>W</sup><sub>Mel</sub> (see chapter 3.4.1). Thus, the putative DD-carboxypeptidase active site could not be analyzed as it is located in the C-terminus outside the predicted secondary structure of AmiD<sup>W</sup><sub>Mel</sub>. For functional analysis of AmiD<sup>W</sup><sub>Mel</sub>, the gene was cloned and transformed into expression strains by

<table>
<thead>
<tr>
<th>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</th>
<th>HIKIQLSKVKYLLVITLVSFlSQGVSSTSSNiENDQDQLEKLPFLKQDLLFDLPAS</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>--------HRRFF---WLVALALLLAGCAGIKVEKGYQDLLTR------------------</td>
<td>35</td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>ALNYGDRAGKVKVLMSLKLATKRDQDLQFLDPAS</td>
<td>113</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>-----------------RGGITLAV</td>
<td></td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>PLEKEAWHSAYRKVSGLLEELKNLSVSLNGTLE--------------------------</td>
<td>164</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>------RAQRAAYPIRKLVLTVSTADDQDSLLLLATDKQVShSNNLVPVPRPRNGKPRWQLV</td>
<td>91</td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>ALIPLAKDIIARYHIPENVNKTADIA---------------PQKLPFGLPWWQLAGQCGA</td>
<td>193</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>----QAQAAYPRIKVLVH_________________________________</td>
<td></td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>HISDRINPKDAHKMGKTYKAGDRNEE---ILKLRQRNLRRFFYKIEPWNDRGVTIFP</td>
<td>281</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>WFDNQGR-----------------VNPYLAGMKPVTVDASLLELLARYGDVYKFDTMRQ--</td>
<td>238</td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>NNASSTDFTDFVWYQSFIHNLPRKIRAEPLKLQHQPQPQDPFFSESYSHGISSSYLT</td>
<td>341</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>--------RRVIMAFQMHFRPTLYNGEAA--DAETQAIAEAELKXQGD--------</td>
<td>276</td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>FSEKISTQLQCSVPSLDKSYVENLRSLLAQYENNIPSTDDLLIMKLYGYSYLRIRWSSL</td>
<td>401</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>YKFFKLNVLEEILEKSGVLSKCLKLDSSKAAEVSSLDSFKVDISLERQFEQQWFQEFK</td>
<td>461</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>----------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>AmiD&lt;sup&gt;W&lt;/sup&gt;&lt;sub&gt;Mel&lt;/sub&gt;</td>
<td>NAWRQFIPQSLLEEQTWTALHEAILEYEAKEEIR</td>
<td>497</td>
</tr>
<tr>
<td>&lt;i&gt;E. coli&lt;/i&gt;</td>
<td>--------------------------</td>
<td>276</td>
</tr>
</tbody>
</table>

3. Results
Dr. Miriam Wilmes, IMMIP. As part of this thesis, the enzyme was overproduced in *E. coli* JM83 by co-solvent assisted periplasmic expression which has been established for chlamydial proteins (Otten et al., 2015). Activity was tested by *in vivo* and *in vitro* assays. The potential dependency on zinc was tested by mutation of the respective residues in the enzyme.

![Figure 42: 3D structure of AmiD<sup>w</sup>Mel bound to zinc as predicted by 3DLigandSite.](image)
The zinc-coordinating residues H79, H187 and D207 are marked in blue, zinc ions are marked in green-gray.

### 3.4.3 Characterization of AmiD<sup>w</sup>Mel *in vivo*

#### 3.4.3.1 AmiD<sup>w</sup>Mel complementation assay with an *E. coli* amidase mutant

*E. coli* AmiD is not involved in cell separation and it has been hypothesized that the insertion into the outer membrane prevents movement of AmiD to the septum (Uehara et al., 2010). As AmiD<sup>w</sup>Mel lacks a lipobox motif, the enzyme might be soluble in the periplasm after cleavage of its predicted signal peptide and thus might be involved in cell division. Hence, it was tested if AmiD<sup>w</sup>Mel can restore the normal phenotype of an *E. coli* ADE24 ∆amiABC triple knockout mutant. *E. coli* ADE24 is characterized by long chains of cells due to the deletion of all three periplasmic amidases involved in cell separation (Klöckner et al., 2014). To prevent impaired growth of cultures, *E. coli* ADE24 harbor pBAD33-amiC which restores cell division defects and which can be blocked by glucose. AmiD<sup>w</sup>Mel without its native signal peptide was cloned in pASK-IBA2 and IBA2C by Dr. M. Wilmes and transformed into *E. coli* ADE24 for periplasmic expression. As part of this thesis, AmiD<sup>w</sup>Mel was cloned with its native signal peptide in pASK-IBA3 and transformed into *E. coli* ADE24 for cytoplasmic expression. Expression of *E. coli* AmiC was blocked by adding 0.8% glucose to the culture, which resulted in long chains (Figure 43A). Expression of AmiD<sup>w</sup>Mel in three independent assays did not rescue cell separation in the *E. coli* ∆amiABC triple mutant in none of the pASK-IBA vectors (Figure 43B-D). The induced empty vector served as a control for all constructs.
Figure 43: Complementation assay of *E. coli* ΔamiABC triple-knockout mutant ADE24 with AmiD<sup>wMel</sup>. A) *E. coli* ADE24 harbor an arabinose-inducible plasmid with amiC (*E. coli*). In the presence of 0.8 % glucose, amiC expression is blocked resulting in long chains of cells. In the presence of glucose and 100 ng/ml tetracycline, expression of AmiD<sup>wMel</sup> with either B) and C) the OmpA leader sequence (pASK-IBA2, pASK-IBA2C) or D) its native signal sequence (pASK-IBA3) did not complement cell division. Cells transformed with the empty vectors pASK-IBA2, pASK-IBA2C and pASK-IBA3 were used as controls. Scale bars = 20 μm.
To confirm that AmiD<sup>w</sup>Mel was expressed in *E. coli* ADE24, cultures were harvested and proteins were extracted. Western Blot analysis revealed that the protein was expressed, but it was half the expected size already after 1 h of expression (Figure 44). Due to the high proteolytic activity of *E. coli* ADE24, no conclusion could be drawn if AmiD<sup>w</sup>Mel is able to restore the normal phenotype in this strain.

**Figure 44: Western Blot analysis of expressed AmiD<sup>w</sup>Mel in *E. coli* ADE24.** Western Blot analysis confirmed the presence of degraded AmiD<sup>w</sup>Mel in the periplasm after 1 h of expression. The outer membrane and cell wall were disrupted and cells were centrifuged at 18,000 g and 4 °C to separate the periplasmic contents (found in the supernatant) from cytoplasmic contents (found in the pellet). The different fractions were separated by SDS-PAGE and detected using Strep-Tactin Alkaline Phosphatase conjugate. The picture is representative of three expressions. L: Ladder, P: Periplasmic fraction, C: Cytoplasmic Fraction. Arrow points to expected protein size of recombinant AmiD<sup>w</sup>Mel.

### 3.4.3.2 AmiD<sup>w</sup>Mel localization

The presence of an N-terminal signal peptide (see chapter 3.4.1) indicated a periplasmic localization of AmiD<sup>w</sup>Mel. To test whether AmiD<sup>w</sup>Mel is transported into the periplasm after expression, the protein was overproduced in *E. coli* JM83 with its native signal sequence in the cytoplasm via pASK-IBA3. The cells were harvested and the outer membrane and cell wall were disrupted by polymyxinB and lysozyme, respectively, to release periplasmic proteins. Western Blot confirmed the presence of AmiD<sup>w</sup>Mel in the periplasm in three independent expressions (Figure 45).
Figure 45: Cellular distribution of AmiD\textsuperscript{wMel} after cytoplasmic expression in \textit{E. coli} JM83. Western Blot analysis confirmed the presence of AmiD\textsuperscript{wMel} in the periplasm after expression. The outer membrane and cell wall were disrupted and cells were centrifuged at 18,000 g and 4 °C to separate the periplasmic contents (found in the supernatant) from cytoplasmic contents (found in the pellet). The different fractions were separated by SDS-PAGE and detected using Strep-Tactin Alkaline Phosphatase conjugate. The picture is representative of three expressions experiments. L: Ladder, P: Periplasmic fraction, C: Cytoplasmic Fraction. Arrow points to expected protein size of recombinant AmiD\textsuperscript{wMel}.

3.4.3.3 Growth kinetics of \textit{E. coli} JM83 overexpressing AmiD\textsuperscript{wMel}

When AmiD\textsuperscript{wMel} was overexpressed in \textit{E. coli} JM83, the turbidity of the culture decreased gradually (Figure 46). This might be the result of AmiD\textsuperscript{wMel} hydrolytic activity on peptidoglycan and subsequent lysis of the host strain. In contrast, cells expressing the empty vector did not show growth defects. To validate that lysis was induced by AmiD\textsuperscript{wMel} activity, the zinc-coordinating active sites H\textsuperscript{97} and D\textsuperscript{207} of the enzyme were mutated to alanine by Dr. M. Wilmes. The overexpressed mutants did not decrease turbidity of the \textit{E. coli} cultures suggesting that bacteria lysis was indeed caused by hydrolytic activity of AmiD\textsuperscript{wMel}.

Figure 46: \textit{In vivo} activity of AmiD\textsuperscript{wMel} and active site mutants expressed in \textit{E. coli} JM83. Periplasmic overexpression of AmiD\textsuperscript{wMel} resulted in lysis of \textit{E. coli} JM83 compared to the amidase active site mutants AmiD\textsuperscript{wMel} H79A and AmiD\textsuperscript{wMel} D207A and the empty vector control pASK-IBA2C. OD\textsubscript{600} was measured every 30 min for 8.5 h. Each point represents mean ± SD (n = 3).
3.4.4 Characterization of AmiD\textsubscript{wMel} \textit{in vitro}

3.4.4.1 Overexpression and purification of AmiD\textsubscript{wMel}

For functional analysis of AmiD\textsubscript{wMel}, the enzyme was produced in \textit{E. coli} JM83 by cosolvent assisted periplasmic expression in NaCl-free LB medium containing D-mannitol. The turbidity of the \textit{E. coli} JM83 culture decreased gradually when AmiD\textsubscript{wMel} was overexpressed (see chapter 3.4.3.3). Thus, cells were harvested around two hours after induction when they started lysing. AmiD\textsubscript{wMel} was purified by Strep-tag affinity chromatography and recombinant protein was detected by Western Blot (Figure 47). A mock purification of the empty vector served as a control. Protein concentration of eluates ranged between 500–1000 µg/ml making the recombinant AmiD\textsubscript{wMel} accessible for \textit{in vitro} activity assays. Contrary to the other investigated wolbachial enzymes in this thesis, AmiD\textsubscript{wMel} could be stored in 50 % glycerol at -20 °C and was stable for at least 8 months in activity assays (data not shown).

![Western Blot Analysis of Six Elution Fractions After AmiD\textsubscript{wMel} Expression and Strep-Tag Purification](image)

**Figure 47: Overexpressed and purified AmiD\textsuperscript{wMel} in pASK-IBA2C.** Western Blot analysis of six elution fractions after AmiD\textsuperscript{wMel} expression and Strep-tag purification. A mock expression and purification of the empty vector pASK-IBA2C served as a negative control. L: Ladder, E: Eluate. The arrow points to expected protein size of AmiD\textsuperscript{wMel}.

3.4.4.2 Peptidoglycan as a substrate for AmiD\textsubscript{wMel}

The activity of purified AmiD\textsubscript{wMel} using peptidoglycan as a substrate was analyzed in a dye-release assay by incubating the enzyme with RBB-stained peptidoglycan. Released reaction products in the supernatant resulting from peptidoglycan cleavage were quantified by
absorbance measurements. Recombinant AmiD<sup>wMel</sup> was fully active at pH 7–9 (Figure 48A) and temperatures ranging from 20 °C–37 °C (Figure 48B). For all further in vitro activity tests a temperature of 30 °C and a pH of 7.5 were chosen.

![Figure 48: Peptidoglycan-degrading activity of AmiD<sup>wMel</sup> at different pH and temperatures.](image)

Released RBB-stained reaction products in the supernatant resulting from peptidoglycan cleavage were quantified by absorbance measurements. After incubation with AmiD<sup>wMel</sup> overnight at 30 °C and pH 7.5, significantly more products were released compared to the empty vector control in six independent assays (Figure 49).

![Figure 49: AmiD<sup>wMel</sup> can use peptidoglycan as a substrate in vitro.](image)

**Results**

To find the optimal conditions for AmiD<sup>wMel</sup> activity, degradation of peptidoglycan was measured by monitoring the absorbance at 595 nm of Remazol Brilliant Blue dye released into the supernatant after incubation with AmiD<sup>wMel</sup> overnight at different conditions regarding pH (5–10) and temperature (20–40 °C). Bars represent mean ± SD (n = 3).

![Figure 48: Peptidoglycan-degrading activity of AmiD<sup>wMel</sup> at different pH and temperatures.](image)

Released RBB-stained reaction products in the supernatant resulting from peptidoglycan cleavage were quantified by absorbance measurements. After incubation with AmiD<sup>wMel</sup> overnight at 30 °C and pH 7.5, significantly more products were released compared to the empty vector control in six independent assays (Figure 49).

![Figure 49: AmiD<sup>wMel</sup> can use peptidoglycan as a substrate in vitro.](image)

Degradation of peptidoglycan was detected by monitoring the absorbance at 595 nm of Remazol Brilliant Blue-dye reaction products released into the supernatant after incubation with AmiD<sup>wMel</sup> overnight at 30 °C and pH 7.5. Product from cells containing the empty vector pASK-IBA2C was used as a negative control. Bars represent mean ± SD (n = 6). Statistical difference was determined using the Unpaired Student’s t-test, two tailed, *** = P ≤ 0.001.
3.4.4.3 Lipid II as a substrate for AmiD<sup>w</sup>Mel

It was tested whether AmiD<sup>w</sup>Mel can remove the pentapeptide side chain of lipid II. Lipid II was incubated with AmiD<sup>w</sup>Mel and the reaction products were extracted and analyzed by TLC and MALDI-TOF. Contrary to<sup>1</sup> E. coli AmiD (Pennartz et al., 2009), AmiD<sup>w</sup>Mel was able to use lipid II as a substrate and hydrolyzed the amide bond between MurNAc and L-Ala (Figure 50).

![Figure 50: AmiD<sup>w</sup>Mel can use lipid II as a substrate in vitro. Lipid II was incubated with AmiD<sup>w</sup>Mel for 4 h at 30 °C. The reaction products were analyzed by A) TLC and B) MALDI-TOF (m/z - lipid II: 1875.4; undecaprenyl-pyrophosphoryl-MurNAc-GlcNAc: 1404.8; pentapeptide (sodium adduct): 511.3). MALDI-TOF analysis was performed by M. Josten, IMMIP.](image)

3.4.4.4 Inhibition of AmiD<sup>w</sup>Mel activity in vitro

Peptidoglycan cleavage by AmiD<sup>w</sup>Mel was partially impaired in the presence of EDTA and the specific zinc-chelator 1,10-phenanthroline (Figure 51A), while lipid II cleavage was completely blocked in EDTA samples and decreased in the presence of 1,10-phenanthroline (Figure 51B). Consistently to the in vivo results (see chapter 3.4.3.3), the mutation of one of the residues involved in zinc-binding to alanine (H79A or D207A) resulted in decreased peptidoglycan cleavage and AmiD<sup>w</sup>Mel D207A was not able to hydrolyze the MurNAc-L-Ala bond in lipid II.
3 Results

Figure 51: Inhibition of AmiD<sup>WMel</sup> activity. The zinc-dependent amidase activity was inhibited in the presence of 1 mM of the non-specific metal chelator EDTA and 5 mM of the Zn<sup>2+</sup>-specific chelator 1,10-phenanthroline as shown by A) Remazol Brilliant Blue dye-release assay on peptidoglycan and B) TLC on lipid II. Moreover, the exchange of one of the zinc-coordinating residues with alanine (H79A or D207A) decreased amidase activity. Bars represent means ± SD. The graph is representative of three experiments with different batches of purified enzyme.

3.4.4.5 Cleavage of anhydromuropeptides

AmiD from <i>E. coli</i> has a broad substrate specificity and can also cleave anhydroMurNAc-L-Ala-bonds produced by lytic transglycosylases during cell growth (Uehara and Park, 2007). Anhydromuropeptides (TetraAnh and TetraTetraAnh) resulting from peptidoglycan digest with the <i>E. coli</i> lytic transglycosylase Slt70 were incubated with AmiD<sup>WMel</sup>. The products were separated by HPLC and confirmed by mass spectrometry. AmiD<sup>WMel</sup> hydrolyzed TetraAnh and TetraTetraAnh in a dose-dependent manner (Figure 52A), whereas the mutant protein AmiD<sup>WMel</sup> D207A was inactive (Figure 52B). The results were obtained and analyzed by Dr. Christian Otten in a cooperation project with the University of Newcastle, UK.
3 Results

Figure 52: Cleavage of anhydromuropeptides by AmiD<sup>wMel</sup> in vitro. A) Anhydromuropeptides (TetraAnh, TetraTetraAnh) derived from peptidoglycan digested with the <i>E. coli</i> lytic transglycosylase Slt70 were incubated for 4 h at 30 °C with AmiD<sup>wMel</sup> or B) the amidase active site mutant AmiD<sup>wMel</sup> (D207A) at different concentrations. The samples were analyzed by HPLC and mass spectrometry. The main product was identified as GlcNAc-MurNAcAnh (m/z = 479.1866, H<sup>+</sup> form; theoretical value: 479.1877). C) Structures of the muropeptides and the reaction products analyzed in A) and B). * = unknown compound unrelated to the reaction. Data and graphs were prepared by C. Otten, University of Newcastle, UK.

The data obtained from in vivo and in vitro assays demonstrated that AmiD<sup>wMel</sup> is capable of cleaving monomeric lipid II, polymeric intact peptidoglycan as well as soluble peptidoglycan fragments including the anhydro form.

3.4.5 Characterization of a putative DD-carboxypeptidase activity of AmiD<sup>wMel</sup>

Contrary to its <i>E. coli</i> homolog, AmiD<sup>wMel</sup> is a relatively big protein and harbors two SXXK, two SX(D/N) and one K(S/T)G motif typically found in PBPs, catalyzing the final steps in cell wall biosynthesis. Of note, an SXXK and SX(D/N) motif are also present in AmiA of <i>Chlamydia pneumoniae</i>, an amidase that has been shown to have additional DD-carboxypeptidase activity (Klöckner et al., 2014). In this thesis, it was tested whether AmiD<sup>wMel</sup> is also a bifunctional enzyme with additional DD-carboxypeptidase activity.
3.4.5.1 DD-carboxypeptidase activity of AmiD<sup>wMel</sup> in vivo

To investigate the potential DD-carboxypeptidase activity of AmiD<sup>wMel</sup> in vivo, the temperature sensitive <i>E. coli</i> mutant strain MCI23 was used in complementation assays as described for PBP6a<sup>wBm</sup> (see chapter 3.1.3). AmiD<sup>wMel</sup> D207 with impaired amidase activity was used to prevent hydrolysis of the exponentially growing <i>E. coli</i> cells. Cell division defects in the temperature sensitive <i>E. coli</i> mutant MCI23 overexpressing AmiD<sup>wMel</sup> D207 at 42 °C were partially rescued with 58 % (± 0.3 SD) of cells being short and 42 % (± 0.3 SD) filamentous (Figure 53A,D). Notably, in some experiments cells showed a granulous structure implicating that the recombinant AmiD<sup>wMel</sup> protein accumulated inclusion bodies. In contrast, 96 % (± 2.6 SD) of cells expressing the empty vector control were elongated (Figure 53B,D). These differences were confirmed by statistical analysis of cell size. Here, cells expressing AmiD<sup>wMel</sup> D207 were significantly shorter than the empty vector control (Figure 53C).

**Figure 53: AmiD<sup>wMel</sup> rescues cell division in a temperature sensitive <i>E. coli</i> MCI23 mutant.** A) <i>E. coli</i> MCI23 expressing recombinant AmiD<sup>wMel</sup> have a mixed set of phenotypes with short and dividing, but also filamentous cells. Scale bar = 20 µm. Arrows point to granulous structures inside the <i>E. coli</i> bacteria observed in some experiments. Scale bar of the zoomed picture = 5 µm. B) <i>E. coli</i> MCI23 expressing the empty vector pASK-IBA2C were unable to divide. Scale bar = 20 µm. C) At least 599 cells from 15 pictures taken from three independent assays per sample were measured by Image J. Boxes extend from the 25<sup>th</sup> to the 75<sup>th</sup> percentile. The line in the middle of the box is plotted at the median. Whiskers represent 1<sup>st</sup> and 99<sup>th</sup> percentiles. Statistical analysis was performed using Mann-Whitney test. *** = P ≤ 0.001. D) Columns represent relative occurrence of different phenotypes from five randomly chosen pictures in each experiment (n = 3). Error bars represent ± SD.
3.4.5.2 Active site analysis of DD-carboxypeptidase activity of AmiD<sup>wMel</sup> in vivo

Amino acid exchange of the serine residue from S<sup>83</sup>TLK to alanine (S83A) did not abolish activity at 42 °C and <i>E. coli</i> MC123 partially restored cell division with 48.3 % (± 2.5 SD) of cells being short and able to divide (Figure 54). In contrast, 95 % (± 5.1 SD) of cells were elongated and unable to divide when the AmiD<sup>wMel</sup> S<sup>400</sup>LYK (S400A) mutant was expressed indicating that S<sup>400</sup>LYK harbors the active site serine. Analysis of cell size confirmed that cells expressing AmiD<sup>wMel</sup> D207A-S400A were significantly longer compared to cells expressing AmiD<sup>wMel</sup>S83A-D207A. Notably, S<sup>400</sup>LYK is found nearby the K<sup>417</sup>SG and S<sup>425</sup>LD motifs, suggesting that the DD-carboxypeptidase catalytic center of AmiD<sup>wMel</sup> might be assigned to the C-terminal part of the protein.

![Figure 54: Complementation assay to test for the ability of AmiD<sup>wMel</sup> active site mutants to rescue cell division in a temperature sensitive <i>E. coli</i> MC123 mutant. Phase-contrast micrographs show A) <i>E. coli</i> MC123 expressing AmiD<sup>wMel</sup> S83A partially rescue cell division at 42 °C, while B) cells expressing AmiD<sup>wMel</sup> S400A cannot restore division resulting in a filamentous phenotype. Scale bars = 20 µm. C) At least 385 cells from 15 pictures taken from three independent assays per sample were measured by Image J. Boxes extend from the 25<sup>th</sup> to the 75<sup>th</sup> percentile. The line in the middle of the box is plotted at the median. Whiskers represent 1<sup>st</sup> and 99<sup>th</sup> percentiles. Statistical analysis was performed using Mann-Whitney test. *** = P ≤ 0.001. D) Columns represent relative occurrence of different phenotypes at 42 °C from 15 randomly chosen pictures in three independent experiments. Error bars represent ± SD.

3.4.5.3 DD-carboxypeptidase activity of AmiD<sup>wMel</sup> in vitro

In vivo results indicated DD-carboxypeptidase activity of AmiD<sup>wMel</sup>. However, the analysis of the reaction products of in vitro AmiD<sup>wMel</sup> activity assays by TLC or MALDI-TOF did not demonstrate the presence of lipid II with a tetrapeptide resulting from a cleaved D-Ala
(see chapter 3.4.4.3 and 3.4.4.4). Thus, a more sensitive fluorescent-linked activity assay using QuantaBlu substrate solution was used to quantify cleaved off D-Ala. As the empty vector control values were very high, DD-carboxypeptidase activity could not be evaluated under the conditions tested even with the positive control VanY from *S. aureus* (Figure 55).

**Figure 55:** *In vitro* QuantaBlu DD-carboxypeptidase activity assay with VanY (*S. aureus*) and AmiD<sup>wMel</sup>. D-Ala cleaved from lipid II after overnight incubation at 30 °C was detected by the activity of D-amino acid oxidase in the presence of QuantaBlu fluorescent substrate at 420 nm. Overexpressed VanY from *S. aureus* served as a positive control. Results show the mean ± SEM (n = 4–6). Statistical difference was determined using the Unpaired student’s t-test, two tailed, *ns* = not significant.

### 3.4.5.4 Penicillin-binding assay of AmiD<sup>wMel</sup>

Since AmiD<sup>wMel</sup> has penicillin-binding motifs in its sequence that are targets for β-lactam antibiotics, a binding of AmiD<sup>wMel</sup> to Bocillin<sup>TM</sup> FL was tested. A weak binding was observed giving a hint that penicillin-binding motifs are accessible for β-lactam antibiotics at least in recombinant AmiD<sup>wMel</sup> (Figure 56).

**Figure 56:** Detection of penicillin-sensitive PBP2 (*S. aureus*) and AmiD<sup>wMel</sup> by Bocillin<sup>TM</sup> FL binding assay. Purified AmiD<sup>wMel</sup> (4 and 8 µg) was incubated with 10 µM Bocillin<sup>TM</sup> FL at 30 °C for 1 h and separated by SDS-PAGE. PBP2 from *S. aureus* served as a positive control. A) Detection of proteins by Coomassie staining. The arrow points to expected protein size of AmiD<sup>wMel</sup>. B) Detection of proteins bound to Bocillin<sup>TM</sup> FL by UV light.
3.4.5.5 *In vivo* β-lactamase activity assay of AmiD<sup>wMel</sup>

To test if AmiD<sup>wMel</sup> has β-lactamase activity, the protein was expressed in *E. coli* JM83 cultures supplemented with CENTA<sup>TM</sup> and incubated for 16 h. Analysis of absorbance measurements showed an increase of λ<sub>405</sub> from 0.48 (± 0.04 SEM) to 1.36 (± 0.15 SEM) in cultures containing the positive control *E. coli* ML-35 pYC in six independent experiments, indicating CENTA<sup>TM</sup> hydrolysis (Figure 57). In contrast, cultures expressing AmiD<sup>wMel</sup> rarely increased from λ<sub>405</sub> = 0.4 (±0.03 SEM) to 0.48 (± 0.09 SEM) in eight independent assays. Cultures expressing the empty vector control slightly increased from λ<sub>405</sub> = 0.4 (± 0.03 SEM) to 0.58 (± 0.07 SEM) in six independent assays. In conclusion, β-lactamase activity of AmiD<sup>wMel</sup> was not observed under the conditions tested.

![Figure 57: β-lactamase activity assay of AmiD<sup>wMel</sup> *in vivo*. *E. coli* JM83 with AmiD<sup>wMel</sup> in pASK-IBA2C were induced with 200 ng/ml AHT. *E. coli* ML35-pYC constitutively expressing a periplasmic β-lactamase were used as a positive control, pASK-IBA2C (empty vector) served as a negative control. AmiD<sup>wMel</sup> data represent means from eight independent assays, the positive and negative control were tested six times. Error bars represent ± SEM.](image)

3.5 Functional analysis of PBP3<sup>wMel</sup>

3.5.1 Primary structure analysis of PBP3<sup>wMel</sup>

Genome analysis of wMel revealed the presence of two putative monofunctional DD-transpeptidases PBP2 and PBP3. Part of this thesis was the investigation of the additional PBP3 protein only found in *Wolbachia* residing in insect cells. PBP3<sup>wMel</sup> (NCBI: WP_010963147.1) consists of 515 amino acids and the protein has a predicted molecular weight of 58.24 kDa with 26 % sequence identity to *E. coli* PBP3 (NCBI: ARB43848.1) (Figure 58). It possesses a set of four SXXK, five SX(D/N) and one K(S/T)G active site motifs. Like its *E. coli* homolog,
PBP3\textsuperscript{wMel} consists of a predicted N-terminal transmembrane domain ranging from amino acids 1–34, but no signal peptide (Supplementary Figure 14).

\begin{verbatim}
PBP3 \textsuperscript{wMel} ---------------MQALLKKNLKSLCIVPLFIFYIIIIFR---IPSLTFDQLTT---SE 41
PBP3 \textsuperscript{E. coli} MKAAKTQFPRQEEHANIFGWRALLGCIGLLALAFLLGRVAWLQVISPDMLVKEGDMSR 60

\vdots

PBP3 \textsuperscript{wMel} NFRKDNIVHKQPDILRNGVVTTSYIDATKVNPSIAALLC-SE 97
PBP3 \textsuperscript{E. coli} SLRQQVQSTSNGMIDSRGPRAPLVASYPKAIWADPKVHAGGGSVGDWRKALANLIP 120

\vdots

PBP3 \textsuperscript{wMel} KNL---YRVLTSEKKFAWIKRHLTPKELLAIKNAGVPGVNFDKRIYPHSNLFSVGLV 155
PBP3 \textsuperscript{E. coli} LDQQLSARINAPGRDYTPYLAQRVNFMDAMYIKKLKIIGLMHLREESRRYYPSGVTAHLIG 180

\vdots

PBP3 \textsuperscript{wMel} ASGYGIAVTPIHLAQTAALINGIFNHATLMNLKAEISQIIISRTSREMVRKLLR 418
PBP3 \textsuperscript{E. coli} ASGYGIAVTPIHLAQTAALINGIFNHATLMNLKAEISQIIISRTSREMVRKLLR 422

\vdots

PBP3 \textsuperscript{wMel} AVTGGTAKEKVKDVKSNDANIAFSGVTLMLDPKRYIIVLIADE 482
PBP3 \textsuperscript{E. coli} AVTGGTAKEKVKDVKSNDANIAFSGVTLMLDPKRYIIVLIADE 482

\vdots

PBP3 \textsuperscript{wMel} PQGHHTGIIAPPWNIMRIPALVTFLRQ---PLEQG 515
PBP3 \textsuperscript{E. coli} PQGHHTGIIAPPWNIMRIPALVTFLRQ---PLEQG 515

\vdots

PBP3 \textsuperscript{wMel} PQQKYGAVGAVFGVMAQGGLATMNIEFALTWGDKEVFINQEGTGGRS 592
PBP3 \textsuperscript{E. coli} PQQKYGAVGAVFGVMAQGGLATMNIEFALTWGDKEVFINQEGTGGRS 592
\end{verbatim}

Figure 58: Amino acid alignment of PBP3\textsuperscript{wMel} and \textit{E. coli} PBP3. PBP3\textsuperscript{wMel} (WP_010963147.1) shares 26 % identity to \textit{E. coli} PBP3 (ARB43848.1). Conserved SXXK, SX(D/N) and K(S/T)G motifs found in PBP3\textsuperscript{wMel} are written in bold letters, motifs which align to \textit{E. coli} PBP3 are additionally framed in black. The predicted transmembrane domain is highlighted gray. * fully conserved residue; ** conservation between groups of strongly similar properties; : conservation between groups of weakly similar properties.

3.5.2 Secondary structure analysis of PBP3\textsuperscript{wMel}

To get a deeper insight into the putative active site serine of the SXXK motif, secondary structure analysis was performed. Here, the three conserved motifs were localized based on sequence alignments to \textit{E. coli}. The SXXK motifs S\textsuperscript{107} EKK and S\textsuperscript{339} PLK are predicted to be located outside the active site (Figure 59). S\textsuperscript{445} AEK is located in a β-sheet next to the K\textsuperscript{442} TG motif, while S\textsuperscript{256} VLK is found in an α-helix. Thus, one of these SXXK motifs might build the catalytic center together with S\textsuperscript{311} SN (α-helix and loop) and K\textsuperscript{442} TG (β-sheet). The gene \textit{pbp3} from wMel was cloned into pASK-IBA2C, transformed into different \textit{E. coli} strains and tested in \textit{in vivo} and \textit{in vitro} activity assays.
3.5.3 Characterization of PBP3<sup>wMel</sup> and active site analysis <em>in vivo</em>

Since PBP3<sup>wMel</sup> is the homolog of <em>E. coli</em> PBP3, it was examined whether overexpression of PBP3<sup>wMel</sup> is sufficient to restore cell division in <em>E. coli</em> MCI23 at the non-permissive temperature of 42 °C. To test dependency on functional SXXK motifs, site-directed mutagenesis was performed. Substitution of S107, S256, and S339 to alanine and <em>in vivo</em> activity assays of these mutants were part of a master thesis (Ritzmann, 2016). Mutagenesis PCR of serine from the fourth SXXK motif S445 was part of this thesis resulting in a PBP3<sup>wMel</sup> S107A-S256A-S339A-S445A quadruple mutant (Figure 60). Successful amino acid substitution was confirmed by nucleotide sequencing of the PBP3<sup>wMel</sup> gene (Supplementary Figure 15).
PBP3<sup>W</sup>Mel expression at 42 °C led to a mixed set of phenotypes of <i>E. coli</i> MCI23 (Figure 61A). Quantitative analysis of six independent assays showed that 66.7 % (± 27.5 SD) of observed cells expressing PBP3<sup>W</sup>Mel were single and dividing cells, while 33.3 % (± 27.5 SD) were elongated. Neither single nor simultaneous mutation of the serines S107, S256, and S339 of SXXK motifs had an impact on PBP3<sup>W</sup>Mel activity at 42 °C (Ritzmann, 2016). However, site-directed mutagenesis of all four SXXK motifs including S445 showed a decrease of PBP3<sup>W</sup>Mel in vivo activity resulting in 21.2 % (± 14.3 SD) single and dividing cells and concomitant increase of elongated cells to 78.8 % (± 14.3 SD) (Figure 61B,D). Statistical analysis of cell size showed that PBP3<sup>W</sup>Mel expressing <i>E. coli</i> were significantly shorter than the quadruple SXXK mutant and the empty vector control (Figure 61E).

Figure 61: Complementation assay to test for the ability of PBP3<sup>W</sup>Mel and PBP3<sup>W</sup>Mel active site mutants to rescue cell division in a temperature sensitive <i>E. coli</i> MCI23 mutant. <i>E. coli</i> MCI23 were grown in LB medium containing chloramphenicol until OD<sub>600</sub> = 0.4. Cultures were induced with 100 ng/ml tetracycline and incubated for 120 min 42 °C. A) <i>E. coli</i> MCI23 expressing recombinant PBP3<sup>W</sup>Mel are mainly short and dividing, while B) cells expressing PBP3<sup>W</sup>Mel S107A-S256A-S339A-S445A are predominantly filamentous. C) <i>E. coli</i> MCI23 expressing the empty vector pASK-IBA2C have filamentous cells. Scale bars = 20 µm. D) Cell size of at least 960 cells from 30 pictures taken from six independent assays was measured by Image J. Boxes extend from the 25<sup>th</sup> to the 75<sup>th</sup> percentile of cell size distribution. The line in the middle of the box is the median. Whiskers represent 1<sup>st</sup> and 99<sup>th</sup> percentiles. Dots represents outliers. Statistical analysis was performed using Kruskal-Wallis test and Dunn’s comparison post-hoc test, *** = P ≤ 0.001. E) Columns represent the mean ± SD occurrence of different phenotypes at 42 °C from five randomly chosen pictures from each of the six experiments.

Additionally, growth of <i>E. coli</i> was monitored to exclude that the different observed phenotypes resulted from potential cell arrests induced by protein induction. In three independent measurements, all cultures were growing exponentially after induction (Figure 62).
Figure 62: Growth kinetics of *E. coli* MC123 during periplasmic expression of PBP3<sup>wMel</sup>. Protein expression was induced at an OD<sub>600</sub> of 0.5 with 100 ng/ml tetracycline. OD<sub>600</sub> was measured every hour. Each point represents mean ± SD (n = 3).

3.5.4 Aztreonam treatment of PBP3<sup>wMel</sup> *in vivo*

Aztreonam is a β-lactam with high affinity for PBP3 leading to arrested cell division and a filamentous phenotype (Weiss et al., 1997). To examine its effect on PBP3<sup>wMel</sup> activity, the antibiotic was added to exponentially growing *E. coli* MC123 cultures at 30 °C. *E. coli* MC123 overexpressing PBP3<sup>wMel</sup> were still able to partially maintain cell division in the presence of aztreonam indicating that PBP3<sup>wMel</sup> activity cannot be blocked by aztreonam (Figure 63A). In contrast, addition of aztreonam to *E. coli* MC123 overexpressing the empty vector at 30 °C resulted in filamentous cells indicating inhibition of the native *E. coli* PBP3 activity and divisome function (Figure 63B). Analysis of six independent assays revealed that untreated cells expressing PBP3<sup>wMel</sup> or the empty vector had similar cell sizes at 30 °C (Figure 63C). In contrast, cells with the induced empty vector were significantly larger than cells expressing PBP3<sup>wMel</sup> in the presence of aztreonam.
Results

3.5.5 In vivo β-lactamase activity assay of PBP3\(^{\text{wMel}}\)

As PBP3\(^{\text{wMel}}\) was resistant to aztreonam in vivo (see chapter 3.5.4) and no penicillin-binding was observed in vitro (Ritzmann, 2016), a potential β-lactamase activity of this enzyme was examined. PBP3\(^{\text{wMel}}\) was expressed in E. coli C43 cultures supplemented with CENTA\(^{\text{TM}}\) and incubated for 16 h. In six independent experiments, absorbance \(\lambda_{405}\) increased of from 0.48 (± 0.04 SEM) to 1.36 (± 0.15 SEM) in cultures containing the positive control E. coli ML-35 pYC in six independent experiments, indicating CENTA\(^{\text{TM}}\) hydrolysis (Figure 64). In contrast, cultures expressing PBP3\(^{\text{wMel}}\) remained constant around \(\lambda_{405} = 0.49\) (± 0.05 SEM). Cultures expressing the empty vector control slightly increased from \(\lambda_{405} = 0.4\) (± 0.03 SEM) to 0.58 (± 0.07 SEM). In conclusion, no β-lactamase activity of PBP3\(^{\text{wMel}}\) was detected under the conditions tested.
3.5.6 *In silico* modeling of PBP3<sup>**W**</sup>_Mel<br><br>*In silico* analysis predicted a binding of the β-lactam antibiotic cefoxitin at two serines (S256 and S445) of the four SXXK motifs (Figure 65). *In vivo* activity assays implied that SXXK motifs can substitute each other and recombinant PBP3<sup>**W**</sup>_Mel was not impaired by the β-lactam aztreonam. Thus, PBP3<sup>**W**</sup>_Mel might be functional in *Wolbachia* even in the presence of a β-lactam.
3.6 Fluorescent labeling of D-Ala-D-Ala dipeptides

3.6.1 Dipeptide labeling of *B. subtilis* 168 and *E. coli* W3110

A novel *in vivo* assay to fluorescently label lipid II using D-Ala-D-Ala dipeptide analogues revealed a ring-like peptidoglycan structure in *Chlamydia*, *Orientia* and *Planctomycetes* for the first time (Liechti et al., 2014; Jeske et al., 2015; Atwal et al., 2017). Ethynyl-D-Ala (EDA-DA) and Ethynyl-L-Ala (ELA-LA) dipeptides (synthesized by Pepmic Co., Ltd.) were applied to Gram-positive *B. subtilis* 168 and Gram-negative *E. coli* W3110 to verify that peptidoglycan was labeled specifically. In both strains, a binding of EDA-DA was observed, while ELA-LA labeled cells did not show a fluorescent signal (Figure 66A,B). Additionally, peptidoglycan sacculi from *B. subtilis* were prepared and digested with lysozyme resulting in a loss of the fluorescence signal (Figure 66C) providing further proof that the dipeptides were indeed specifically incorporated into peptidoglycan.
Figure 66: Dipeptide labeling in *E. coli* and *B. subtilis*. A) Fluorescent labeling of lipid II in *E. coli*. *E. coli* W3110 were incubated for 60 min in medium containing 1 mM of the dipeptide probe EDA-DA (top row) or ELA-LA (bottom row), respectively. Subsequent binding of the probe to an azide-modified Alexa Fluor® 594 (red) was achieved by click chemistry. DAPI (blue) was used for nuclear staining. Scale bar = 5 µm. B) Fluorescent labeling of lipid II in *B. subtilis*. *B. subtilis* 168 were incubated for 60 min in medium containing 1 mM of the dipeptide probe EDA-DA (top row) or ELA-LA (bottom row), respectively. Subsequent binding of the probe to an azide-modified Alexa Fluor® 594 (red) was achieved by click chemistry. DAPI (blue) was used for nuclear staining. Scale bar = 5 µm. C) Fluorescent labeling of lipid II in *B. subtilis* sacculi. *B. subtilis* 168 were incubated for 60 min in medium containing 1 mM of the dipeptide probe EDA-DA. Afterwards, the peptidoglycan sacculi were prepared and binding of the probe to an azide-modified Alexa Fluor® 594 was achieved by click chemistry. The cell wall sacculi were digested with 200 ng lysozyme resulting in a loss of the dipeptide signal. Scale bar = 5 µm.
3.6.2 Dipeptide labeling of wAlbB

A specific labeling of EDA-DA co-localized with Wolbachia specific antibodies wPal and FtsZ was observed (Figure 67A) visualizing a lipid II-containing peptidoglycan-like structure in Wolbachia for the first time. Moreover, ELA-LA cells did not show a fluorescent signal indicating that Wolbachia might contain D-Ala in their lipid II peptide chain as already concluded previously (Vollmer et al., 2013) (Figure 67B). Wolbachia had a cell size varying between 0.45–1.8 µm, thus a detailed distribution of the labeled lipid II could not be determined with the microscope used (ZeissAxio VertA.1, Carl Zeiss AG). Attempts with a confocal microscope using Z-stacks and advanced microscope technologies (Zeiss LSM800 Airyscan, Carl Zeiss AG) to gain a higher resolution did not reveal a ring-like structure of the labeled dipeptides as shown for Chlamydia (Figure 67C). Notably, EDA-DA was detected only in some Wolbachia cells and the whole bacterial surface was labeled, which was also observed in O. tsutsugamushi (Atwal et al., 2017). Negative controls with EDA-DA applied on C6/36 insect cells without wAlbB did not show a fluorescent signal (Supplementary Figure 16).
Figure 67: Fluorescent labeling of lipid II in *Wolbachia*. *w*AlbB infected C6/36 insect cells were incubated for 72 h with 1 mM of EDA-DA or ELA-LA, respectively. Binding of the probe to Alexa Fluor® 594 azide (red) was achieved by click chemistry. *w*AlbB were stained with anti-FtsZ or anti-*w*Pal antibody (green). DAPI (blue) was used for nuclear staining. A) Fluorescent labeling of lipid II by EDA-DA in *w*AlbB using anti-FtsZ antibody. Scale bar = 10 µm. B) Fluorescent labeling of lipid II by EDA-DA in one *w*AlbB infected C6/36 cell using anti-FtsZ antibody. Cells incubated with ELA-LA did not contain labeled lipid II. Scale bar = 5 µm, zoom: 2 µm. C) Fluorescent labeling of lipid II in one *w*AlbB infected C6/36 cell using anti-*w*Pal antibody. Scale bar = 5 µm, zoom = 2 µm. A,B) were observed with an epifluorescence microscope (Zeiss Axio VertA.1, Carl Zeiss AG). C) were visualized using a confocal microscope (Zeiss LSM800 Airyscan, Carl Zeiss AG).
3.6.3 Dipeptide labeling of fosfomycin-treated wAlbB

To demonstrate specific incorporation of EDA-DA into *Wolbachia*, cells incubated with EDA-DA were pretreated with fosfomycin. This specific inhibitor of MurA, which catalyzes the first step of the lipid II biosynthesis from UDP-GlcNAc, was demonstrated to result in an enlarged phenotype in wAlbB due to inhibited cell division (Vollmer et al., 2013). Here, treatment with fosfomycin led to the expected enlarged *Wolbachia* phenotype and no incorporation of EDA-DA into the cells (Figure 68).

![Figure 68: Fluorescent labeling of lipid II in Wolbachia.](image)

**Figure 68: Fluorescent labeling of lipid II in Wolbachia.** C6/36 insect cells infected with wAlbB were treated daily with 512 µg/ml fosfomycin for twelve days and then incubated for 72 h with 1 mM of the dipeptide probe EDA-DA. Subsequent binding of the probe to an azide-modified Alexa Fluor® 594 (red) was achieved by click chemistry. *Wolbachia* were stained with an anti-wPAL antibody (green). DAPI was used for nuclear staining (blue). Scale bar = 5 µm. Cells were visualized using a confocal microscope (Zeiss LSM710, Carl Zeiss AG).

3.6.4 Cell-free wAlbB viability in different media

*Wolbachia* can temporarily survive in an extracellular environment (Dobson et al., 2002; Frydman et al., 2006; Rasgon et al., 2006). To further demonstrate that *Wolbachia* have some form of peptidoglycan-like structure, wAlbB were purified from the C6/36 insect cells and suspended in ultrapure water, PBS or Leibovitz medium. wAlbB remained intact and viable in all media for at least one hour (Figure 69) indicating the presence of a mechanical stress-bearing structure as recently shown for *O. tsutsugamushi* in a similar assay (Atwal et al., 2017).
Figure 69: Viability of isolated *Wolbachia* suspended in different media. *w*AlbB infecting C6/36 insect cells were purified and resuspended in PBS, ultrapure water, or Leibovitz medium. LIVE/DEAD® BacLight™ staining was added after 1 h incubation and cells were visualized under a fluorescence microscope. *w*AlbB remained viable in all media. A mock purification with uninfected C6/36 insect cells served as a negative control. Scale bar = 10 µm.

3.7 Cell-free *w*AlbB culture

The requirements for *Wolbachia* strain *w*AlbB growth in a host cell-free *in vitro* culture system were characterized in a former project (Vollmer, 2012). Supplementation with cell lysate derived from *Aedes albopictus* C6/36 insect cells allowed extracellular *w*AlbB replication rates in a mean of 6.4-fold. An insect cell lysate fraction containing cell membranes was identified as requisite for cell-free replication of *Wolbachia* (Vollmer, 2012). The required factors from this fraction were dependent on cultivation of the insect cells in medium containing fetal bovine serum. The endobacteria replicated for up to twelve days and could infect uninfected C6/36 cells (Vollmer, 2012). Replication rates in the insect cell-free culture were lower compared to *w*AlbB grown inside insect cells (Vollmer, 2012). In this work, the cell-free *w*AlbB culture was further studied and growth conditions were altered (e.g. by supplementation with substances) in order to enhance stability and growth. Moreover, cell-free *w*AlbB were
incubated with different antibiotics to test the efficacy and impact on proliferation and morphology.

3.7.1 Cell-free \textit{wAlbB} with modified growth conditions

3.7.1.1 Incubation on actin-coated streptavidin plates

Cell-free \textit{wAlbB} cells do not attach to the plate bottom impeding medium change of the culture. Centrifugation of the culture (18,400 g for 5 min) to separate \textit{Wolbachia} from the cell culture medium harmed the bacteria (data not shown). To overcome this limiting factor of the cell-free culture, actin-coated streptavidin plates were used. \textit{Pal}^{wBm} specifically binds to actin filaments of \textit{B. malayi} and might be crucial in maintenance of endosymbiosis (Melnikow et al., 2013). Cell-free \textit{wAlbB} were seeded on coated plates and kept in culture for twelve days. Cell-free \textit{Wolbachia} incubated on the actin-coated plates were slightly increasing up to day six, but then decreased. Additionally, it was tested whether a medium change might enhance growth of the potentially adherent cells. However, resuspension in fresh culture medium on day six led to a loss of bacteria instead of enhancing growth (Supplementary Figure 17).

3.7.1.2 Cell-free growth in a lowered oxygen environment

Oxygen levels inside the C6/36 cells are unknown and growth of \textit{wAlbB} might be adapted to lower levels of oxygen compared to the earth atmosphere. Using a carbonic gas chamber, oxygen levels were decreased from 20.9 % to 3 %, and carbonic gas increased from 0.004 % to 5 %. Additionally, cultures were maintained up to 15 days to test whether growth was enhanced in the carbonic gas chamber. Cell-free cultures incubated under lower levels of oxygen showed similar proliferation rates (6.9-fold ± 1 SD) compared to the standard cell-free \textit{wAlbB} culture (7.2-fold ± 0.8 SD) and growth plateaued after twelve days (Supplementary Figure 18).

3.7.1.3 Supplementation of cell-free \textit{wAlbB} standard culture medium

After 9–12 days of replication, cell-free \textit{wAlbB} numbers decrease suggesting that substances necessary to replicate might be expended (Vollmer, 2012). To enhance growth, freshly prepared insect cell lysate (equivalent to 0.95 x 10^6 uninfected C6/36 cells) was applied to the culture and proliferation was monitored via qPCR. Proliferation rates were slightly higher after twelve days (4.9-fold ± 0.5 SD) compared to the standard cell-free culture (4-fold ± 0.3 SD) in the conducted assays, but growth was not elongated (Supplementary Figure 19).

Recent studies indicate that \textit{Wolbachia}-infected insect cells might indeed incorporate cholesterol maybe as a substitute for lipopolysaccharide (Caragata et al., 2013; Geoghegan et
al., 2017). Therefore, insufficient amounts of cholesterol were considered as a potential limiting factor of cell-free Wolbachia growth. Freshly prepared water-soluble cholesterol was added to the cell-free culture, but no advantages regarding proliferation were observed compared to the standard conditions (Supplementary Figure 20).

Lipid Mixture Solution (PeproTech) contains non-animal-derived fatty acids and lipids to improve cell growth in serum-free media. The lipid mixture solution was added to the cell-free wAlbB culture to examine any beneficial effects, but supplementation inhibited cell-free growth rather than enhancing proliferation (Supplementary Figure 21).

To enhance cell-free wAlbB growth, biotin, cystine, glucose, PLP, and sodium bicarbonate, which are present in an optimized cell-free medium designed for intracellular C. burnetii (Omsland et al., 2009), were added to the cell-free wAlbB standard medium. Higher proliferation rates were observed in cultures supplemented with glucose (9.03-fold ± 1.6 SD) compared to the standard conditions (7.8-fold ± 2.7 SD), but replication decreased after nine days (Supplementary Figure 22). None of the other applied substances enhanced cell-free proliferation and moreover, supplementation of biotin and sodium bicarbonate inhibited wAlbB replication.

The co-cultivation of B. malayi and B. pahangi infective-stage L3 larvae with the yeast R. minuta supports molting to the fourth larval stage in vitro (Smith et al., 2000). It was suggested that the larvae are benefiting from an unknown secreted product of the yeast. This compound might also be beneficial for the growth of Wolbachia, thus R. minuta (10^4–10^7 cells/ml) were co-cultured with cell-free wAlbB. However, the presence of R. minuta harmed the cell-free culture leading to a depletion of wAlbB in a concentration-dependent manner (Supplementary Figure 23).

### 3.7.2 Growth of cell-free wAlbB in the presence of antibiotics

#### 3.7.2.1 Cell-free growth in the presence and absence of penicillin/streptomycin

The standard insect cell culture medium includes the addition of 1 % penicillin and streptomycin to prevent growth of unwanted bacteria since Wolbachia were shown to be resistant to these two antibiotics (O'Neill et al., 1997). These experiments were never performed under cell-free conditions, thus it was tested whether penicillin or streptomycin potentially inhibit proliferation of cell-free wAlbB. Cell-free cultures were prepared as described in chapter 2.11.3 with or without 1 % penicillin/streptomycin and growth was monitored via qPCR. The results showed similar wAlbB proliferation rates under cell-free conditions in the presence
(9-fold ± 1.7 SD) or absence (9.3-fold ± 3.8 SD) of penicillin or streptomycin (Figure 70). Thus, these antibiotics were further used to prevent growth of other bacteria strains in the culture.

![Figure 70: Cell-free wAlbB growth in the presence and absence of penicillin and streptomycin.](image)

**Figure 70: Cell-free wAlbB growth in the presence and absence of penicillin and streptomycin.** Cell-free Wolbachia (cfwo) were incubated in medium with or without 1% penicillin/streptomycin (Pen/Strep) for twelve days. Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). For every time point the mean ± SEM of six samples from two independent experiments is shown.

3.7.2.2 Cell-free growth in the presence of antibiotics effective against Wolbachia

The extracellular cultivation of Wolbachia provides an excellent tool for understanding the biology and symbiosis of Wolbachia and allows treatment with antibiotics that do not pass the insect cell membranes. Cell-free growth in the presence and absence of corallopyronin A, doxycycline, fosfomycin and rifampicin was examined, four antibiotics which are known to affect Wolbachia (Volkmann et al., 2003; Schiefer et al., 2012; Vollmer et al., 2013). Untreated cell-free wAlbB cultures served as a positive control, wAlbB cultures incubated without cell lysate from insect cells only in culture medium served as a negative control, because this treatment does not facilitate cell-free replication. As growth rates showed a high variation in the conducted assays, one assay is exemplarily presented here (Figure 71). Untreated cell-free wAlbB cultures were able to replicate (4-fold ± 0.7 SD), while the growth rate of the medium control was low (1.2-fold ± 1 SD). All antibiotic-treated Wolbachia cultures replicated, albeit growth rates were decreased in rifampicin-treated cells (3.1-fold ± 1.5 SD). As no inhibition of cell-free wAlbB growth could be observed in the other three positive controls corallopyronin A (3.9-fold ± 1.1 SD), doxycycline (4.9-fold ± 1.2 SD) and fosfomycin (4.6-fold ± 0.2 SD), analysis of growth rates via gDNA and qPCR was considered as an improper tool to detect effects of antibiotics with unknown impact to Wolbachia.
Figure 71: Cell-free wAlbB growth in the presence and absence of corallopyronin A, doxycycline, fosfomycin and rifampicin. Cell-free Wolbachia (cfwo) were incubated in growth medium with or without corallopyronin A, doxycycline, fosfomycin or rifampicin for twelve days. Cfwo incubated in medium served as a negative control. Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The graph is representative for six independent experiments. For every time point the mean ± SEM of three samples is shown.

A second approach to measure effects of antibiotics on cell-free wAlbB was the analysis of gene expression by isolation of total RNA of the culture, translation into cDNA and subsequent measurements via qPCR. Different experiments showed a high variance of expression levels of the 16S rRNA gene, thus the data from one experiment are exemplarily shown here (Figure 72). Since the 16S rRNA gene was not stably-expressed in untreated wAlbB, this attempt turned out as inappropriate and was rejected. Therefore, the effect of antibiotics on cell-free wAlbB was investigated by observing the phenotype of cells via microscopy.

Figure 72: Levels of expressed 16S rRNA in cell-free wAlbB in the presence and absence of corallopyronin A, doxycycline and rifampicin. Cell-free Wolbachia (cfwo) were incubated with or without corallopyronin A, doxycycline, fosfomycin or rifampicin for twelve days. Cfwo incubated in medium without insect cell lysate served as a negative control. Every three days, RNA was extracted and transcribed into cDNA. Levels of 16S rRNA were monitored by qPCR of the transcribed cDNA. The graph is representative for six experiments. For every time point the mean ± SEM of three samples is shown.
3.7.3 Morphology of cell-free wAlbB in the presence of antibiotics

Cell-free wAlbB cultures were incubated with different antibiotics (see Table 28). After twelve days, fosfomycin-treated Wolbachia were significantly larger around 3.69 µm (± 1.35 SD) and wPal was detected as a punctate staining pattern, whereas untreated cell-free Wolbachia had an average size of 1.06 µm (± 0.35 SD) and evenly distributed wPal (Figure 73). These results confirm previous observations of enlarged fosfomycin-treated Wolbachia residing in host cells indicating sensitivity to this antibiotic (Vollmer et al., 2013).

Figure 73: Cell-free cultured Wolbachia are sensitive to fosfomycin treatment. Cell-free Wolbachia cultures were incubated for twelve days without antibiotic or treated daily with 512 µg/ml fosfomycin. A) Cells were fixed and Wolbachia were visualized by immunofluorescence microscopy using wPAL anti-serum and an Alexa Fluor® 488 conjugated secondary goat anti-rabbit antibody as well as DAPI for DNA staining. Scale bar = 5 µm. B) Statistical difference (n = 22) was determined using Mann-Whitney test, *** = P ≤ 0.001. Boxes extend from the 25th to the 75th percentile. The line in the middle of the box is plotted at the median. Whiskers extend from the smallest to the largest value.
However, none of the other tested antibiotics showed an aberrant phenotype including those targeting lipid II or peptidoglycan synthesis (ampicillin, bacitracin, vancomycin) (Figure 74).

Figure 74: Cell-free Wolbachia morphology after antibiotic treatment. Cell-free Wolbachia cultures were incubated for twelve days with different antibiotics. Cells were fixed and Wolbachia visualized by immunofluorescence microscopy using wPAL anti-serum and an Alexa Fluor® 488 conjugated secondary goat anti-rabbit antibody. Scale bar = 5 µm.
4 Discussion

*Wolbachia* are obligate intracellular bacteria with a reduced genome and it is hypothesized that all genes retained are essential for *Wolbachia* survival (Wu et al., 2004; Foster et al., 2005). *Wolbachia* are not challenged by osmotic pressure and a peptidoglycan structure as present in free-living bacteria has not been detected, but *Wolbachia* possess all genes required for the synthesis of the peptidoglycan precursor lipid II. These genes are expressed *in vivo* and *Wolbachia* membrane preparations synthesize lipid II *ex vivo* (Henrichfreise et al., 2009). Furthermore, a crucial role of lipid II in the multi-enzyme machinery forming the divisome is estimated since inhibition of an early step of lipid II synthesis by fosfomycin leads to enlarged *Wolbachia* cells (Vollmer et al., 2013). The investigation of *Wolbachia* enzymes involved in lipid II metabolism does not only provide insight into *Wolbachia* biology but might identify novel targets for the development of antibiotics for use in depleting these essential endobacteria from filarial nematodes causing lymphatic filariasis and onchocerciasis in humans. Due to genetic intractability of *Wolbachia*, *E. coli* was used as surrogate host to investigate wolbachial enzyme activity *in vivo*.

4.1 Functional characterization of PBP6a\(^{wBm}\)

The final reaction in cell wall biosynthesis is the cleavage of the terminal D-Ala residue of the pentapeptide side chain accompanied by the formation of an interpeptide bridge (Peters et al., 2016). The degree of crosslinking is regulated by a monofunctional DD-carboxypeptidase cleaving the terminal D-Ala of the pentapeptide, thereby influencing the activities of the elongasome and the divisome due to their dependence on the presence of lipid II pentapeptide chains (Den Blaauwen et al., 2008). The function of the putative DD-carboxypeptidase PBP6a in *Wolbachia* is unknown thus far. In this thesis, a first insight into its role in wolbachial lipid II processing was gained by *in silico* analysis of the protein structure as well as *in vivo* and *in vitro* experiments. PBP6a\(^{wBm}\) is a homolog of the DD-carboxypeptidase PBP6 from *E. coli*. *In silico* secondary structure analysis of PBP6a\(^{wBm}\) predicted the presence of a putative active site center composed of SXXK, SX(D/N) and K(S/T)G motifs. However, it should be considered that this modeling was based on homologies to the presumed *E. coli* ortholog. Thus, the predicted structure can only give a hint of the putative protein architecture, but the exact structure of PBP6a\(^{wBm}\) remains unclear at this point.
In this thesis, the in vivo activity of recombinant PBP6α\textsuperscript{wBm} was investigated in E. coli. The deletion of PBP6 in E. coli does not result in a detectable altered phenotype (Nelson and Young, 2001; Chowdhury et al., 2010). Still, the effect of this DD-carboxypeptidase on cell shape can be analyzed in vivo by overproducing the enzyme in the temperature-dependent PBP3-deficient E. coli strain MCI23 which leads to partial restoration of the normal cell shape (Begg et al., 1990; Otten, 2014). DD-carboxypeptidases cleave the terminal D-Ala from the pentapeptide side-chain of lipid II, yielding lipid II with a tetrapeptide. The subsequent cleavage of the lipid II tetrapeptide by the LD-carboxypeptidase A results in high levels of lipid II tripeptide that shifts the product equilibrium, thus favoring transpeptidation reactions by PBP3 (Beck and Park, 1977; Van Heijenoort, 2011). The high amount of lipid II tripeptide, which is the preferred substrate of PBP3, enables residual transpeptidation activity of this enzyme leading to partial complementation of cell division (Botta and Park, 1981; Pisabarro et al., 1986; Begg et al., 1990). Here, this assay was used to analyze the putative DD-carboxypeptidase activity of PBP6α\textsuperscript{wBm}. The growth defect of E. coli MCI23 at the non-permissive temperature of 42 °C was partially complemented in the presence of overexpressed recombinant PBP6α\textsuperscript{wBm}. Notably, long PBP6α\textsuperscript{wBm} expression of more than two hours resulted in formation of spherical cells and lysis (data not shown). Unregulated lipid II modification due to continuous overexpression of a DD-carboxypeptidase probably leads to an increased septation at the expense of elongation, resulting in spherical growth and cell lysis as shown during PBP3 and PBP5 overexpression in E. coli (Nelson and Young, 2001; Den Blaauwen et al., 2008). The observed mixture of phenotypes with variation in cell length of PBP6α\textsuperscript{wBm} expressing E. coli MCI23 might be due to lowered enzyme activity caused by the high temperature of 42 °C. As aforementioned, lipid II with a tripeptide is the preferred substrate of PBP3, but this enzyme is still impaired and only possesses residual activity at 42 °C. Additionally, it should be considered that peptidoglycan synthases are tightly regulated and show differential activity during different cell cycle stages. While the E. coli DD-carboxypeptidase PBP5 is highly active during exponential growth, PBP6α expression increases in the stationary phase (Sarkar et al., 2011). Hence, missing synchronization of cell cycles in this assay might lead to a mixture of phenotypes. Probably, single E. coli MCI23 cells might have been arrested during different cell cycle stages when the temperature was switched to 42 °C. This could have an influence on the degree of activity of recombinant PBP6α\textsuperscript{wBm} leading to mixed phenotypes. However, previous investigations on the activity of the DD-carboxypeptidase PBP5 in E. coli after synchronization of cell cycles revealed that synchronization was already lost after two divisions (Mirelman et al., 1977). Therefore, cell cycle synchronization was not reasonable for the complementation
assays and was neglected. Nevertheless, the results of the assays performed in this thesis provide a first hint that PBP6awBm is an active DD-carboxypeptidase in vivo.

The general mechanism of DD-carboxypeptidase activity is based on the conserved motifs SXXK, SX(D/N), and K(S/T)G. Although details of the exact catalytic mechanism of serine-based PBPs have not been elucidated yet, a general mechanism consisting of acylation and deacylation of the peptide substrates under involvement of all three conserved motifs has been predicted (Dougherty and Pucci, 2011). This prediction is mainly based on studies of the DD-carboxypeptidase PBP5 of E. coli (Nelson and Young, 2001; Sauvage et al., 2008). In this enzyme, the nucleophilic properties of the active site serine of the SXXK motif are enhanced by the abstraction of a proton by the hydroxyl group of lysine of the same motif, promoting the nucleophilic attack on the terminal D-Ala carbonyl group of a pentapeptide. This leads to an acyl-enzyme intermediate and cleavage of the terminal D-Ala from the pentapeptide chain (Sauvage and Terrak, 2016). Subsequent deacylation is catalyzed by serine of the SX(D/N) motif and polarized by lysine of the K(S/T)G motif (Dougherty and Pucci, 2011). Since the nucleophilic attack during the first reaction step of a DD-carboxypeptidase requires the polarized hydroxyl group of the active site serine, amino acid substitution of serine by alanine within SXXK motifs was expected to impair PBP6awBm activity. A dependence of DD-carboxypeptidase activity on functional SXXK motifs was already demonstrated in PBP6 from C. pneumoniae (Otten, 2014). When PBP6awBm with a single mutated SXXK motif was expressed at the non-permissive temperature of 42 °C in E. coli MCI23, cell division was partially restored indicating that SXXK motifs can substitute each other. Mutation of both SXXK motifs present in PBP6awBm almost completely abolished enzyme activity resulting in filamentous E. coli MCI23 cells (mean: 91 %) unable to divide at 42 °C. However, more were filamentous (mean: 97 %) in the negative control with the induced empty vector. The remaining single and dividing cells in the double SXXK mutant of PBP6awBm were likely caused by expression stress as shown by control experiments with PalwBm.

The in vitro activity assays analyzed by TLC and MALDI-TOF showed lipid II with a tetrapeptide further supporting that PBP6awBm is a functional DD-carboxypeptidase. Mutation of SXXK motifs led to abolished activity of PBP6awBm indicating that activity might depend on functional SXXK motifs as shown for the chlamydial ortholog PBP6 (Otten, 2014). Enzyme activity of PBP6awBm was slower compared to the positive control Vany from S. aureus, which might be a result of suboptimal in vitro conditions for the recombinant wolbachial enzyme. Apart from that, Wolbachia have a slower metabolism with a generation time in cell culture of 14 h compared to free-living bacteria (e.g. less than one hour in E. coli and B. subtilis) and
therefore also enzyme activity might be slower (Fenollar et al., 2003; Taheri-Araghi et al., 2015). PBPs are the targets of β-lactam antibiotics as high affinity acylation of the SXXXK active site serine blocks the enzyme into an inactive form (Sauvage and Terrak, 2016). Inhibition assays using β-lactams were only performed in vitro, because there is no specific inhibitor known for PBP6a. The application of broad spectra β-lactam antibiotics in vivo would impair a variety of PBPs in E. coli MCI23 potentially leading to false positive results. The applied β-lactams (ampicillin and penicillin G) did not inhibit PBP6a\textsuperscript{wBm} activity in vitro and moreover, the enzyme did not bind to fluorescent- or radiolabeled penicillin in binding assays. These results are in line with previous findings that Wolbachia are resistant to β-lactams (O’Neill et al., 1997). However, it should be considered that penicillin-binding assays were performed with purified recombinant enzymes. Due to a potential different folding of recombinant enzymes in E. coli, it is possible that the native PBP6a\textsuperscript{wBm} might bind β-lactams. In silico modeling predicted that the second and conserved SXXXK binding motif of PBP6a\textsuperscript{wBm} might be accessible for β-lactams. As the first SXXXK motif is not assumed to be involved in binding, PBP6a\textsuperscript{wBm} might still be active in the presence of a β-lactam, because in vivo assays indicate that one functional SXXXK motif is sufficient to maintain activity of this enzyme. Further in vivo activity assays excluded that PBP6a\textsuperscript{wBm} resistance to β-lactams was caused by a potential β-lactamase activity of the enzyme. The conserved function of the PBP6a\textsuperscript{wBm} DD-carboxypeptidase activity provides first proof that wolbachial lipid II is further processed and this modification might be essential for the cell cycle in Wolbachia. In free-living bacteria, DD-carboxypeptidases regulate the degree of crosslinking of peptide stems to mature peptidoglycan, thus lipid II moieties in Wolbachia might at least be connected via peptide chains building a peptidoglycan-like structure.

4.2 Functional characterization of PBP2\textsuperscript{wBm}

Identical to DD-carboxypeptidases, DD-transpeptidase activity is based on the conserved motifs SXXXK, SX(D/N), and K(S/T)G (Sauvage and Terrak, 2016). The active site serine of the SXXXK motif plays a crucial role in the two-step crosslinking reaction. Firstly, it performs a nucleophile attack on the carbonyl group of the terminal D-Ala-D-Ala amide bond of a pentapeptide which leads to the formation of an acyl-enzyme intermediate and subsequent release of the terminal D-Ala. Secondly, an amino group of a peptide from a neighboring glycan chain attacks this complex building a cross bridge connecting both peptides with concomitant release of the DD-transpeptidase (Sauvage and Terrak, 2016). The role of PBP2\textsuperscript{wBm} in the cell cycle of Wolbachia is unknown and first assays to characterize this putative DD-transpeptidase
Discussion

were performed in this thesis. Of note, PBP2^wBm was re-annotated in NCBI to a putative PBP3, a DD-transpeptidase involved in cell division. However, based on sequence alignments, PBP2^wBm showed a higher similarity to PBP2 from different species than to PBP3, thus the term PBP2^wBm was kept as a description for this enzyme in this study. Secondary structure analysis revealed a putative functional active site with SXXK, SX(D/N), and K(S/T)G motifs. PBP2^wBm was investigated in vivo using the temperature sensitive strain E. coli MC123 with impaired PBP3 activity at 42 °C. Thereby, it was examined whether PBP2^wBm exhibits activity in vivo and if it is involved in cell elongation or cell division. In rod-shaped E. coli, PBP2 is an essential component of the peptidoglycan biosynthesis multi-enzyme complex and promotes cell elongation as well as shape maintenance (Den Blaauwen et al., 2008; Typas et al., 2010). Thus, it was unsurprising that PBP2^wBm with its native transmembrane domain was not active in the used E. coli MC123 model. The transmembrane domain helps in the orientation of this enzyme and PBP2^wBm is expected to be recruited to the elongasome rather than to the divisome. In contrast, PBP2^ΔTM^wBm restored complementation of E. coli MC123 at 42 °C indicating enzyme activity in vivo. PBP2^ΔTM^wBm without its native transmembrane domain might reach its target lipid II in the divisome due to solubility in the periplasm. PBP2^ΔTM^wBm activity was presumably dependent on functional SXXX motifs as expression of the protein with mutated motifs led to decreased levels of E. coli MC123 able to divide. Similar to PBP6α^wBm, an apparent remaining activity was observed, which was likely caused by protein expression stress. PBP2^ΔTM^wBm was resistant to mecillinam showing wolbachial resistance to β-lactams on a molecular level. Further in vivo activity assays excluded that PBP2^wBm resistance was caused by a potential β-lactamase activity of the enzyme. In silico analysis predicted a binding of β-lactams only by the serine residue of the second SXXX motif. In vivo assays with a single mutated SXXX motif confirmed activity PBP2^ΔTM^wBm with only one functional active site. Summing up, the in vivo results suggest that PBP2^wBm might be functional in the E. coli divisome or in the elongasome in a mecillinam-resistant manner. It should be noted that PBP2^wBm might also have DD-carboxypeptidase activity as the in vivo complementation assay cannot clearly distinguish between DD-carboxy- and DD-transpeptidase activity. But because PBP2^wBm was able to substitute for mecillinam-inhibited PBP2 from E. coli, it is likely that PBP2^wBm indeed has DD-transpeptidase activity. Since there was no E. coli strain available with a PBP2 knock-out during the study, additional control experiments could not be performed. A putative PBP3 which might act as a DD-transpeptidase specifically in the divisome is disrupted by multiple frameshifts in the genome of wBm (Foster et al., 2005). Therefore, it might be speculated that PBP2^wBm can substitute PBP3 DD-transpeptidase function during division. This
Discussion

would not automatically exclude a participation of this enzyme in cell elongation as it might have taken over both tasks in *Wolbachia* due to genome reduction. This was shown for *Chlamydia*, which harbor PBP2 and PBP3, where both enzymes were shown to be involved in cell division (Ouellette et al., 2012). The fact that PBP2 is present in the genome of *W*Bm and moreover, shows *in vivo* activity in assays with recombinant protein, strongly indicates that at least a rudimentary peptidoglycan might be present in *Wolbachia* of *Brugia malayi*. However, functional characterization of PBP2<sup>W*Bm</sup> *in vitro* did not clearly reveal transpeptidation activity. In general, the cross-linking of lipid II peptide moiety by monofunctional DD-transpeptidases is poorly characterized *in vitro* even in well investigated bacteria due to a lack of established assays (Dougherty and Pucci, 2011). Furthermore, analysis of DD-transpeptidases can be cumbersome as most of these enzymes are membrane-anchored and difficult to purify in sufficient quality for biochemical characterization (Egan et al., 2015). In this thesis, reaction products resulting from PBP2<sup>W*Bm</sup> *in vitro* activity were analyzed by TLC. A slight extinction of the lipid II band after incubation with PBP2<sup>W*Bm</sup> was observed, which can be a hint for DD-transpeptidase activity, but generally this assay cannot detect cross-linked polymers. It should be considered that recombinant PBP2<sup>W*Bm</sup> could only be stored for a couple of days after expression due to high instability and degradation of the protein. Thus, it cannot be excluded that some batches contained degraded protein, although they were used for activity assays immediately after purification. Still, the mechanism of DD-transpeptidase activity includes DD-carboxypeptidase activity resulting in a cleaved D-Ala and a lipid II tetrapeptide which can be detected *in vitro* as shown in this study for PBP6<sup>W*Bm</sup>. Lipid II with a tetrapeptide was not detected in the performed *in vitro* assays, thus the putative DD-transpeptidase activity of PBP2<sup>W*Bm</sup> remains unclear and needs further study. In *E. coli*, peptidoglycan synthases were shown to be controlled by outer membrane proteins (Typas et al., 2010; Egan et al., 2014). Since an interaction between PBP2<sup>W*Bm</sup> and Pal<sup>W*Bm</sup> was measured, it was hypothesized that lipid II mDAP monomers might be cross-linked by the action of PBP2<sup>W*Bm</sup> regulated by Pal<sup>W*Bm</sup>. Thus, purified Pal<sup>W*Bm</sup> was added to the *in vitro* DD-transpeptidase reaction mixture, but no activity of PBP2<sup>W*Bm</sup> was observed by TLC under these conditions (data not shown). PBP2<sup>W*Bm</sup> is predicted to be a monofunctional DD-transpeptidase suggesting that its activity might be dependent on the association with a bifunctional PBP with DD-transpeptidase and glycosyltransferase activity or with a monofunctional glycosyltransferase (Den Blaauwen et al., 2008). PBP2 from *S. aureus* is a bifunctional class A PBP (Barrett et al., 2005). A PBP2 mutant from *S. aureus* with knocked out DD-transpeptidase activity was kindly provided by Dr. Anna Müller (AG Tanja Schneider, University of Bonn) and *in vitro* DD-transpeptidase activity assays with
PBP2\textsubscript{wBm} were repeated in the presence of the active glycosyltransferase. However, activity of PBP2\textsubscript{wBm} was not observed under these conditions by TLC (data not shown). These results strongly indicate that PBP2\textsubscript{wBm} activity might be dependent on other molecules which are lacking under \textit{in vitro} conditions. Interestingly, the monofunctional DD-transpeptidase PBP2 from \textit{E. coli} interacts with RodA, a transmembrane protein which was recently identified as a functional glycosyltransferase in \textit{E. coli} and \textit{B. subtilis} in absence of bifunctional PBPs (Cho et al., 2016; Meeske et al., 2016). The transmembrane protein FtsW, which builds a sub-complex with PBP3, is predicted to act as a glycosyltransferase in the divisome, but this hypothesis needs experimental validation (Cho et al., 2016; Meeske et al., 2016). FtsW and RodA belong to the so-called SEDS (shape, elongation, division and sporulation) cluster. Notably, SEDS proteins and monofunctional peptidoglycan DD-transpeptidases are spread wider among bacteria than bifunctional PBPs (Egan et al., 2015). Since RodA and FtsW interact with the monofunctional DD-transpeptidases PBP2 and PBP3, they might represent ancestral cognate enzyme pairs for peptidoglycan synthesis (Henrichfreise et al., 2016). In free-living bacteria, RodA-PBP2 and FtsW-PBP3 are specialized glycosyltransferase-transpeptidase pairs found in the elongasome or divisome, respectively (Henrichfreise et al., 2016). The absence of bifunctional PBPs for example in free-living \textit{Planctomycetes} as well as in intracellular \textit{Chlamydia} and \textit{Wolbachia} suggests that monofunctional peptidoglycan SEDS-transpeptidase pairs might have been retained as principal peptidoglycan polymerase systems (Henrichfreise et al., 2016). A putative RodA protein is annotated in the wBm genome (NCBI: WP_011256217.1). \textit{In vitro} activity assays with PBP2\textsubscript{wBm} in combination with RodA\textsubscript{wBm} and subsequent measurements by TLC and MALDI-TOF might be reasonable approaches to reveal glycosyltransferase and DD-transpeptidase activity and consequently to detect a peptidoglycan-like polymer. Notably, it was already demonstrated that \textit{Wolbachia} strain wAlbB expresses FtsW and RodA (Vollmer et al., 2013). It remains to be seen if the RodA/FtsW homolog in \textit{Wolbachia} has such an activity for the assembly of peptidoglycan together with a monofunctional DD-transpeptidase.

4.3 Functional characterization of PBP3\textsubscript{wMel}

Filarial \textit{Wolbachia} like wBm only harbor one putative monofunctional DD-transpeptidase, whereas \textit{Wolbachia} residing in insect cells, e.g. wMel, encode both PBP2 and PBP3. In free-living bacteria, PBP3 is part of the divisome driving the septation process by transpeptidation of lipid II with peptidoglycan at the septation site (Den Blaauwen et al., 2008), but the role of this enzyme in \textit{Wolbachia} is unknown. \textit{In silico} analysis of the primary and secondary structure predicted a putative active site for DD-transpeptidase activity. The
purification of recombinant PBP3\textsuperscript{wMel} and functional characterization \textit{in vivo} and \textit{in vitro} were performed as part of a master thesis (Ritzmann, 2016). In this study, the \textit{in vivo} activity of recombinant PBP3\textsuperscript{wMel} was further investigated. Overexpressed PBP3\textsuperscript{wMel} partially restored the growth defects of \textit{E. coli} MCI23 at the non-permissive temperature. Although cell complementation was not restored completely, which might be explained by sub-optimal conditions for the wolbachial enzyme at 42 °C, the results indicate that PBP3\textsuperscript{wMel} exhibits activity \textit{in vivo} and is capable of lipid II modification. To provide evidence that PBP3\textsuperscript{wMel} \textit{in vivo} activity is based on the typical mode of action described for PBPs, the serine residues from all four SXXK motifs identified in PBP3\textsuperscript{wMel} were substituted by alanine by site-directed mutagenesis. Single SXXK mutations did not result in an altered phenotype, indicating normal cell division of \textit{E. coli} MCI23 (Ritzmann, 2016). Simultaneous mutation of all four SXXK motifs resulted in an increase of filamentous cells indicating impaired PBP3\textsuperscript{wMel} activity. In PBP3 from \textit{C. pneumoniae}, the ability to complement cell division of \textit{E. coli} MCI23 at the non-permissive temperature was dependent on all functional SXXK motifs, but in contrast, the single SXXK motifs were able to substitute each other \textit{in vitro} (Otten, 2014).

To confirm the mode of action of PBP3\textsuperscript{wMel} as a DD-transpeptidase within the \textit{in vivo} model, additional experiments using the specific PBP3 inhibitor aztreonam were conducted. This antibiotic leads to a filamentous phenotype due to impaired cell division (Georgopapadakou et al., 1982). When aztreonam was added to the exponentially growing \textit{E. coli} MCI23 cells overexpressing PBP3\textsuperscript{wMel} at the permissive temperature of 30 °C, cell sizes increased compared to the untreated controls. Of note, cell sizes (median: 6.9 µm) were similar to those observed in the complementation assays at 42 °C with overexpressed PBP3\textsuperscript{wMel} (median: 6.1 µm). In contrast, cells expressing the empty vector were significantly larger (median: 11.5 µm) in the presence of aztreonam. This result confirms an inhibition of the \textit{E. coli} PBP3 and supports the conclusion that partial restoration of division in cells overexpressing PBP3\textsuperscript{wMel} originated from the wolbachial enzyme. Aztreonam is a β-lactam, thus the low affinity of aztreonam to PBP3\textsuperscript{wMel} supports previous findings of \textit{Wolbachia} resistance to this antibiotic class (O'Neill et al., 1997; Fenollar et al., 2003). Aztreonam resistance was shown in some \textit{E. coli} strains which is manifested by a four-amino-acid insertion (YRIK or YRIN) in PBP3 (Alm et al., 2015). Structural analysis revealed that this insertion impacts the accessibility of some β-lactam drugs to the DD-transpeptidase pocket (Alm et al., 2015). Neither YRIK nor YRIN are present in PBP3\textsuperscript{wMel}, but \textit{in silico} analysis predicted a possible binding of the β-lactam cefoxitin only at two of the four active site serines of SXXK motifs. This indicates an inaccessibility of the other two SXXK motifs, which could maintain enzyme activity. Further
in vivo activity assays excluded that PBP$^{w_{Mel}}$ resistance to β-lactams was caused by a potential β-lactamase activity of the enzyme.

4.4 Interaction of Pal$^{w_{Bm}}$ with lipid II and PBP2ΔTM$^{w_{Bm}}$

In Gram-negative bacteria, the predominantly single-layered peptidoglycan sacculus is connected to the outer membrane by covalent and noncovalent interactions with various outer membrane proteins (Typas et al., 2010). Pal is an outer membrane protein which binds specifically to uncross-linked mDAP and is part of the membrane-spanning Tol-Pal complex (Gerding et al., 2007; Yeh et al., 2010). The Tol-Pal complex is essential for proper constriction of the outer membrane during cell division and interacts with other outer membrane proteins to connect the outer membrane, peptidoglycan and the inner membrane, thus facilitating membrane integrity (Godlewska et al., 2009). Wolbachia lack peptidoglycan-binding proteins except for Pal (Wu et al., 2004; Turner et al., 2009; Typas et al., 2012). Pal is one of two identified lipoproteins in Wolbachia (Voronin et al., 2014). In filarial infections, the pro-inflammatory capacity of B. malayi and O. volvulus is higher in the presence of Wolbachia and their lipoproteins have been identified as key ligands (Hise et al., 2007; Turner et al., 2009; Tamarozzi et al., 2011). In Wolbachia of B. malayi, Pal$^{w_{Bm}}$ was found to be among the most abundant proteins and is localized in the outer membrane (Voronin et al., 2014). It is likely that wolbachial Pal is necessary to connect the inner and outer membrane, especially during cell division, and this interaction partner might be lipid II (Vollmer et al., 2013). First evidence for this was shown in the Wolbachia strain wAlbB which was treated with fosfomycin, an antibiotic blocking lipid II synthesis, resulting in a perturbed localization of wolbachial Pal and enlarged cells unable to divide (Vollmer et al., 2013). The protein-lipid II interaction studies shown in this thesis suggest that lipid II might be connected to the outer membrane via Pal$^{w_{Bm}}$. The preferred substrate of Pal$^{w_{Bm}}$ was lipid II containing mDAP, giving a further hint of the Wolbachia lipid II composition. Noteworthy, Wolbachia retained the ability to synthesize mDAP de novo, indicating that mDAP is found at position three of the lipid II pentapeptide chain like in other Gram-negative bacteria as well as in Gram-positive bacteria of the genus Bacillus (Foster et al., 2005; Henrichfreise et al., 2009). During cell division, lipid II or a further processed form of the molecule possibly anchored in the inner membrane might be linked to the outer membrane by interacting with wolbachial Pal, forming a ring-like structure necessary for constriction of the outer membrane. A second potential interaction partner of the wolbachial Pal was PBP2. In E. coli, it was demonstrated that the outer membrane-anchored lipoproteins
LpoA and LpoB control peptidoglycan synthases (Paradis-Bleau et al., 2010; Typas et al., 2010). Each Lpo protein stimulates the DD-transpeptidase activity of its cognate PBP by binding and concomitantly inducing conformational changes (Egan et al., 2014). The protein-protein interaction studies conducted in this thesis revealed an interaction between the lipoprotein Pal\textsuperscript{wBm} and PBP2\textDelta TM\textsuperscript{wBm}. The N-terminus containing the transmembrane domain of PBP2\textsuperscript{wBm} might be anchored in the inner membrane, while the C-terminus harboring the active site might be stimulated by binding to Pal\textsuperscript{wBm}. Moreover, it can be speculated that the PBP2\textsuperscript{wBm}-Pal\textsuperscript{wBm} complex might maintain membrane integrity by connecting the inner and outer membrane.

### 4.5 Functional characterization of AmiD\textsuperscript{wMel}

The genome of arthropod Wolbachia such as wMel encode one putative peptidoglycan hydrolase, homologous to the N-acetylmuramoyl-L-alanine amidase AmiD from E. coli, although a functional cell wall has not been detected (Wu et al., 2004). In contrast to all other characterized amidases (AmiA, AmiB, AmiC) from E. coli, AmiD has a broad substrate specificity and its exact role is unclear (Kerff et al., 2010). Park and Uehara (2007) proposed that the breakdown of cell wall fragments in the periplasm by AmiD is a secondary strategy to prevent immune responses in the host. The enzyme belongs to the amidase 2 family (PF01510 in the Pfam database). Eukaryotic peptidoglycan recognition proteins (PGRPs) have at least one carboxyterminal PGRP domain, which is homologous to bacteriophage and bacterial type 2 amidases (Dziarski and Gupta, 2006). PGRPs are involved in innate immune responses against bacteria (Dziarski and Gupta, 2006). Drosophila relies entirely on innate immunity and two pathways respond to different classes of microorganisms (Buchon et al., 2014). The Toll pathway is mainly activated in response to Gram-positive bacteria and fungi, whereas the immune deficiency (Imd) pathway is mostly triggered by Gram-negative bacteria. Here, recognition of bacteria is mostly achieved by PGRPs. The membrane anchored receptor PGRP-LC and the cytoplasmic receptor PGRP-LE upstream of the Imd pathway sense peptidoglycan fragments containing mDAP in the peptide side chains (Myllymäki et al., 2014). The minimum structure for recognition by PGRP-LC is a monomer of GlcNAc-MurNAc with an internal 1,6-anhydro-bond attached to a tripeptide (Stenbak et al., 2004). In this study, AmiD\textsuperscript{wMel} was functionally characterized to better understand its role in insect Wolbachia biology. The presence of an N-terminal signal peptide predicted a periplasmic localization of AmiD\textsuperscript{wMel} but no insertion into the outer membrane like its E. coli homolog (Uehara and Park, 2007). The periplasmic localization was confirmed in vitro, and activity assays revealed that
AmiD<sup>wMel</sup> hydrolyzes the amide bond between MurNac and L-alanine of the peptide stem of various substrates like monomeric lipid II, polymeric peptidoglycan and anhydromuropeptides. This activity was inhibited by the exchange of one of the zinc-coordinating residues as well as by the non-specific metal chelator EDTA and the zinc-specific inhibitor 1,10-phenanthroline. A zinc-dependent activity was also shown in AmiD from <i>E. coli</i> (Uehara and Park, 2007). In vivo assays using an <i>E. coli</i> strain with knocked-out AmiA, B and C demonstrated an involvement in cell division of AmiA from <i>C. pneumoniae</i> (Klöckner et al., 2014). Due to rapid degradation of AmiD<sup>wMel</sup> in the used <i>E. coli</i> strain, this assay was not suitable for this study. Thus, it cannot be ruled out that AmiD<sup>wMel</sup> is involved in the turnover of a rudimentary peptidoglycan-like structure as the recycling pathway of C<sub>55</sub>-P remains unclear in <i>Wolbachia</i> (Henrichfreise et al., 2009; Vollmer et al., 2013). However, the question remains why AmiD is only conserved in <i>Wolbachia</i> found in arthropods. AmiD<sup>wMel</sup> was able to hydrolyze anhydromuropeptides like its <i>E. coli</i> homolog (Uehara and Park, 2007). Notably, the 1,6-anhydro bonds of anhydromuropeptides are generated by periplasmic lytic transglycosylases cleaving the glycosidic bond between MurNac and GlcNac units. The conservation of the capability to cleave anhydromuropeptides gives a first hint that <i>Wolbachia</i> may contain a peptidoglycan-like structure with connected glycan strands. However, neither a bifunctional PBP with DD-transpeptidase and peptidoglycan glycosyltransferase activity that could link the sugar moieties of lipid II nor a lytic transglycosylase that could catalyze glycan chain cleavage during bacterial growth have been identified in the <i>Wolbachia</i> genomes (Wu et al., 2004; Foster et al., 2005). Nevertheless, the aforementioned identification of RodA as a glycosyltransferase supports the hypothesis of a potential peptidoglycan structure in <i>Wolbachia</i>.

The size of AmiD<sup>wMel</sup> with 497 amino acids is striking (AmiD from <i>E. coli</i>: 257 amino acids) leading to the assumption of a potential additional function of this enzyme. Contrary to homologs from free-living bacteria, AmiD<sup>wMel</sup> contains conserved SXXK, SX(D/N) and K(S/T)G motifs in its C-terminus typically found in PBPs and also in AmiA from <i>C. pneumoniae</i>. This chlamydial AmiA is an amidase involved in septum cleavage and additionally functions as a DD-carboxypeptidase (Klöckner et al., 2014). Thus, AmiD<sup>wMel</sup> was investigated for a putative additional DD-carboxypeptidase activity in vivo and in vitro. In vivo assays with <i>E. coli</i> MCI23 provided first hints of DD-carboxypeptidase activity, which was dependent on the functional active site serine S400. These results suggested that AmiD<sup>wMel</sup> is an enzyme with dual activity having N-acetylmuramoyl-L-alanine amidase activity in the N-terminal and DD-carboxypeptidase activity in the C-terminal part of the protein. Additionally, an interaction between fluorescent penicillin and AmiD<sup>wMel</sup> was observed in vitro indicating...
that the PBP active site motifs are indeed present in this enzyme and accessible to β-lactams. However, DD-carboxypeptidase activity was not confirmed in vitro. Analysis of the reaction products of AmiD\textsubscript{wMel} by TLC and MALDI-TOF did not reveal lipid II containing a tetrapeptide. Possibly, the DD-carboxypeptidase activity was too low which might explain why lipid II containing a tetrapeptide was not detected by these methods. Additional assays, in which free D-Ala is detected even in low concentrations, turned out to be inappropriate to reliably measure DD-carboxypeptidase activity as no significant differences between the negative and the positive control could be calculated. Thus, further assays are necessary to investigate and confirm the putative DD-carboxypeptidase activity of AmiD\textsubscript{wMel}. Nevertheless, the functional conservation of N-acetylmuramoyl-L-alanine amidase activity indicates that AmiD\textsubscript{wMel} plays an important role in the lifecycle of insect \textit{Wolbachia}, but its involvement in cell division remains unclear. Likely, AmiD\textsubscript{wMel} might suppress host immune responses by removing the peptide chain from the sugar moieties. Because insect \textit{Wolbachia} are parasites and can horizontally infect other insects (Werren et al., 2008), this enzyme may have been maintained for example in \textit{wMel}, \textit{wRi} and \textit{wPip} to aid this specific endosymbiotic lifestyle and protect these endobacteria. In contrast, genomes of sequenced \textit{Wolbachia} from filarial nematodes show that these strains have lost the ability to synthesize AmiD. Moreover, nematodes do not express homologs of PGRP-LC or Imd (Irazoqui et al., 2010; Ermolaeva and Schumacher, 2014) and thus would not recognize the same peptidoglycan metabolism/recycling products, allowing \textit{Wolbachia} of filarial nematodes to lose AmiD during evolution as mutualistic endosymbionts. In conclusion, the enzymatic activity of AmiD\textsubscript{wMel} may have a crucial role in cleavage of a peptidoglycan-like structure and allow \textit{Wolbachia} to avoid host organism immune responses by degrading cell wall fragments in the periplasm that could be recognized by innate immune receptors (Buchon et al., 2014).

4.6 Growth requirements of \textit{Wolbachia wAlbB} in a cell-free culture

The examination of \textit{Wolbachia} is challenging as they live well protected from the environment by four lipid membrane layers: the host cell membrane, the membrane of the vacuole in which \textit{Wolbachia} reside in the cytoplasm and the bacterial outer and inner membrane. In vitro culture systems are few and attempts to culture \textit{Wolbachia} of filarial nematodes have not been successful (Slatko et al., 2014). Only strains naturally occurring in arthropods have been established in cell cultures (O'Neil et al., 1997; Turner et al., 2006). Therefore, possibilities to investigate \textit{Wolbachia} are limited. An extracellular culture system would open the door for the application of a broad spectrum of molecular biological techniques.
and facilitate the elucidation of *Wolbachia* biology. For example, the efficacy of large antibiotics, which are not able to pass all four lipid membrane layers, could be examined. First steps towards a cell-free system were made by Rasgon et al. (2006). *Wolbachia* strain *w*AlbB purified from an insect cell line was maintained in a cell-free culture medium for up to one week, but could not proliferate outside the host cell. Further attempts regarding *ex-vivo* growth failed, but some components were advantageous regarding survival of *Wolbachia*, e.g. compatible solutes, actin and mammal blood (Uribe-Alvarez et al., 2018). A host cell-free culture of *w*AlbB with viable cells which were replicating and infective up to twelve days was established in a former project (Vollmer, 2012). An insect cell lysate fraction containing cell membranes was identified as requisite for cell-free replication of *Wolbachia*, but replication was limited to 9-12 days (Vollmer, 2012). Further experiments on single components of the membrane fraction were performed, for example with certain membrane lipids. However, the results were ambiguous and it was assumed that there are several positive and negative factors influencing the culture in a complex manner (J. Vollmer, pers. communication). Usage and insufficient supply of nutrients might be a reasonable explanation, but as *Wolbachia* replicate slowly, a competition for nutrients seems unlikely (Vollmer, 2012).

Part of this thesis was to examine if additional supplemented substances that are not present in the standard cell culture medium might enhance growth and stability of cell-free *w*AlbB. The survival of *Anaplasma phagocytophilum* and *Ehrlichia chaffeensis*, which are closely related to *Wolbachia*, is dependent on the incorporation of cholesterol derived from their host to maintain membrane integrity (Lin and Rikihisa, 2003). Like *Wolbachia*, *A. phagocytophilum* and *E. chaffeensis* do not synthesize lipid A and it was proposed that cholesterol might be necessary to promote membrane stability as a substitute for lipopolysaccharide (Lin and Rikihisa, 2003; Wu et al., 2004). Recent studies indicate that *Wolbachia*-infected insect cells might indeed incorporate cholesterol (Caragata et al., 2013; Geoghegan et al., 2017). Further, *Wolbachia* reside in cholesterol-rich Golgi-related vesicles derived from the host forming a vacuole surrounding each bacterium (Cho et al., 2011). Insects assimilate cholesterol from their environment which is incorporated into the plasma membrane and into internal membranes like those from the Golgi apparatus (Rolls et al., 1997). Thus, cholesterol might be a limiting factor for cell-free *w*AlbB proliferation and supplementation with the membrane fraction of an insect cell lysate might not be sufficient to keep up growth for more than twelve days. The supplementation of water-soluble cholesterol did not lead to elongated replication of cell-free *w*AlbB. The application of fresh cell lysate after nine days showed higher cell-free *w*AlbB proliferation after twelve days compared to the standard culture.
in the performed assays, but taken as a whole, proliferation rates were not higher than the observed mean of 6.4-fold from previous assays (see chapter 3.7). Based on these results, cholesterol and certain components from the insect cell membrane that are potentially taken up by *Wolbachia* were concluded not to be key factor for limited proliferation. Since *Wolbachia* replication was high between days 3–9, a complete medium change after nine days to supply *Wolbachia* with fresh culture medium was reasonable. This was challenging as the bacteria did not attach to the plate surface. Centrifugation of the culture to separate *Wolbachia* from the cell culture medium led to a loss of the bacteria. Thus, cell culture plates were coated with actin to allow attachment of the *Wolbachia* to the surface and to potentially facilitate medium change. Several studies demonstrate a close association of *Wolbachia* and other intracellular bacteria with the host cell cytoskeleton (Ferree et al., 2005; Galán and Cossart, 2005; Melnikow et al., 2013; Landmann et al., 2014; Reed et al., 2014; Souza Santos and Orth, 2015). In *Drosophila*, *Wolbachia* localize at the anterior pole of the mosquito’s oocytes using microtubules, thus ensuring transmission to the next generation (Ferree et al., 2005). In *B. malayi*, wolbachial surface proteins form a complex with actin and tubulin and this binding is supposed to be crucial in maintenance of endosymbiosis (Melnikow et al., 2013). Moreover, the supplementation of actin was shown to improve survival of isolated *Wolbachia* (Uribe-Alvarez et al., 2018). In this thesis, cell-free *wAlbB* were cultured on an actin-coated streptavidin plate to examine if the bacteria benefit from actin and if they attach to the substrate, which would have facilitated medium change. However, cell-free growth on actin-coated plates was decreased compared to the standard conditions. It cannot be excluded that substances from the wash buffer used for actin-coating on the streptavidin plates were harmful to the bacteria, although plates were rinsed several times with culture medium before use. Medium change after six days led to a loss of bacteria leading to the conclusion that *Wolbachia* were not attached to the actin-coated plates. The binding of *Wolbachia* to actin might be more crucial to keep maintenance in the host cell culture rather than to be involved in replication itself.

As shown for other intracellular bacteria, culturing in a lowered oxygen environment can increase cell-free growth (Omsland et al., 2009). Here, proliferation rates were similar in cell-free *wAlbB* incubated under a lower oxygen level compared to standard conditions. Thus, oxygen levels are presumably not the limiting factor of cell-free *Wolbachia* growth. Of note, the variance of *wAlbB* replication rates in cell-free cultures between different experiments was similar to those of *Wolbachia* cultured inside insect cells reflecting growth variability that might originate from variances in temperature, cell culture passage and culture medium. An optimized culture medium was already designed for cell-free growth of the obligate endobacteria
C. burnetii using expression microarrays, genomic reconstruction and metabolite typing (Omsland et al., 2009). The cell-free wAlbB medium was compared to the optimized cell-free medium for C. burnetii and substances, which were present in the medium for C. burnetii, were supplemented to the cell-free wAlbB medium. An increase of proliferation was observed in cultures supplemented with glucose. The glucose and glycogen metabolism in B. malayi is associated with Wolbachia symbiont fitness and it was shown that the disaccharide sucrose, consisting of glucose and fructose, improves survival of isolated Wolbachia (Voronin et al., 2016; Uribe-Alvarez et al., 2018). Thus, this compound might be beneficial for wolbachial growth. Indeed, growth rates slightly increased in the presence of glucose, but proliferation could not be elongated. Moreover, biotin and sodium bicarbonate harmed the culture. To determine exact nutrient requirements and to design a Wolbachia-specific cell-free medium, differences in gene expression of Wolbachia cultured in insect cells and cell-free should be examined in a future project.

Another possible explanation why cell-free Wolbachia replication stops after 9-12 days might be the regulation of Wolbachia densities by an unknown intrinsic or host-derived mechanism. It is striking that cell-free wAlbB were only proliferating at an initial concentration of 0.5 – 1 x 10^3 cells/µl. In contrast, in cell-free cultures containing higher densities of Wolbachia with 10^4 or 10^5 cells/µl, Wolbachia numbers rarely increased (Vollmer, 2012). This indicates that Wolbachia might sense cell densities and regulate cell division by internal communication patterns. The two-component regulatory system (TCS) is the predominant form of signaling used in a majority of prokaryotes, including bacteria (Beier and Gross, 2006). It is composed of a sensor histidine kinase and a paired response regulator (Mitrophanov and Groisman, 2008; Jung et al., 2012). Stimuli such as nutrients, osmolarity, oxygen, salinity and quorum sensing cues are recognized by sensor histidine kinases (Mascher et al., 2006). This activates cognate response regulators which for example coordinate induction of sporulation, regulation of bacterial differentiation or formation of biofilms (Stock et al., 2000). TCS genes are highly conserved in various Wolbachia strains, but very little is known about their function to date (Cheng et al., 2006; Brilli et al., 2010). A bioinformatic study showed that wolbachial TCS genes are consistently found clustered with metabolic genes within different Wolbachia strains including wAlbB and wBm (Christensen and Serbus, 2015). Considering these findings, it might be hypothesized that Wolbachia are able to sense for example nutrients or quorum sensing molecules and consequently regulate cell division. This could explain why cell-free Wolbachia growth stops after 9-12 days of incubation and could further explain the observation that Wolbachia cell numbers inside the C6/36 insect cells do not reach a density that would
negatively affect the survival of the insect cell. In *Drosophila*, *Wolbachia* replication was indicated to be tissue-dependent as growth rates differ significantly between head and ovaries (McGraw et al., 2002). *Wolbachia* replication is also dependent on the stage of the host life cycle. In *A. albopictus*, *Wolbachia* replication stops during the diapause of mosquito eggs in which no host cell division occurs, highlighting the dependence of *Wolbachia* proliferation on host cell division (Ruang-Areerate et al., 2004). In the filarial nematode *B. malayi*, *Wolbachia* numbers are low and remain constant in microfilaria and insect-borne larval stages, but proliferation increases suddenly after the infection of a vertebrate host (McGarry et al., 2004; Taylor et al., 2013). This seems to play an essential role in larval development as demonstrated by the arrested larval growth and development in response to antibiotic treatment (Taylor et al., 2012). *B. malayi* and *B. pahangi* infective-stage larvae co-cultured *in vitro* with the yeast *R. minuta* have been shown to support consistent and reproducible molting to the fourth larval stage (Smith et al., 2000). It was suggested that the larvae are benefiting from an unknown secreted product of the yeast. Since proliferation rates of *Wolbachia* severely increase in this phase of the larvae (McGarry et al., 2004; Taylor et al., 2013), the bacteria might also benefit from secretion products of *R. minuta*. In this thesis, cell-free wAlbB were co-cultured with viable *R. minuta*. The co-cultivation harmed the *Wolbachia* leading to a concentration-dependent decrease of bacteria rather than enhanced growth. Thus, it might be assumed that the secreted yeast product might be more beneficial for the viability of filarial larvae than for *Wolbachia*. In a future experiment, *R. minuta* lysate in different concentrations might be used. This would prevent that bacteria are overgrown by the yeast. Notably, it was recently shown that wAlbB is able to grow in artificially infected *Saccharomyces cerevisiae* (Uribe-Alvarez et al., 2018). Compared to controls, infected yeast lost viability early, but this system might potentially provide a promising future model of interactions that occur in a naturally infected eukaryote host (Uribe-Alvarez et al., 2018).

Summing up, these findings provide insight into the complexity of *Wolbachia* replication and endosymbiont-host dependency. Further research will be necessary to elucidate the multiple mechanisms that influence and regulate *Wolbachia* replication and to enhance growth as well as stability of the wAlbB cell-free culture.

### 4.7 Antibiotic treatment of *Wolbachia* wAlbB in a cell-free culture

Several antibiotics tested in *Wolbachia*-infected cell cultures did not deplete the bacteria and it was a matter of debate whether they were ineffective because they could not reach their
target or because *Wolbachia* are indeed resistant. The cell-free system meets all requirements to examine antibiotics directly applied to *Wolbachia*. Thus, another part of this thesis was the application of antibiotics to the cell-free *wAlbB* culture. Different antibiotics were supplemented to the cell-free culture medium, gDNA was prepared and growth rates were monitored via qPCR of the 16S rRNA gene. To exclude that penicillin or streptomycin, which are supplements of the normal cell culture medium, have an inhibitory effect on cell-free *wAlbB* proliferation, cultures with and without these antibiotics were tested. Here, no differences in growth rates were observed supporting previous findings that *Wolbachia* are resistant to β-lactams (O’Neill et al., 1997). Proliferation rates were also examined with the *Wolbachia*-affecting antibiotics corallopyronin A, doxycycline, fosfomycin and rifampicin. However, cell-free *wAlbB* growth rates were not decreased in the presence of corallopyronin A, doxycycline or fosfomycin. Only treatment with rifampicin led to decreased cell-free growth, but a complete inhibition of growth was not observed here as well. It might be assumed that an effect on growth would only be observed using antibiotics with bactericidal activity like rifampicin, but this assumption does not hold true as fosfomycin also acts bactericidal (Michalopoulos et al., 2011). Generally, it should be considered that gDNA was prepared and measured from the whole culture and it is possible that DNases are lower or absent in the cell-free culture. Thus, gDNA fragments of dead cells were potentially measured by qPCRs leading to a seemingly increase of *Wolbachia*. To solve this issue, expression levels of the 16S rRNA gene prepared from the cell-free culture were measured. However, no differences between antibiotic treated and untreated cultures were revealed due to low expression after twelve days also in untreated controls. A study in *wMel* confirmed that rRNA expression levels are high and variable among samples (Gutzwiller et al., 2015). Thus, this approach is not suitable to reliably compare antibiotic treated and untreated *wAlbB* cultures.

Another approach to determine bacteria numbers is counting of cells under a microscope and discrimination between living and dead bacteria by LIVE/DEAD® staining. This was applied to the cell-free *Wolbachia*, but in the majority of experiments, only few cells were detected after twelve days also in the controls cultures without antibiotic treatment. Other previous attempts to count cell-free *Wolbachia* also turned out to be inappropriate as a high variance between measured cells per qPCR and actually counted cells was revealed (J. Vollmer, pers. communication). Therefore, this approach was rejected and the impact on the morphology of antibiotic-treated *wAlbB* was investigated to reveal potential antibiotic-effects on *Wolbachia*. Cell-free *Wolbachia* were fixed, stained and visualized under a microscope. In a previous study, *wAlbB* residing in C6/36 insect host cells were treated with the lipid II-synthesis
blocking antibiotic fosfomycin, which led to enlarged bacteria (Vollmer et al., 2013). This finding indicated that lipid II is essential for cell division in *Wolbachia*. Moreover, fosfomycin treatment on *Wolbachia* revealed a perturbed localization of wPal suggesting an interaction of this lipoprotein with lipid II or its processed form (Vollmer et al., 2013). This assumption is supported by the results of the interaction assays in this thesis (see chapter 4.4). The incubation of cell-free wAlbB with fosfomycin also showed an aberrant phenotype with enlarged cells and delocalized wPal appearing in a spot-like pattern. None of the other antibiotics tested revealed a visible aberrant phenotype. Ciprofloxacin, clindamycin, corallopyronin A, doxycycline, rifampicin, sulfamethoxazole and trimethoprim do not target cell wall biosynthesis, thus an impact on cell morphology was unlikely. For antibiotics targeting the cell wall or synthesis steps (ampicillin, bacitracin, vancomycin) an aberrant phenotype was more likely. For example, ampicillin-treated *C. trachomatis* have aberrant, enlarged reticulate bodies (Liechti et al., 2014). Here, no changes compared to the control cells were observed after twelve days of incubation with the respective antibiotic. On the one hand, it can be proposed that *Wolbachia* are indeed resistant to these antibiotics and therefore no change of morphology was detected. On the other hand, it might be assumed that antibiotics were unstable and thus ineffective. Since stability, solubility and shelf life of antibiotics were considered while preparing the assays, this possibility can be neglected. Another explanation for the inefficacy of the substances might be an inaccessibility of their targets. For instance, most Gram-negative bacteria are naturally resistant to vancomycin as this molecule cannot pass the outer membrane (Geraci, 1977). *Wolbachia* likely have an unusual outer membrane since they are unable to synthesize lipid A, a key moiety of lipopolysaccharide (Foster et al., 2005). Thus, certain compounds, which are too large to pass the outer membrane of Gram-negative bacteria, might pass the unique *Wolbachia* outer membrane. This was already demonstrated for corallopyronin A which normally depletes only Gram-positive bacteria, but is also highly active against *Wolbachia* (Schiefer et al., 2012). In contrast, it should be considered that compounds that normally pass the Gram-negative outer membrane might not be able to reach their target in *Wolbachia* due to their unique outer membrane.

In conclusion, the investigation of *Wolbachia* cultures in terms of antibiotic susceptibility remains challenging. To establish rapid and reliable tools to analyze antibiotic assays, several attempts could be beneficial. The amplification of genes like the wolbachial surface protein (wsp) WD1063 might be more eligible than 16S rRNA to measure replication or depletion of cell-free *Wolbachia*. Wsp is stably-expressed in *Wolbachia* making it suitable to compare expression levels of antibiotic treated and untreated cells (Gutzwiller et al., 2015).
Wolbachia growth inside yeast cells can be determined by PCR of wsp and this approach might be applied to the cell-free wAlbB culture (Uribe-Alvarez et al., 2018). Additionally, Wolbachia replication or depletion can also be estimated by the detection of wsp by Western Blot and analysis of band intensity (Uribe-Alvarez et al., 2018). As another approach, fluorescence-activated cell sorting of LIVE/DEAD® stained Wolbachia after antibiotic treatment might lead to more detailed and accurate results instead of analysis with a microscope.

### 4.8 Lipid II labeling of wAlbB

Wolbachia possess all genes to build the peptidoglycan precursor lipid II and a previous study confirmed that recombinant proteins and purified Wolbachia membranes synthesize lipid I and II in vitro and that the pathway is essential for Wolbachia cell division (Henrichfreise et al., 2009). It was proposed that Wolbachia might have a peptidoglycan-like molecule built of peptide cross-links and that lipid II might be needed for the coordination of cell division (Foster et al., 2005; Henrichfreise et al., 2009). However, the exact molecular structure and further processing of Wolbachia lipid II is unknown. Wolbachia have lost most genes for amino acid biosynthesis de novo, but retained the genes for mDAP biosynthesis (Foster et al., 2005). Wolbachia most likely maintained the mDAP pathway because this amino acid is essential for the synthesis of lipid II and cannot be provided by the eukaryotic host. In this thesis, Pal\textsuperscript{wBm} was shown to preferentially bind to lipid II containing mDAP, giving a hint that this amino acid is found in the peptide moiety. Although Wolbachia lack typical amino acid racemases, they express MetC, which was shown to have an alternative alanine racemase activity in E. coli (Kang et al., 2011). MetC\textsuperscript{wBm} also possesses L-alanine racemase activity in vitro, giving a first hint that Wolbachia might provide D-Ala for the terminal dipeptide in the pentapeptide of lipid II (Vollmer et al., 2013). Wolbachia such as wBm harbor the gene for the D-Ala-D-Ala ligase Ddl required to synthesize the D-Ala dipeptide that is linked to the UDP-MurNAc-tripeptide by MurF (Foster et al., 2005). The expression of Ddl has already been shown in wAlbB (Vollmer et al., 2013). An in vivo assay with fluorescently labeled lipid II using D-Ala-D-Ala dipeptide analogues revealed a ring-like peptidoglycan structure for the first time in Chlamydia, Orientia and Planctomycetes (Liechti et al., 2014; Jeske et al., 2015; Atwal et al., 2017). In this thesis, this technique was established in a C6/36 insect cell line infected with wAlbB. Fluorescent labeling showed a specific co-localization of anti-Wolbachia sera and the labeled D-amino acid dipeptide visualized a lipid II-containing and putative peptidoglycan-like structure in Wolbachia for the first time. The results further demonstrate that the cell wall
precursor lipid II is synthesized \textit{in vivo} and most likely contains D-Ala-D-Ala. No labeling was monitored after fosfomycin treatment confirming the specific visualization of lipid II by EDA-DA. Isolated \textit{Wolbachia} from the insect cell culture remained viable in different media (water, PBS and Leibovitz medium). Previous studies also demonstrated that \textit{Wolbachia} can temporarily survive in an extracellular environment (Dobson et al., 2002; Frydman et al., 2006; Rasgon et al., 2006). The viability of isolated intracellular bacteria in different media has also been shown in \textit{O. tsutsugamushi} and has been interpreted as an indicator for the presence of a mechanical stress-bearing structure as provided by peptidoglycan (Atwal et al., 2017).

The examination of a dipeptide antibody via highly resolving transmission electron microscopy could provide further insights into cell wall localization and structure in \textit{Wolbachia}. Similar to \textit{Orientia}, only few \textit{Wolbachia} cells contained detectable dipeptides leading to the speculation it might only be synthesized at division sites (Atwal et al., 2017). In free-living bacteria, FtsZ recruits divisome proteins and confers the inner contractile force for the cell, whilst the outer force is provided by the peptidoglycan sacculus (Ghosh and Sain, 2008). In \textit{Wolbachia}, FtsZ might constitute the inner contractile force, but the outer contractile force is unknown. Concluding that the observed lipid II structure consists of a polymer, it might be postulated that this confers the outer force in cell division. This hypothesis is in accordance with previous findings that lipid II plays a crucial role during cell division in \textit{Wolbachia} (Foster et al., 2005; Henrichfreise et al., 2009; Vollmer et al., 2013).

\textbf{4.9 Lipid II metabolism and its role in \textit{Wolbachia} biology}

In free-living bacteria, synthesized lipid II is flipped across the cytoplasmic membrane into the periplasm (Ruiz, 2016). To date, the identity of the enzyme translocating lipid II across the cell membrane remains a matter of debate. Several enzymes (FtsW, MurJ and RodA) might function as flippases and are discussed controversially (Ruiz, 2016). As \textit{Wolbachia} annotate all three potential flippases, it is likely that the wolbachial lipid II molecule is translocated across the cytoplasmic membrane into the periplasm by one of these enzymes (Vollmer et al., 2013). Recent studies indicate glycosyltransferase activity of RodA in \textit{E. coli} and \textit{B. subtilis} in absence of bifunctional PBPs, and FtsW is hypothesized to have similar activity (Cho et al., 2016; Meeske et al., 2016). Thus, FtsW and RodA might be glycosyltransferases rather than flippases concluding that lipid II is likely translocated into the periplasm by MurJ. Once in the periplasm, lipid II is incorporated into the growing peptidoglycan by glycosyltransferases, DD-carboxypeptidases and DD-transpeptidases in free-living bacteria. The genome from \textit{wMel} contains the lipid II processing enzymes PBP2, PBP3, PBP6a, and AmiD, whereas filarial \textit{wBm}
only encodes the genes for PBP2 and PBP6a. The results of this thesis are a first characterization of wolgachial lipid II processing enzymes and give a hint why they have been maintained in the genome. Lipid II of \(wBm\) is likely processed by the DD-transpeptidase PBP2 leading to connected peptide moieties. The degree of crosslinking might be regulated by the DD-carboxypeptidase PBP6a. In \(wMel\), the DD-transpeptidase PBP3 might lead to additional amounts of connected lipid II peptide moieties during cell division which could be recycled by AmiD to suppress host immune responses. In \(E. coli\), PBP2 is mainly involved in the elongasome building peptidoglycan, while PBP3 is only functional in the divisome (Goffin et al., 1996; Höltje, 1998). In case of \(Wolbachia\), a distinct separation of these multi-enzyme complexes might not hold true. Here, orchestration of lipid II processing as well as cell division may be achieved by the formation of overlapping multi-enzyme complexes (Figure 75).

**Figure 75: Proposed model of lipid II processing in Wolbachia.** Lipid II might be flipped into the periplasm by MurJ. Pal \((wBm)\) might interact with lipid II and PBP2 \((wBm)\). PBP2 DD-transpeptidase activity might be catalyzed by the putative glycosyltransferase RodA building glycan chains with concomitant cleavage of the undecaprenyl phosphate \((C_{55}-P)\) from MurNAc. The degree of crosslinking might be regulated by the DD-carboxypeptidase PBP6a \((wBm)\). PBP3 \((wMel)\) might have DD-transpeptidase activity during cell division together with the putative glycosyltransferase FtsW in insect Wolbachia. Peptidoglycan is cleaved by an unknown lytic transglycosylase resulting in anhydromureptides. AmiD \((wMel)\) cleaves the bond between peptide chain and sugars in peptidoglycan, lipid II and anhydromureptides. AmiD might furthermore have additional DD-carboxypeptidase activity. However, almost all peptidoglycan recycling enzymes are missing from annotated Wolbachia genomes and the further processing of \(C_{55}-P\) remains unclear.
Pal might interact with lipid II and PBP2 connecting the inner and outer membrane (see chapter 4.4). Active monofunctional PBPs together with RodA and FtsW might synthesize at least a peptidoglycan-like macromolecule putatively essential for cell division, which would confirm previous hypotheses (Foster et al., 2005; Henrichfreise et al., 2009; Vollmer et al., 2013). Investigating more enzymes involved in the orchestration of lipid II will further unravel cell wall metabolism in Wolbachia. In wBm, MurJ (NCBI: WP_011256323) and RodA are encoded, while the homolog of FtsW is disrupted by multiple frameshifts (Foster et al., 2005). In wMel, the sequences of MurJ, RodA and FtsW were found (Foster et al., 2005). The characterization of these enzymes is part of current and future studies. In Chlamydia, MreB is essential for growth and cell division (Ouellette et al., 2012). This rod shape-determining protein forms actin-like filaments and interacts with PBP2 to direct its synthesis of peptidoglycan as shown in free-living bacteria (Jones et al., 2001; Divakaruni et al., 2005). As MreB is present in wBm (NCBI: WP_011256355) and can specifically be inhibited by S-(3,4-dichlorobenzyl) isothiourea, it might be a potential point of application to deplete Wolbachia (Noritaka et al., 2002). Thus, the characterization of wobachial MreB might be reasonable.

The lipid II processing enzymes of this study were also investigated regarding their potential as targets for antibiotics. β-lactams react with the serine of the SXXK motif forming a long-lived acyl-enzyme covalent complex, consequently blocking enzyme activity (Nicola et al., 2010). The results of this thesis demonstrated that the activity of wolbachial PBPs is dependent on functional SXXK motifs, but Wolbachia are resistant to β-lactam antibiotics (O’Neill et al., 1997). The application of β-lactams to cell-free Wolbachia and to wolbachial PBPs confirmed resistance to this class of antibiotics. The underlying molecular mechanism is probably an inaccessibility of some SXXK motifs to β-lactams. Wolbachia PBPs all have more SXXK motifs than their E. coli orthologs and the active site serines were demonstrated to potentially substitute each other in function. This might be an advantage in terms of resistance when a β-lactam is present and not bound to all SXXK motifs. Surprisingly, AmiD<sup>wMel</sup> showed binding to penicillin. Its putative additional DD-carboxypeptidase activity needs further validation (see chapter 4.5), and now it can only be speculated whether this activity is inhibited by β-lactams. However, as cells remained unaffected by applied β-lactams in the cell-free wAlbB culture, wolbachial PBPs and AmiD appear not to be suitable targets for β-lactam antibiotics. Apart from β-lactams, other antibiotics such as glycopeptides or lantibiotics inhibit the last stage of peptidoglycan polymerization by binding to the lipid II substrate (Sauvage and Terrak, 2016). Notably, a newly discovered natural product, teixobactin, isolated from Eleftheria terrae, inhibits cell wall synthesis in Gram-positive bacteria by binding to lipid II.
and lipid III (precursor of teichoic acid) (Ling et al., 2015). Teixobactin is also active against an *E. coli* mutant with a defective outer membrane permeability barrier (Ling et al., 2015). *Wolbachia* most probably have an unusual outer membrane due to missing lipid A (Foster et al., 2005). Thus, antibiotics like teixobactin that are only active against Gram-positive bacteria might also be effective against *Wolbachia* and should be considered in antibiotic assays.

*wMel* have two more enzymes (AmiD and PBP3) involved in cell wall metabolism that are absent in *wBm*, suggesting differences of a putative peptidoglycan structure (Foster et al., 2005). These differences might reflect the occurrence of a mutualistic lifestyle and in contrast to a parasitic lifestyle (Foster et al., 2005). After the identification of RodA as an active glycosyltransferase (Cho et al., 2016; Meeske et al., 2016) it should be taken in account that *Wolbachia* might have a mature cell wall. Even more, the explanation that these bacteria have incomplete peptidoglycan machineries does not hold true anymore as the truly minimal maybe ancestral sets (RodA-PBP2 and FtsW-PBP3) remained concealed (Henrichfreise et al., 2016). Supporting this hypothesis, recent studies demonstrate that a peptidoglycan-like structure can be detected in intracellular *Chlamydia* and *Orientia* which also do not have all peptidoglycan synthesizing enzymes, but possess homologs of the SEDS proteins FtsW and RodA (Pilhofer et al., 2013; Liechti et al., 2014; Jeske et al., 2015; Van Teeseling et al., 2015; Atwal et al., 2017). In this study, a lipid II-containing and putative peptidoglycan-like structure was detected in *wAlbB* for the first time (see chapter 4.8). Moreover, it was demonstrated that AmiD*Mel* is a peptidoglycan hydrolase capable of cleaving structures specifically obtained by lytic transglycosylases from glycan strands (see chapter 4.5). These results strongly indicate that at least insect *Wolbachia* may contain peptidoglycan with connected glycan strands. *E. coli* L-forms are assumed to lack peptidoglycan due to inhibited PBP1a and PBP1b (Joseleau-Petit et al., 2007). Still, they grow in isotonic medium which is blocked after additional inhibition of PBP2 or PBP3, suggesting that at least a basal level of peptidoglycan synthesis is essential for cell division (Joseleau-Petit et al., 2007). Presumably, cell wall biosynthesis and cell division are tightly connected and cannot be separately eliminated in the course of evolution (Otten, 2014). Comparative analysis of major obligate intracellular bacteria predicted some sort of peptidoglycan-like structure in *Wolbachia* termed into a group of “peptidoglycan-intermediate” organisms along with *Chlamydia*, *O. tsutsugamushi* and *Anaplasma marginale* (Otten et al., 2017). In conclusion, the results of this study together with latest research findings regarding peptidoglycan in intracellular bacteria and newly discovered SEDS glycosyltransferases support the assumption that *Wolbachia* are not cell wall-less bacteria, but rather have a physical structure composed of lipid II that can interact with outer membrane proteins.
Supplement

Supplementary Figure 1: Amino acid alignment of PBP6a_wBm and PBP6a_wMel. * fully conserved residue; : conservation between groups of strongly similar properties; . conservation between groups of weakly similar properties. Conserved SX(SK), SX(D/N) and K(S/T)G motifs found in PBP6a_wBm and PBP6a_wMel are written in bold letters, motif alignments are framed in black.

<table>
<thead>
<tr>
<th># Measure</th>
<th>Position</th>
<th>Value</th>
<th>Cutoff</th>
<th>signal peptide?</th>
</tr>
</thead>
<tbody>
<tr>
<td>max. C</td>
<td>23</td>
<td>0.366</td>
<td></td>
<td></td>
</tr>
<tr>
<td>max. Y</td>
<td>23</td>
<td>0.487</td>
<td></td>
<td></td>
</tr>
<tr>
<td>max. S</td>
<td>19</td>
<td>0.751</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mean S</td>
<td>1-22</td>
<td>0.619</td>
<td>0.420</td>
<td>YES</td>
</tr>
<tr>
<td>D-cutoff</td>
<td>0.420</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name = Sequence SP = 'YES' Cleavage site between pos. 22 and 23: SYS-YQ D = 0.549</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Figure 2: Prediction of a signal peptide in PBP6a<sup>stim</sup> (Signal P) for secretion in the periplasm, but no transmembrane domain (TMHMM).

PBP6a         ------------ATGA-------------GTATATTAGACAAT-------------T-----GGTAAATCTCGCT  32
PBP6a_SP      TCTAGATACAGAGGCCCAAATATGAAAAGAGCTACGCCGATGAGTTGCAACTGCT  60
* **         .*.:*::*****..*       *    *  ..:*  ***
PBP6a         GCAAAGCAAGCAGTAGTTTTAGATTTAGCCTCAGACTTGTTCATTTTTGAGCATAATTCC  144
PBP6a_SP      GCAAAGCAAGCAGTAGTTTTAGATTTAGCCTCAGACTTGTTCATTTTTGAGCATAATTCC  174
*        *:****:** *:           : .. **  :******************
PBP6a         GCAAAGCAAGCAGTAGTTTTAGATTTAGCCTCAGACTTGTTCATTTTTGAGCATAATTCC  204
PBP6a_SP      GCAAAGCAAGCAGTAGTTTTAGATTTAGCCTCAGACTTGTTCATTTTTGAGCATAATTCC  234
******************************************************************************
PBP6a         TATTTAAAAGCTGGAATAATAGACATGAAGGATAAATTTCGAGTAAGTAGAAAAGCGTGG  264
PBP6a_SP      TATTTAAAAGCTGGAATAATAGACATGAAGGATAAATTTCGAGTAAGTAGAAAAGCGTGG  294
******************************************************************************
PBP6a         GAAAGAAAAGGCTCTTCTATGTTTTTAAAGGAAGGTCAATCTGTTTCGGTGAAAGAATTG  324
PBP6a_SP      GAAAGAAAAGGCTCTTCTATGTTTTTAAAGGAAGGTCAATCTGTTTCGGTGAAAGAATTG  354
******************************************************************************
PBP6a         CTTGAAGGAGTTACAACGGTCTCGGGTAACGATGCCTGCATAACGTTAGCTGAGGGCATT  384
PBP6a_SP      CTTGAAGGAGTTACAACGGTCTCGGGTAACGATGCCTGCATAACGTTAGCTGAGGGCATT  414
******************************************************************************
PBP6a         GCCGGGTCAGAAGAGAATTTCGTGGTTGAAATGAACGAAGTTGCACAAAATTTGAACCTA  444
PBP6a_SP      GCCGGGTCAGAAGAGAATTTCGTGGTTGAAATGAACGAAGTTGCACAAAATTTGAACCTA  474
******************************************************************************
PBP6a         AGCGACAGTTACTTTGTCAATTCAAGCGGGTGGCCAGATAAAGATCATTTCATGAGTGCA  504
PBP6a_SP      AGCGACAGTTACTTTGTCAATTCAAGCGGGTGGCCAGATAAAGATCATTTCATGAGTGCA  534
******************************************************************************
PBP6a         AAAGATTTGGTAGTACTAGCAAAAAGGATTTTTACTGATTTCCCTGAATATTATGATTTA  564
PBP6a_SP      AAAGATTTGGTAGTACTAGCAAAAAGGATTTTTACTGATTTCCCTGAATATTATGATTTA  594
******************************************************************************
PBP6a         TTTTCTAAACAATATCTAACATATAACGATATCATACAAAAAAATAAAAATCTTTTACTT  624
PBP6a_SP      TTTTCTAAACAATATCTAACATATAACGATATCATACAAAAAAATAAAAATCTTTTACTT  654
******************************************************************************
PBP6a         TTTCATGATATTGGAGTTGATGGCTTAAAGACCGGTTATACAAACGCTGGTGGTTACGGC  684
PBP6a_SP      TTTCATGATATTGGAGTTGATGGCTTAAAGACCGGTTATACAAACGCTGGTGGTTACGGC  714
******************************************************************************
PBP6a         ATTGTAATTTCTGCAAAACGAAACGATAGGAGAATTTTCGCTGTTGTAAATGGCTTAAAC  744
PBP6a_SP      ATTGTAATTTCTGCAAAACGAAACGATAGGAGAATTTTCGCTGTTGTAAATGGCTTAAAC  774
******************************************************************************
PBP6a         ACTGAAAAAGAGCGAATAGAAGAAGCAAAAAGACTGATACAATATTCCTTCAATCATTTT  804
PBP6a_SP      ACTGAAAAAGAGCGAATAGAAGAAGCAAAAAGACTGATACAATATTCCTTCAATCATTTT  834
Supplementary Figure 3: Nucleic acid alignment of PBP6a_{wBm} and cloned PBP6a_{wBm} (SP) in pASK-IBA2C.

Mut12        CAANNCTTAGATMCAACGGGCAAAAAATGAAACGACGATCTTCTGAGTCGAC
PBP6a        -------------ATGAG---------TATATTAGACAAAT------- T----GGTAATC
* ***         *.:*::*****..*       *    *  ..:**************
Mut12        TGGCTG------GTTTCGCTACCGTAGCGCAGGCCGGAGACCATGGTTACCAATTTAGAA
PBP6a        CTGCTGTTAGTTTCTACGCTTCCTTTTTC--------TTCATATCTACATTAAAG
** *********************** *********************************
Mut12        CGTGGGAAAGAAAAGGCTCTTCTATGTTTTTAAAGGAAGGTCAATCTGTTTCGGTGAAAG
PBP6a        CGTGGGAAAGAAAAGGCTCTTCTATGTTTTTAAAGGAAGGTCAATCTGTTTCGGTGAAAG
************************************************************
Mut12        AATTGCTTGAAGGAGTTACAACGGTCTCGGGTAACGATGCCTGCATAACGTTAGCTGAGG
PBP6a        AATTGCTTGAAGGAGTTACAACGGTCTCGGGTAACGATGCCTGCATAACGTTAGCTGAGG
************************************************************
Mut12        GCATTGCCGGGTCAGAAGAGAATTTCGTGGTTGAAATGAACGAAGTTGCACAAAATTTGA
PBP6a        GCATTGCCGGGTCAGAAGAGAATTTCGTGGTTGAAATGAACGAAGTTGCACAAAATTTGA
************************************************************
Mut12        ACCTAAGCGACAGTTACTTTGTCAATTCAAGCGGGTGGCCAGATAAAGATCATTTCATGA
PBP6a        ACCTAAGCGACAGTTACTTTGTCAATTCAAGCGGGTGGCCAGATAAAGATCATTTCATGA
************************************************************
Mut12        GTGCAAAAGATTTGGTAGTACTAGCAAAAAGGATTTTTACTGATTTCCCTGAATATTATG
PBP6a        GTGCAAAAGATTTGGTAGTACTAGCAAAAAGGATTTTTACTGATTTCCCTGAATATTATG
************************************************************
Mut12        ATTTATTTTCTAAACAATATCTAACATATAACGATATCATACAAAAAAATAAAAATCTTT
PBP6a        ATTTATTTTCTAAACAATATCTAACATATAACGATATCATACAAAAAAATAAAAATCTTT
************************************************************
Mut12        TACTTTTTCATGATATTGGAGTTGATGGCTTAAAGACCGGTTATACAAACGCTGGTGGTT
PBP6a        TACTTTTTCATGATATTGGAGTTGATGGCTTAAAGACCGGTTATACAAACGCTGGTGGTT
************************************************************
Mut12        ACGGCATTGTAATTTCTGCAAAACGAAACGATAGGAGAATTTTCGCTGTTGTAAATGGCT
PBP6a        ACGGCATTGTAATTTCTGCAAAACGAAACGATAGGAGAATTTTCGCTGTTGTAAATGGCT
************************************************************
Mut12        TAAACACTGAAAAAGAGCGAATAGAAGAAGCAAAAAGACTGATACAATATTCCTTCAATC
PBP6a        TAAACACTGAAAAAGAGCGAATAGAAGAAGCAAAAAGACTGATACAATATTCCTTCAATC
************************************************************
Mut12        ATTTTAATACTAAGAAGATATTTGCTAAGGATAGTGTAGTTGAGGAAATAAATGTTCTAT
PBP6a        ATTTTAATACTAAGAAGATATTTGCTAAGGATAGTGTAGTTGAGGAAATAAATGTTCTAT
************************************************************
Supplementary Figure 4: Nucleic acid alignment of PBP6a<sup>Wm</sup> and cloned PBP6a<sup>Wm</sup> active site mutant S48A-S56A (Mut12) in pASK-IBA2C. Mutated bases are highlighted gray.

Supplementary Figure 5: Penicillin-binding assay. PBP2<sup>Wm</sup> and PBP6a<sup>Wm</sup> were incubated for 1 h, 2 h, 3 h or overnight (o/n) with Bocillin<sup>TM</sup> FL. PBP2 from <i>S. aureus</i> served as a positive control.

# Measure  Position  Value    Cutoff   signal peptide?
max. C    28       0.111
max. Y    13       0.150
max. S     3       0.289
mean S    1-12    0.232
D     1-12    0.180   0.420   NO
Name = Sequence SP = 'NO' D = 0.180 D-cutoff = 0.420 Networks = SignalP-TM
Supplementary Figure 6: Prediction for a transmembrane domain in PBP3\(_{\text{Bm}}\) by TMHMM, but not for a signal peptide as predicted by Signal P.

PBP2 \(_{\text{Bm}}\)

MWVHIKVKFVNRRAFILGGIQGLTISIFSCRLYSLQIRNRQKYEKALDNRRIRVAAIMPKRG 60

PBP2 \(_{\text{Mel}}\)

MWVHIKVKFVNRRAFILGGIQGLTISIFSCRLYSLQIRNRQKYEKALDNRRIRVAAIMPKRG 60

Supplementary Figure 7: Amino acid alignment of PBP2\(_{\text{Bm}}\) and PBP2\(_{\text{Mel}}\) (WP_010962786.1). * fully conserved residue; : conservation between groups of strongly similar properties; . conservation between groups of weakly similar properties. Conserved SXXK, SX(D/N) and K(S/T)G motifs found in PBP2\(_{\text{Bm}}\) and PBP2\(_{\text{Mel}}\) are written in bold letters, motif alignments are framed in black.

PBP2 \(_{\text{Bm}}\)

---MWVHIKVKFVNRRAFILGGIQGLTISIFSCRLYSLQIRNRQKYEKALDNRRIRVAAIMPKRG 58

PBP3 \(_{\text{Bm}}\)

MQALMKNL-RSLCFIVPLFFY---IIRIFISL-------TFDQITSENFPRKDKVH 51

PBP2 \(_{\text{Bm}}\)

RGRILDNGIELAVDKISYVVLFDKQKISS------------------------EEV 91
**Supplementary Figure 8**: Amino acid alignment of PBP2<sub>Wm</sub> and PBP3<sub>Wm</sub> (WP_010963147.1). * fully conserved residue; : conservation between groups of strongly similar properties; - conservation between groups of weakly similar properties. Conserved SXXK, SX(D/N) and K(S/T)G motifs found in PBP2<sub>Wm</sub> and PBP3<sub>Wm</sub> are written in bold letters, motif alignments are framed in black.
Supplementary Figure 9: Nucleic acid alignment of PBP2\text{\textsuperscript{\textregistered}}\textsubscript{\textregistered} and cloned PBP2\text{\textsuperscript{\textregistered}}\textsubscript{\textregistered}TM\textsubscript{\textsuperscript{\textregistered}}\textsubscript{\textregistered} in pASK-IBA6C.
Supplementary Figure 10: Nucleic acid alignment of PBP2\textsuperscript{Bm} (PBP2\textsuperscript{orig}) and cloned PBP2\textsuperscript{Bm} in pASK-IBA6C.
Supplementary Figure 11: Nucleic acid alignment of PBP2\textsuperscript{wBm} and cloned PBP2\textsuperscript{wBm} active site mutant S107A-S265A (Mut12) in pASK-IBA6C. Mutated bases are highlighted gray.

Supplementary Figure 12: Prediction for a signal peptide as predicted in Pal\textsuperscript{wBm} by SignalP.
Supplementary Figure 13: Prediction for a signal peptide as predicted in AmiD^Mel by Signal P.
Supplementary Figure 14: Prediction for a transmembrane domain in PBP3<sup>WT</sup>, but not for a signal peptide.
<table>
<thead>
<tr>
<th></th>
<th>PBP3</th>
<th>Mut1234</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CCAACTTACAGAAATAAGGCAGAAGCTACAAAAAGTTTAAATCGGCAGCTCTTGGGGTA</td>
<td>CCAACTTACAGAAATAAGGCAGAAGCTACAAAAAGTTTAAATCGGCAGCTCTTGGGGTA</td>
</tr>
<tr>
<td>2</td>
<td>TATGAGATGGGGTCGGTATTAAAATACTTTACAATAGCCGCAGCGCTTGATGCAAACGCT</td>
<td>TATGAGATGGGGGCGGTATTAAAATACTTTACAATAGCCGCAGCGCTTGATGCAAACGCT</td>
</tr>
<tr>
<td>3</td>
<td>ACAAAAAACTTGGGATTTATATGACGTATCAACACCAATCACCATCGGAAAGTATAAAATT</td>
<td>ACAAAAAACTTGGGATTTATATGACGTATCAACACCAATCACCATCGGAAAGTATAAAATT</td>
</tr>
<tr>
<td>4</td>
<td>CAGGATTTTCATAAATCTAAAATTCCAAAAATTACTGTGCAAGATATATTTGTAAAATCA</td>
<td>CAGGATTTTCATAAATCTAAAATTCCAAAAATTACTGTGCAAGATATATTTGTAAAATCA</td>
</tr>
<tr>
<td>5</td>
<td>CAGGATTTTCATAAATCTAAAATTCCAAAAATTACTGTGCAAGATATATTTGTAAAATCA</td>
<td>CAGGATTTTCATAAATCTAAAATTCCAAAAATTACTGTGCAAGATATATTTGTAAAATCA</td>
</tr>
<tr>
<td>6</td>
<td>TTTAAAGCTATGAAAGCTATTTTCTCCTTTGAAAATAGAAATACCAGAAAAATCCACACCG</td>
<td>TTTAAAGCTATGAAAGCTATTTTCTCCTTTGAAAATAGAAATACCAGAAAAATCCACACCG</td>
</tr>
<tr>
<td>7</td>
<td>ATAATCCCGGATAAATGGAGTGAAACCACTTTAATAACAGCATCTTATGGTTATGGCATA</td>
<td>ATAATCCCGGATAAATGGAGTGAAACCACTTTAATAACAGCATCTTATGGTTATGGCATA</td>
</tr>
<tr>
<td>8</td>
<td>GCCTGTAACTCCTATACATCTTGCACAAACTGCAGCAGCATTAATCAACAATGGGATATTT</td>
<td>GCCTGTAACTCCTATACATCTTGCACAAACTGCAGCAGCATTAATCAACAATGGGATATTT</td>
</tr>
<tr>
<td>9</td>
<td>CATAACGCAACCTTGATGTTGAATAAAAGAAGTATAGGAGAGCAAATTATCTCAAGAAGA</td>
<td>CATAACGCAACCTTGATGTTGAATAAAAGAAGTATAGGAGAGCAAATTATCTCAAGAAGA</td>
</tr>
<tr>
<td>10</td>
<td>ACTTCCAGGGAAATGAGAAAATTATTACGTGCAGCAGTAACAGATGGCACTGGCAGAAAA</td>
<td>ACTTCCAGGGAAATGAGAAAATTATTACGTGCAGCAGTAACAGATGGCACTGGCAGAAAA</td>
</tr>
<tr>
<td>11</td>
<td>GCAAAAATAAAGGCATATTCAATAGGAGGAAAAACTGGA GCGGCGGAAAAAGTTGTAGAT</td>
<td>GCAAAAATAAAGGCATATTCAATAGGAGGAAAAACTGGA GCGGCGGAAAAAGTTGTAGAT</td>
</tr>
<tr>
<td>12</td>
<td>GGTAAATATAGCAAAGATGCAAACATAGCATCATTTATAGGAGTGCTAACTATGCTTGAC</td>
<td>GGTAAATATAGCAAAGATGCAAACATAGCATCATTTATAGGAGTGCTAACTATGCTTGAC</td>
</tr>
<tr>
<td>13</td>
<td>CCAAGGTACATAGTGCTAATTGCTATTGATGAGCCTCAAGGGATGCACCATACCGGGGGA</td>
<td>CCAAGGTACATAGTGCTAATTGCTATTGATGAGCCTCAAGGGATGCACCATACCGGGGGA</td>
</tr>
<tr>
<td>14</td>
<td>ATAATTGCTGCGCCTATAGTAAAGAACATTATAAATAGAATAGCGCCTATACTAAATGTT</td>
<td>ATAATTGCTGCGCCTATAGTAAAGAACATTATAAATAGAATAGCGCCTATACTAAATGTT</td>
</tr>
<tr>
<td>15</td>
<td>ACACCTGAGATGGAGCGCTTGGAGCCACCCGCAGTTCGAAAAATAA</td>
<td>ACACCTGAGATGGAGCGCTTGGAGCCACCCGCAGTTCGAAAAATAA</td>
</tr>
</tbody>
</table>

**Supplementary Figure 15:** Nucleic acid alignment of PBP3<sub>Mel</sub> and cloned PBP3<sub>Mel</sub> active site mutant S107A-S256A-S339A-S445A (Mut1234) in pASK-IBA2C. Mutated bases are highlighted gray.
**Supplementary Figure 16:** C6/36 insect cells without wAlbB were incubated for 72 h in medium containing 1 mM of the dipeptide probe EDA-DA. Subsequent binding of the probe to an azide-modified Alexa Fluor 594 (red) was achieved by click chemistry. *Wolbachia* were stained with an anti-FtsZ antibody (green). DAPI (blue) was used for nuclear staining. Scale bar = 10 µm.

**Supplementary Figure 17:** Cell-free wAlbB growth on actin-coated streptavidin plates. Cell-free *Wolbachia* (cfwo) were incubated in growth medium either on untreated or actin-coated 96-well plates for twelve days. Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The graph is representative for two experiments. For every time point the mean ± SEM of six samples is shown.
Supplementary Figure 18: Cell-free wAlbB growth in a lowered oxygen environment. Cell-free Wolbachia (cfwo) were incubated in growth medium under standard conditions or in a carbonic gas chamber for twelve days. Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The graph is representative for three experiments. For every time point the mean ± SEM of three samples is shown.

Supplementary Figure 19: Addition of fresh insect cell lysate to cell-free wAlbB. Cell-free Wolbachia (cfwo) were incubated in growth medium for twelve days. One culture was supplemented with additional cell lysate (equivalent to 0.95 x 10^6 uninfected C6/36 cells) after nine days (d9). Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The graph is representative for two experiments. For every time point the mean ± SEM of three samples is shown.
Supplementary Figure 20: Cell-free *Wolbachia* growth supplemented with cholesterol. Cell-free *Wolbachia* (cfwo) were incubated in growth medium for twelve days in the presence or absence of water-soluble cholesterol (0.1 or 1 mg/ml). Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The graph is representative for two experiments. For every time point the mean ± SEM of six samples is shown.

Supplementary Figure 21: Supplementation of culture medium with lipid mixture solution. Cell-free *Wolbachia* (cfwo) were incubated in growth medium for twelve days in the presence or absence of a lipid mixture solution (PeproTech). Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The experiment was performed once. For every time point the mean ± SEM of three samples is shown.
Supplementary Figure 22: Addition of supplements to the cell-free wAlbB culture medium. Cell-free Wolbachia (cfwo) were incubated in growth medium for twelve days in the presence or absence of biotin, cystine, glucose, PLP, sodium bicarbonate. Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The graph is representative for two experiments. For every time point the mean ± SEM of three samples is shown.

Supplementary Figure 23: Co-cultivation of Rhodotorula minuta and cell-free wAlbB. Cell-free Wolbachia (cfwo) were incubated in growth medium for twelve days in absence or presence of 1x10^4-1x10^7 Rhodotorula minuta cells/ml. Growth was monitored every three days by qPCR and data were normalized to day 0 (X-axis). The experiment was performed once. For every time point the mean ± SEM of six samples is shown.
Literature


Bockarie, M. J. and Deb, R. M. (2010). Elimination of lymphatic filariasis: do we have the drugs to complete the job? Current Opinion in Infectious Diseases 23(6), 617-620.


**Chlamydia** and **Wolbachia**: why is lipid II needed? Molecular Microbiology 73(5), 913-923. doi: 10.1111/j.1365-2958.2009.06815.x.


Ramaiah, K. and Ottesen, E. A. (2014). Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLOS Neglected Tropical Diseases 8(11), e3319.


Ritzmann, N. (2016). Functional characterization of a putative metallo-beta-lactamase and the penicillin-binding proteins PBP6a from *Wolbachia* endosymbiont of *Brugia malayi* (wBm) and


specific stimuli in a MyD88/TLR2-dependent manner. The Journal of Immunology 177(2), 1240-1249.


Uehara, T., Parzych, K. R., Dinh, T. and Bernhardt, T. G. (2010). Daughter cell separation is controlled by cytofisering ring-activated cell wall hydrolysis. The EMBO Journal 29(8), 1412-1422.


List of abbreviations

µg  Microgram
µl  Microliter
µm  Micrometer, micron
µM  Micromolar
ad  Adjust volume to
AHT  Anhydrotetracycline
AmiD<sup>wMel</sup>  N-acetylmuramoyl-L-alanine amidase from Wolbachia endosymbiont of Drosophila melanogaster
Aqua dest.  Aqua destillata
BCIP  (5-bromo-4-chloro-1H-indol-3-yl) dihydrogen phosphate
BLI  Biolayer interferometry
bp  Base pair(s)
BSA  Bovine serum albumin
°C  Degree Celsius
C<sub>55</sub>-P  Undecaprenyl phosphate
d  Day
Da  Dalton
DAAO  D-amino acid oxidase
D-Ala  D-alanine
D-Ala-D-Ala  D-alanyl-D-alanine
DAPI  4′,6-Diamidin-2-phenylindol
DMSO  Diethyl sulfoxide
DNA  Deoxyribonucleic acid
dNTP  Deoxynucleotide triphosphate
EDA-DA  Ethynyl-D-alanyl-D-alanine
EDTA  Ethylenediaminetetraacetic acid
ELA-LA  Ethynyl-L-alanyl-L-alanine
FCS  Fetal calf serum
g  Gravimetric force
GlcNAc  N-acetylglucosamine
h  Hour
HMW  High molecular weight
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPLC</td>
<td>High performance liquid chromatography</td>
</tr>
<tr>
<td>kb</td>
<td>Kilobase</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodalton</td>
</tr>
<tr>
<td>l</td>
<td>Liter</td>
</tr>
<tr>
<td>L-Ala</td>
<td>L-alanine</td>
</tr>
<tr>
<td>LB-medium</td>
<td>Lysogeny broth medium</td>
</tr>
<tr>
<td>Lipid II</td>
<td>Undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide-GlcNAc</td>
</tr>
<tr>
<td>L-Lys</td>
<td>L-lysine</td>
</tr>
<tr>
<td>LMW</td>
<td>Low molecular weight</td>
</tr>
<tr>
<td>M</td>
<td>Molar</td>
</tr>
<tr>
<td>MALDI-TOF</td>
<td>Matrix-assisted laser desorption/ionization time-of-flight</td>
</tr>
<tr>
<td>MDA</td>
<td>Mass drug administration</td>
</tr>
<tr>
<td>min</td>
<td>Minute</td>
</tr>
<tr>
<td>m-DAP</td>
<td>Meso-diaminopimelic acid</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>ml</td>
<td>Milliliter</td>
</tr>
<tr>
<td>mM</td>
<td>Millimolar</td>
</tr>
<tr>
<td>MurNAc</td>
<td>N-acetylmuramic acid</td>
</tr>
<tr>
<td>MW</td>
<td>Molecular weight</td>
</tr>
<tr>
<td>NaOH</td>
<td>Sodium hydroxide</td>
</tr>
<tr>
<td>NBT</td>
<td>Nitro blue tetrazolium chloride</td>
</tr>
<tr>
<td>NCBI</td>
<td>National Center for Biotechnology Information</td>
</tr>
<tr>
<td>ng</td>
<td>Nanogram</td>
</tr>
<tr>
<td>nm</td>
<td>Nanometer</td>
</tr>
<tr>
<td>nM</td>
<td>Nanomolar</td>
</tr>
<tr>
<td>NOD</td>
<td>Nucleotide-binding oligomerization domain</td>
</tr>
<tr>
<td>OD$_{600}$</td>
<td>Optical density at 600nm</td>
</tr>
<tr>
<td>Pal$^{wBm}$</td>
<td>Peptidoglycan-associated outer membrane lipoprotein from <em>Wolbachia</em> endosymbionts of <em>Brugia malayi</em></td>
</tr>
<tr>
<td>PAMP</td>
<td>Pathogen-associated molecular pattern</td>
</tr>
<tr>
<td>PBP</td>
<td>Penicillin-binding protein</td>
</tr>
<tr>
<td>PBP2$^{wBm}$</td>
<td>Penicillin-binding protein 2 from <em>Wolbachia</em> endosymbionts of <em>Brugia malayi</em></td>
</tr>
<tr>
<td>PBP3$^{wMel}$</td>
<td>Penicillin-binding protein 3 from <em>Wolbachia</em> endosymbionts of <em>Drosophila melanogaster</em></td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>PBP6a&lt;sup&gt;Wm&lt;/sup&gt;</td>
<td>Penicillin-binding protein 6a from <em>Wolbachia</em> endosymbionts of <em>Brugia malayi</em></td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PFA</td>
<td>Paraformaldehyde</td>
</tr>
<tr>
<td>pH</td>
<td>Pondus hydrogenii, hydrogen ion concentration</td>
</tr>
<tr>
<td>Pi</td>
<td>Inorganic phosphate</td>
</tr>
<tr>
<td>PMA</td>
<td>Phosphomolybdic acid</td>
</tr>
<tr>
<td>qPCR</td>
<td>Quantitative real-time PCR</td>
</tr>
<tr>
<td>RBB</td>
<td>Remazol brilliant blue</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>rpm</td>
<td>Rotations per minute</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>s</td>
<td>Second</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SPR</td>
<td>Surface plasmon resonance</td>
</tr>
<tr>
<td>TEMED</td>
<td>Tetramethylethylenediamine</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin layer chromatography</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-Like-Receptor</td>
</tr>
<tr>
<td>Tris</td>
<td>Tris(hydroxymethyl)aminomethan</td>
</tr>
<tr>
<td>UDP</td>
<td>Uridine diphosphate</td>
</tr>
<tr>
<td>UDP-GlcNAc</td>
<td>Uridine diphosphate N-acetylglucosamine</td>
</tr>
<tr>
<td>UDP-MurNAc</td>
<td>Uridine diphosphate N-acetylmuramic acid</td>
</tr>
<tr>
<td>V</td>
<td>Volt</td>
</tr>
<tr>
<td>v/v</td>
<td>Volume per volume</td>
</tr>
<tr>
<td>wALB B</td>
<td><em>Wolbachia pipiens</em> strain <em>Aedes albopictus</em> B</td>
</tr>
<tr>
<td>wBm</td>
<td><em>Wolbachia</em> endosymbionts of <em>Brugia malayi</em></td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>wMel</td>
<td><em>Wolbachia</em> endosymbionts of <em>Drosophila melanogaster</em></td>
</tr>
<tr>
<td>w/v</td>
<td>Weight per volume</td>
</tr>
</tbody>
</table>